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ABSTRACT
BACKGROUND 
Newborn Screening for Cystic Fibrosis
Cystic Fibrosis (CF) is an autosomal recessive disorder that results in a shortened lifespan 
if appropriate treatment is not initiated sufficiently early. Approximately one in every
2,000 to one in every 3,500 Caucasians bom in Europe is affected by CF, which manifests 
itself in severe disorders of the lungs and the digestive system. Newborn screening for CF 
based on the analysis of bloodspot immunoreactive trypsinogen (IRT) has recently been 
introduced in a number of countries, including the UK. Also, it has been reported that 
pancreatitis associated protein (PAP) is elevated in bloodspots from neonates with CF and 
a strategy involving a combination of IRT and PAP may offer enhanced specificity. The 
study aims to develop an algorithm based on universal IRT measurements and subsequent 
PAP measurements in newborns with elevated IRT levels which will allow high detection 
rates to be maintained while at the same time decreasing the number o f cases referred for 
DNA analysis and the accompanying detection of CF carriers.
Prenatal Screening
The aim of antenatal screening programmes is to offer couples reproductive choice, for 
example, termination o f the pregnancy if the foetus is found to have a serious disorder 
such as CF. In this study, the physiological effects on women pregnant with a baby 
affected by CF were investigated. Several maternal serum markers were tested in this 
project in blood samples from women carrying a CF foetus. These markers are known to 
be associated with a number of adverse outcomes in pregnancy such as low birth weight, 
pre-term birth, pre-eclampsia, and stillbirth. The markers tested were alpha-fetoprotein 
(AFP), pregnancy-associated plasma protein (PAPP-A), human chorionic gonadotrophin 
(hCG), free beta subunit o f hCG (FphCG), unconjugated estriol (UE3) and Inhibin-A.
MATERIALS AND METHODS 
Newborn
In this project, blood spot samples with elevated immunoreactive trypsinogen (IRT) 
samples were from 314 infants together with 2886 controls. In addition there were 189 
blood spots from premature babies, 182 from low birth weight babies, 29 from confirmed 
CF cases and 32 from CF carriers. The samples therefore comprised a total of 3636 blood 
spots.
Currently, in Scotland, the routine newborn screening test for CF uses the Delfia 
fluoroimmunoassay method (Perkin Elmer, Finland) to measure IRT. Also available from 
the routine newborn bloodspot screening programme were the results from tandem mass 
spectrometry (MS/MS) testing for phenylketonuria (PKU) measuring phenylalanine 
(PHE) and tyrosine (TYR). In this project, pancreatitis-associated protein (PAP) in all the 
3636 blood spots was also measured using a commercially-available enzyme linked 
immunoassay (Dynabio SA, Marseille, France).
Pregnancy
In the present study, a group of 55 women with CF pregnancies was identified from 
antenatal screening records and serum samples taken for routine prenatal screening were 
recovered from frozen storage. Serum samples from an additional 330 pregnancies, both 
first trimester (10-13 weeks) and second trimester (15 to 20 weeks) cases were randomly 
chosen as controls. The Dissociation Enhanced Lanthanide Fluro Immuno Assay method 
(DELFIA) was used to measure AFP, HCG, PAPP-A, and free 0HCG. The assays for 
unconjugated estriol (UE3) and Inhibin-A were conducted using the Access 2 
immunoassay system (Beckman Coulter).
RESULTS
Newborn Markers and Detection of CF cases
The main findings in the study are the following. Median PAP concentrations in the CF 
cases and carriers were significantly elevated over the control median (x 9.9 and x 2.3 
respectively). If referral for DNA testing was based on an IRT level >99.5th centile and a 
PAP level >1.2 multiples of the control median, 25% fewer DNA analyses would be 
required and the number of carriers detected reduced from 32 to 24 with no loss of 
detection o f CF cases. Therefore, carrying out PAP assays only on infants with elevated 
IRT results improves specificity by reducing the number of cases requiring DNA analysis.
The predictive value o f IRT and PAP measurements were examined using the Likelihood 
Ratio (LR) method. IRT and PAP results showed no significant correlation in CF cases 
(Pearson correlation p = 0.669). The product of the likelihood ratios can therefore be 
calculated thus combining the information from two markers. Setting a threshold LR o f 30 
as the action point for DNA testing would result in a 43% reduction in DNA testing and a 
50% reduction in the number of CF carriers identified. One CF case would be missed. If a 
likelihood ratio cut off of 500 was chosen this would reduce detection of carriers by 88 % 
and referrals for DNA analysis by 75%. However detection of 3 CF cases would be 
missed. Therefore, selecting cases for DNA analysis based on subsequent measurement of 
PAP in infants with elevated IRT offers a potentially cost-effective method for reducing 
the number o f DNA tests and incidental detection of carriers without the need to measure 
PAP in all infants.
iii
Marker levels and mutation type in CF Cases
Data presented by Sarles et al (2005) suggest that PAP levels may appear lower in cases 
where the mutation types are associated with a milder CF phenyotype. Thirteen out of the 
29 CF cases examined in this research were homozygous for the common mutation delta 
F508 with the remaining 16 cases having other combinations o f mutation. IRT, PAP, PHE, 
and TYR concentrations were compared between the two groups o f mutation types (Delta 
F508 homozygous vs. other mutations). It was found that both IRT and PAP medians 
were considerably lower in the “other” mutation group than in the delta F508 homozygous 
group (IRT: 147.8 ng/ml vs. 187.7 ng/ml), (PAP: 1.03 ng/ml vs. 2.54 ng/ml) and that only 
two o f the 10 CF cases with the lowest PAP results were homozygous for the delta F508 
mutation. However, no statistically significant differences in median level between the 
two mutation groups for any markers were found using the Mann-Whitney test. This may 
reflect the relatively small number of cases compared and it is recommended that studies 
on a more extensive series of CF cases and mutation types should be conducted to 
investigate this possibility further.
Marker Levels and Mutation type in CF carriers
The delta F508 mutation was found in 22 of the CF carriers from a total of 32 carriers. The 
remaining 10 carriers had other mutations. Little difference was found in the median 
concentration for each marker between the two types of mutation. A comparison o f IRT, 
PAP, PHE and TYR concentrations between the two groups o f mutation types (AF508 vs. 
other mutation) using Mann-Whitney test showed no significant differences in median 
level for any markers between these two groups.
Age at bloodspot sampling
The variations in the levels o f blood spot markers with day of sampling were examined in 
this study. In the control group o f 2876 samples, the regression analysis at age of
sampling showed significantly reduced PAP levels (p <0.001) with earlier age at 
sampling. No significant associations were found for IRT (p = 0.959), PHE (p=0.276) or 
TYR (p = 0.249). In Scotland, most bloodspot samples for newborn screening are 
collected when the baby is between 5 and 8 days old, with around 5% of samples being 
collected later. However, in many other countries, bloodspot sampling is carried out 
earlier, when the baby is between 1 and 3 days old. As published data from centres which 
use earlier sampling will be unreliable, it is therefore important to establish normal ranges 
and distribution parameters for each marker locally.
Premature Babies
Marker studies were conducted in 182 infants bom prematurely (that is, before 37 weeks 
of gestation). A linear regression analysis was carried out to discover any relationship 
between premature birth and levels of IRT, PAP, PHE and TYR concentrations. All 
markers showed a diminishing trend with advancing gestation, which was statistically 
significant for IRT (p <0.001), PAP (p <0.001) and TYR (p =0.015) but not statistically 
significant for PHE (p = 0.226). Hence, there will be a risk of false positive results in 
premature infants when using IRT and PAP to screen for CF unless higher IRT and PAP 
cut-offs are used.
Low Birth Weight Babies
In this study o f 3632 blood spot samples, 189 were from babies who had been bom with 
low birth weight (i.e. less than 2500 grams). Linear regression was used to examine the 
relationship between low birth weight and levels of IRT, PAP, PHE and TYR 
concentration. This showed that there was a significant association with PAP (p=0.002), 
where the level decreased with increasing birth weight, whereas no significant changes 
were found for IRT (p =0.212), PHE (p =0.180) and TYR (p =0.436). Hence, there will
be a tendency to overestimate the risk in very low birth weight infants in any screening 
programme for CF which uses PAP.
Ethnicity
The data was divided into two groups to discover whether there was any difference in the 
IRT, PAP, PHE and TYR markers between different ethnic groups. Because numbers 
were small, two ethnic categories were defined. Group 1 included all babies from 
British/Irish (A) and any other Caucasian background (C). Group 2 included all babies 
from other ethnic backgrounds. The median was calculated for IRT, PAP, PHE and TYR 
in both these groups. The results revealed that the only statistically significant difference 
between these groups was for TYR in the controls. In fact, there was an insufficient 
number o f babies in Group 2 in the CF and CF carriers samples groups for the comparison 
to be meaningful.
Gestational Markers and Detection of Cystic Fibrosis
The majority of pregnant women in the UK take up the offer of a prenatal screening test 
for Down syndrome and other foetal abnormalities based on the analysis of a series of 
serum markers o f placental and foetal origin. These markers are known to vary in 
concentration across a range of other foetal and maternal abnormalities thus providing a 
useful alert for improving the management and delivery of such pregnancies. Using the 
Mann-Whitney test, an analysis o f markers AFP (p = 0.335), hCG, (p = 0.539), PAPP-A, 
(p = 0.632), Free (3-hCG (p = 0.824), UE3, (p =0.840) and Inhibin-A (p = 0.650) showed 
that these concentration levels remained unchanged in the serum of mothers of children 
affected by CF. Thus, none of these routinely used screening markers offers any potential 
for the identification of CF pregnancies.
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CHAPTER 1 : 
INTRODUCTION
1
1.1 BACK G RO UND
Sir Archibald Garrod (1857-1936) was a physician who coined the term ‘Inborn Errors of 
Metabolism' (IEM). He first used this term to describe alkaptonurea (Scriver, 1995). This 
is a rare inherited disorder of organic acid metabolism that causes urine to turn from 
yellow to brown and then to black when exposed to air. This is due to the build up of a 
storage product homogentisic acid which accumulates as a result of a metabolic block 
caused by deficiency o f an enzyme, homogenetisic acid oxidase. Patients affected with 
this disorder are likely to suffer from arthritis in the spine and joints. Moreover, they may 
also suffer from heart, kidney and prostate problems. Although Garrod did not know the 
identity of the deficient enzyme, he established the principle underlying the cause o f the 
majority of inborn errors. Garrod also suggested that the disease followed an autosomal 
pattern of inheritance as it was found in both males and females (Scriver, 1995).
Later, as the pattern o f inheritance became better understood, it was recognised that genes 
are a significant determinant of human health, with a mutated gene following a predictable 
pattern of inheritance within families. Single gene inheritance is also referred to as 
Mendelian inheritance. There are four types o f single-gene (Mendelian) inheritance: 
autosomal recessive, autosomal dominant, X-linked dominant and X-linked recessive. 
Other types of inheritance include mitochondrial inheritance and multifactorial 
inheritance.
There is a large number of IEMs whose clinical consequences vary from benign to lethal 
(Table 1.1). Multiple mutations in a gene e.g. coding for a specific enzyme may lead to 
heterogeneity within individual IEMs. Some are treatable but many are not: e.g. 
phenylketonuria (PKU) is a treatable disease when it is diagnosed early in the newborn 
period whereas Tay-Sachs disease is a non treatable disorder.
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If a child is bom with a serious metabolic disorder, the child may appear healthy at birth 
but will at some point become ill. Medical investigation into the illness can establish that 
the child is affected with a specific metabolic disorder, e.g. an amino acid disorder. 
Therefore, if  all amino acids are tested and elevated phenylalanine levels are found, PKU 
may be diagnosed. However, this diagnosis will come too late for effective treatment to be 
given to the child, as it may be days, months or even years before the clinical symptoms 
indicating a metabolic disorder become apparent. Hence, there is a need for a system to 
identify at-risk families before it is too late and the damage is done to an affected baby.
With our knowledge of enzymes and understanding of the pathways in many diseases, it is 
possible to diagnose many inborn errors of metabolism prenatally through biochemical or 
DNA tests. Therefore, if  it is known that a particular disease runs in the family and a 
couple wish to have a baby, prenatal diagnosis can be offered. The parents can then be 
given the choice of continuing or terminating the pregnancy if the baby is affected. They 
can also be told if  the baby is a carrier of the disorder, which may be of benefit when the 
child reaches adulthood allowing appropriate testing to be carried out on their partner 
before they start a family. Prenatal diagnosis is only possible in families where there is a 
known history of a particular condition. For the majority of babies bom with an IEM, this 
is an unexpected occurrence and it would be impossible to test for all possible conditions. 
Thus it is impossible to significantly reduce the burden of inherited metabolic disorders 
through prenatal diagnosis. A more practical approach is to test newborn babies for a 
limited number of conditions which can be treated using techniques which can be applied 
to the whole population. This is newborn screening.
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Table 1-1: Classification, incidence and inheritance of some inborn errors of metabolism 
(Scriver, 1995)
Classification IEM Incidence Mode of 
Inheritance
Carbohydrate: (GSD I) Type la (Von Gierke) -1:100,000 AR*
(GSD I) Type lb -1:200,000 AR
(GSD I) Type III
(GSD I) Type IV (Andersen
disease)
-1:125,000
-1:1,000,000
AR
AR
Amino acid PKU -1:10,000 AR
Maple syrup urine disease -1:180,000 AR
Fatty Acid 
Oxidation
Medium-chain acyl-co A 
dehydrogenase deficiency
-1:20,000 AR
organic Acid Alcaptonuria 1:100,000- 
million
AR
Purine Lesch-Nyhan syndrome Rare XLR*
Steroid
metabolism
Congenital adrenal hyperplasia due 
to 21 -hydroxylase deficiency (21 - 
OH CAH),
1:10,000 to 
1:18,000
AR
Lysosomal
storage
Gaucher’s disease Very rare AR
Membrane
Transport
Disorders
Cystic Fibrosis 1:2000-3000 AR
*AR: autosomal recessive. *XLR: X-linked recessive
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1.2 SCREENING
Screening takes place in two stages. First, the primary screening test is done to detect early 
disease or risk factors in large numbers of apparently healthy people. Second, a diagnostic 
test is carried out on individuals who are screen positive to confirm the presence or 
absence of specific disease as a basis for treatment decisions.
In 1968 Wilson and Jungner proposed several criteria for screening diseases (Table 1.2) 
(Wilson and Jungner, 1968). These proposed principles were to be followed when 
establishing any screening programme in order for it to succeed.
The condition, severity, prevalence, mortality or morbidity o f the disease should be 
important and well-defined within the community, and there must also be a need to 
understand its natural history. Before the implementation of a screening programme, 
diagnosis and treatment facilities should be available for affected individuals. When 
introducing a screening programme, the advantages and disadvantages for those being 
screened should be carefully considered, and only when it has been decided that the 
advantages outweigh the disadvantages should the screening programme go ahead. 
Considerations of outcome and treatment are vital factors to be taken into account. The 
test must be acceptable to the population, and it must also be safe, sensitive, accurate, and 
cost-effective. The technology employed should ideally be capable o f screening the 
population for more than one disease at a time, and there should be as little delay as 
possible in obtaining the results of the test so that medical intervention is possible when 
required. Furthermore, precise monitoring of the effectiveness o f a test and a quality 
assessment procedure should be in place.
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Table 1-2: Wilson and Jungner screening criteria (Wilson and Jungner, 1968).
Understanding the nature of the disease
• The condition should be a significant health problem
• There must be a distinctive latent or early symptomatic phase
• There should be a clear understanding of the history o f the condition, including
development from latent to declared disease.
Understanding the test
• Availability of appropriate test or examination
• The test or examination have to be acceptable to the population
• The case finding needs to be ongoing process rather than a ‘one-off project
• Outcome affected by early diagnosis 
Treating the disease
• There should be a recognised treatment for patients diagnosed with the disease
• Facilities for diagnosis and treatment should be accessible
• A policy should be an established regarding whom to treat as patients 
Cost considerations
• Cost o f screening test
• Cost of follow-up diagnostic test
•  The costs of the case finding, including diagnosis and treatment of diagnosed 
patients, balanced in economic terms relative to potential expenditure on overall medical 
care.
A Quality Assessment process has to be established, and the effectiveness of the test must 
be carefully monitored. Finally, a screening programme should be evaluated. This should 
include the rate o f uptake of the test, its acceptability to the population and its total cost 
(Murray and Clarke, 2002).
There are four important parameters for measuring the effectiveness of a screening test.
The first o f these is sensitivity, which is the proportion of true positive cases among all
affected cases; in other words, the proportion o f cases which are detected by a test. The
second parameter is specificity, which is the proportion of true negative results among all
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non-affected cases, i.e. the extent to which a test detects only affected cases. The third is 
positive predictive value, being the proportion of true positive results within the high risk 
group, that is, the proportion of cases actually affected among cases considered screen 
positive. The final parameter is the negative predictive value which is the proportion of 
true negative results within the low risk group, which is to say the proportion of 
individuals, which are actually unaffected among cases considered negative in a test. Thus 
both the positive and negative aspects of the programme must be evaluated (Grimes and 
Schulz, 2002).
1.2.1 Types of Screening
1.2.2 Prenatal screening
Various types o f screening are carried out at different stages in an individual’s life. For 
example, there is screening during the pregnancy to detect neural tube defects and 
chromosomal abnormalities. Various infectious diseases are also screened for during 
pregnancy. In the UK these include rubella, syphilis, HIV and hepatitis B. The aim of 
screening for some o f these disorders, for instance, syphilis, is to detect maternal infection 
which can be treated with antibiotics and followed by treatment for baby after birth (Wald 
and Leek, 2000).
Screening for inherited haematological disorders is also carried out during pregnancy. 
These include the sickling disorders and thalassaemia. Screening, especially in early 
pregnancy, is important in at-risk ethnic groups so that prenatal diagnosis and termination 
can be offered if  that is the parents’ wish. The second type comprises red cell enzyme 
deficiencies such as glucose-6-phosphate dehydrogenase deficiency. The third type of 
screening is for the bleeding disorders, such as haemophilia (Wald and Leek, 2000).
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1.2.3 Adult screening
Adult pre-symptomatic screening programmes for various types of cancer, such as breast 
cancer, are offered. Breast cancer screening aims to diagnose women in the early stage of 
breast cancer, which results in an increase in the chance to cure the disease. The screening 
test involves the use of a mammography X-ray (Kuhl et al., 2005). Cervical cancer can be 
screened for using liquid based cytology (LBC). Cells contained in a sample collected 
from the cervix of the women are spread out as a thin layer of cells on a slide and 
examined using a microscope to see if there are any malignant cells present (Beerman et 
al., 2009).
1.2.4 Carrier screening
Screening for carriers of Tay-Sachs disease is offered for specific ethnic groups (e.g 
Ashkenazi Jews) who are at high risk of being carriers o f this disorder. Tay-Sachs disease 
is an autosomal recessive trait with 1 in 30 Ashkenazi Jews being a carrier. In other ethnic 
groups however, the carrier rate is much less, around 1 in 300. The screening test is 
performed by measuring serum-beta-N-acetylhexosaminidase A or by DNA analysis in 
couples. If both of the partners are carriers, prenatal diagnosis can be offered (Connor & 
Ferguson-Smith, 2004).
1.2.5 Newborn screening
Inherited metabolic disorders are generally rare conditions which may lead to serious 
physical and mental handicap in the affected child. The majority are recessively inherited, 
and there is a 1 in 4 chance o f a recurrence in any future pregnancy. Many of these 
conditions may not be suspected clinically at birth and the characteristic signs and 
symptoms appear later. Genetic screening for such conditions aims for the early
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identification of individuals and the provision of treatment that will allow the child to 
grow and develop normally.
Over the last 40 years, different screening tests have been designed to detect many inborn 
errors of metabolism and for certain other conditions which strictly do not fall within the 
classical definition of inborn errors of metabolism.
1.2.6 The Development of Newborn Screening
1.2.6.1 The Bacterial Inhibition Assay
In 1963 a method for screening newborn babies for metabolic disorders was developed by 
an American microbiologist, Dr. Robert Guthrie (Guthrie and Susi, 1963). The test 
consists of two principal parts. The first is a simple, semi-quantitative method of 
measuring an increased level of phenylalanine in blood to detect children with the amino 
acid disorder PKU. The second is the development of the specimen in the form of a dried 
blood spot collected on a special absorbent card (henceforth known as the "Guthrie 
Card").
The principle underlying the screening test is a bacterial inhibition assay which stems 
from the finding that bloodspots with phenylalanine in increased concentration can 
overcome the inhibition of growth o f the bacterium bacillus subtilis ATCC 6051 by B-2- 
thienylalanine on an agar plate.
Guthrie developed the BIA principle to screen for other metabolic disorders, e.g. 
galactosaemia and maple syrup urine disease. Millions of newborn babies across the world 
have been screened using this method.
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1.2.6.2 The Dried Bloodspot Sample
The second component of Guthrie’s strategy for newborn screening is the use of the dried 
blood spot samples (DBS). Blood is collected from the heel of a baby in their first week of 
life and applied within circles on a dry filter paper and allowed to dry. There are several 
advantages to using DBS compared to using other methods like venepuncture and serum 
collection. Table 1.3 briefly illustrates some of these advantages.
Table 1-3: Advantages of using the DBS method instead of venepuncture (Kirby, et al., 
1981; Mei et al., 2001).
Risk
aspect
Venepuncture & serum Dried blood spots (DBS)
Venepuncture can be quite 
troublesome to perform (e.g. poor 
veins)
Requires training
Risks of needle stick injury
Increased risk if  an infectious hazard 
e.g. HIV & HCV is present.
Possibility o f leakages and breakages 
in transit, requirement for 
transportation at controlled (low) 
temperature._______________________
Simple to perform
Requires minimal training 
Minimal risks
Represents a low infectious hazard
Cannot leak or be broken in transit 
and no requirement for 
transportation in non-ambient 
condition
Economic Collection & processing of samples is 
aspect expensive
Needles and syringes are costly
Whole blood requires to be packed in 
unbreakable containers sent by special 
delivery.
Transportation of frozen sera may 
need the use of dry ice or liquid 
___________ nitrogen___________________________
Collection & processing of
samples is cheap
DBS cards are inexpensive
Easily shipped in sealed envelopes 
by post
Easy to transport, with no need for 
dry ice or liquid nitrogen
Since Guthrie developed the use of the dried filter paper card to screen newborn babies,
there have been many suggestions regarding improving the quality of the filter paper card
and standardising the collection of the specimen. The National Committee for Clinical
Laboratory Standards in the USA (NCCLS) isued a written standard on the collection of
dried blood spot specimens on filter paper (Hannon, 1997).
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The bloodspot card is also a medical record as it provides information on the baby; for 
example, baby’s ID number, baby’s name, mother’s name, address, birth weight, gender, 
date of first milk feed, type of feed (breast/formula/other), whether the baby has had a 
blood transfusion or medication, and the baby’s family history. Other information is 
required, such as the date of the specimen collection and the name of the person who took 
the specimen. The babies’ ancestry should also be recorded. A barcode may also be 
printed on the card which can be used for sample tracking and analysis.
1.3 SCREENING FOR IEMs
Newborn screening for PKU and other IEMs is established in many developed countries. 
The range of tests varies between different countries. In the UK, 5 disorders are currently 
screened for: PKU, Congenital Hypothyroidism (CHT), Sickle-cell Disorders (SCD), 
Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD), and Cystic 
Fibrosis (CF). Programmes in other countries may also include Galactosaemia (GALT), 
Maple Syrup Urine Disease (MSUD), Congenital Adrenal Hyperplasia (CAH) and up to 
twenty additional amino acid and fatty acid disorders, through the use of tandem mass 
spectrometry (MSMS) technology, notably in the USA. Electrospray tandem mass 
spectrometry is used to screen for 10 conditions in Germany (Jeannette, 2011). In the UK, 
MS/MS is used only to screen for PKU and MCADD. In the USA, the American College 
o f Medical Genetics recommended a core panel of 29 screening conditions with 25 
additional secondary targets in every state (Klein, 2011). Screening is also being 
introduced and developed in other countries, e.g. countries in the Asia Pacific Region 
(table 1.4) and in the Middle East (table 1.5), with some countries offering selective 
screening programmes appropriate to their ethnic populations. However, in many 
countries across the world, establishing newborn screening programmes poses various
11
challenges. For instance poor economies, differences in language, religion and culture, 
geographic extremes, unstable governments and various public health priorities lead some 
governments to focus more on problems of malnutrition or the control o f infectious 
disease than on newborn screening.
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Table 1-5: Newborn screening development in the Middle East region (Saadallah and 
Rashed, 2007).
Country Population
(million)
Birth
rate/1000
Fertility
rate/woman
Estimated number of 
infants/year
Algeria 32.93 17.10 1.89 563 103
Bahrain 0.70 17.80 2.60 12 460
Egypt 78.89 22.94 2.83 1 809 737
Iran 68.69 17.00 1.80 1 167 730
Iraq 26.78 31.98 4.18 856 424
Jordan 5.91 21.25 2.63 125 588
Kuwait 2.42 21.94 2.91 53 095
Lebanon 3.87 18.52 1.90 71 672
Libya 5.90 26.49 3.28 156 291
Morocco 33.2 21.98 2.68 729 736
Oman 3.10 36.40 5.77 112 344
Palestinians3 1.43 39.50 5.78 56 485
Palestinians'3 2.46 31.67 4.28 77 908
Qatar 0.89 15.56 2.81 13 848
Saudi Arabia 27.02 29.34 4.00 792 767
Somalia 8.86 45.13 6.76 399 851
Sudan 41.24 34.53 4.72 1 424 017
Syria 18.88 27.76 3.4 524 108
Tunisia 10.18 15.52 1.74 157 994
UAE 2.60 18.96 2.88 49 296
Yemen 21.46 42.89 6.58 920 419
Total (million) 397.41 Total 10 074 873
a Gaza Strip, 
b West Bank.
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1.3.1 Analytical Techniques Used in Bloodspot Screening
There are several analytical techniques used in bloodspot screening. For example 
thalassaemia and SCD screening is usually carried out by biochemical techniques such as 
cellulose acetate electrophoresis (CA), isoelectric focusing (IEF), high performance liquid 
chromatography (HPLC) and by DNA methods. These techniques are the most commonly 
used methods to detect variant haemoglobin worldwide (Davies et al., 2000).
The measurement o f immunoreactive trypsinogen (IRT) levels in dried blood spots to 
screen for CF was originally carried out by radioimmunoassay (RIA) with polyclonal 
antibodies (Crossley et al., 1979). This was replaced by an enzyme-linked immunosorbent 
assay (ELISA) using monoclonal antibodies as an alternative approach, and using dried 
blood spots in a 96-well microtitre plate. This method was more efficient for large sample 
numbers than RIA, which involves the use of tubes and required radioactive materials 
(Bowling and Brown, 1988). Further developments in laboratory techniques have led to 
automated methods of measuring IRT as a primary test to detect CF with dried blood spots 
using the automated dissociated enhanced lanthanide fluoroimmunoassay (DELFIA) 
technique (Soini and Kojola, 1983). This technique has been automated in the 
AutoDELFIA immunoassay system, which is started by loading the microtitration plates 
containing punched dried blood spot samples and assay reagents. It includes an external 
PC which controls the running o f the system. The principal advantage of this technique is 
that it has a high sample throughput with good accuracy and precision of bloodspot IRT 
measurement.
Other ELISAs have been developed for blood spot screening, e.g. for CHT measuring 
thyroxin (T4) or thyroid stimulating hormone (TSH) and for CAH measuring 17-OH 
progesterone and these have also been adapted to the DELFIA method.
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A recent method used to screen newborn babies is (MS/MS) (Chace et al., 2003). This 
technique has a high rate of sensitivity and specificity and can be used to screen for a large 
range of different conditions, all from a single dried blood spot specimen in a microtitre 
plate.
The system consists of two mass spectrometers coupled in tandem by a collision chamber. 
Samples are extracted, ionised and introduced into the first mass spectrometer where ions 
with a specific mass/charge ratio (m/z) are selected and pass into the collision chamber 
where they are fragmented by collision with molecules of the inert gas, argon. The product 
ions then enter the second mass spectrometer which is tuned to allow through only the 
principal daughter ions of interest for the analyte under investigation. These have specific 
mass/charge ratios and are characteristic of the metabolites of interest, e.g. phenylalanine 
and its internal standards which are included in the extraction solution in each well of the 
microtitre plate. As the internal standards are of known concentration, the signal responses 
from the standards can be compared with the native species and used to calculate their 
relative concentrations.
1.3.2 Disorders Detected By Newborn Bloodspot Screening
1.3.2.1 Phenylketonuria (PKU)
PKU an autosomal recessive disorder caused by deficiency in the enzyme phenylalanine 
hydroxylase (PAH). PAH converts the amino acid phenylalanine to tyrosine, and if PAH 
is missing phenylalanine is converted instead to phenylpyruvic acid, and brain damage and 
mental retardation will occur. The PAH gene is located on chromosome 12 (q22-q24.1); it 
is considered to be a homopolymer and it has about 90,000 nucleotide base pairs with 13 
exons. Seventy haplotypes were identified by the restriction fragment length
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polymorphism (RFLP) method. Of these 70 haplotypes, six haplotypes account for more 
than 90 per cent of classical PKU in European families (Wald and Leek, 2000).
PKU occurs in about 1:10,000 live births, with great ethnic variations. In Turkey, due to 
high consanguinity within the population, PKU incidence is one in every 4000 births, 
while Finland has the lowest prevalence in Europe with 1 case per 100,000 births. Asians, 
Africans and Americans can also be affected with PKU disorder (Blau et al., 2010).
There are two types of PKU: classical PKU, and non-PKU type which is due to 
deficiencies of other enzymes such tetrahydrobiopterin. Affected individuals with classical 
PKU type will suffer from mental retardation if the disease is untreated. Other clinical 
findings include microcephaly, decreased pigmentation of hair and skin, eczematous rash 
and vomiting (Wald and Leek, 2000).
The first test used to identify individuals affected with PKU was a ferric chloride test on 
urine often carried out due to the presence of a” mousey”  smell in the nappy. Its 
disadvantage, however, is that it is unreliable in newborn screening due to the variable 
appearance o f characteristic metabolites. The bacteriological inhibition assay was the 
mainstay in newborn screening for the many years. The Guthrie test is a semi-quantitative 
technique. The test’s advantage is its low cost. Fluorometric assay is also used to detect 
elevated levels of phenylalanine in the blood (Wald and Leek, 2000). This quality of this 
technique is easier to control. However the BIA method for phenylalanine has been 
largely superseded in recent years by the introduction of MSMS (Millington et al., 1990). 
This powerful technology can be used to screen for multiple disorders from a single blood 
spot punch.
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1.3.2.2 Galactosaemia
Galactosaemia is an inherited autosomal recessive disorder caused by a deficiency of the 
enzyme galactose-1-phosphate uridyltransferase (GALT). This enzyme acts as a catalyst 
for the production of glucose-1-phosphate and uridyldiphosphate from galactose-1- 
phosphate and UPD-glucose. In the United Kingdom the incidence of galactosaemia is 
around 1:44,000 while, in Japan the incidence of newborn babies affected by 
galactosaemia is 1:667,000 (reviewed by Seymour et al., 1997).
Various clinical symptoms appear in individuals affected with this disorder, for instance, 
jaundice, hepatosplenomegaly, and cataracts, which manifest themselves in the few days 
following the birth of a baby. Individuals affected with galactosaemia are also more 
susceptible to infections, amino acidaemia and albuminuria. Cirrhosis of the liver which 
can lead to liver failure and death results from the severe form of galactosaemia (reviewed 
by Seymour et al., 1997). The early symptoms of galactosaemia can be resolved by 
excluding glucose from the diet, and this is the basis of the initial management o f the 
disorder.
To detect galactosaemia, neonatal dried blood spot screening can be employed alone, or 
combined with galactose-1-phosphate levels. Schickling and his colleagues (reviewed by 
Seymour et al., 1997) conducted a study which involved the screening of 350,000 
newborn babies. Their results demonstrated that the use of colorimetric enzymatic micro 
assay for galactose and galactose-1-phosphate had a false-positive rate of 0.028%, of 
which 40 % were compound hetrozygotes and were associated mainly with the Duarte 
variant. However, this study did not show any false negatives, and also demonstrated that 
the test is inexpensive to carry out.
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Thibodeau and his co-workers (reviewed by Seymour et al., 1997) conducted another 
study in which they screened 299,420 newborn babies using the Beutler assay to 
determine GALT activity alone. This study also reported no false negatives, and revealed 
a false-positive rate which averaged 0.16% over 3 years. However, certain disadvantages 
to employing the Beutler assay were demonstrated in this study; for instance, humidity 
and temperature affected the assay during transportation of the blood spots, and, in 
addition, the method was affected by the degree o f drying o f the blood spots. 
Galactosaemia screening has been abandoned in the UK as a clinical diagnosis was often 
made before the newborn screening result was available. However, a raised phenylalanine 
level secondary to liver damage may be detected by MSMS.
1.3.2.3 Congenital hypothyroidism (CHT)
The thyroid gland is one of the large endocrine glands located in the middle o f the lower 
neck, below the larynx. The function of the thyroid gland is to regulate the rate of body 
metabolism and developmental function in other body systems, through secreting thyroxin 
(T4) and triiodothyronine (T3) hormones. In addition, there is another important function 
of thyroid hormone, which is the development of the central nervous system. Congenital 
hypothyroidism can be found in many countries all over the world (Park and Chatterjee, 
2005).
CHT is one of most important and prevalent disorders which affect newborn babies. It 
occurs sporadically and the incidence rate of this disorder is around 1 in 3000 to 4000 live 
births. CHT can cause mental retardation due to the failure of the thyroid gland to grow if 
the patient is not treated with an adequate thyroxin supplement. In addition, iodine 
deficiency can cause CHT in areas where iodine is not present in adequate quantities. 
However, in areas where iodine is present in adequate amounts, CHT is caused by a defect
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or dysfunction of the thyroid gland. The thyroid gland may well be present, be it large or 
small, but production of the thyroid hormone is reduced (hypoplastic) or absent 
(athyreosis) in CHT patients. In certain cases these abnormal glands are the result of 
genetic defects such as iodine trapping defect, thyrotropin resistance, thyroglobulin, and 
iodotyrosine deiodinase deficiency. In some cases, however, there is no identifiable cause 
for the dysfunction (Park and Chatterjee, 2005). In certain cases, hypothyroidism detected 
by screening may be transient. This is usually due to the presence of maternal antibodies 
which temporarily impair thyroid function for a few weeks.
CHT symptoms vary considerably from one patient to another. Some have no clinical sign 
at 5 days which may be due to the extent of thyroid hormone deficiency and the length of 
time the body has been deprived of the thyroid hormone. Infants bom with CHT which is 
left untreated will suffer from various illnesses, which can include constipation, 
hypothermia, umbilical hernia, growth retardation and jaundice. However, most children 
bom with congenital hypothyroidism and treated with thyroxin grow and develop 
normally in all respects (Rastogi and LaFranchi, 2010).
A number of clinical laboratory tests are available to screen for CHT, for example, fluoro- 
immunoassay (FIA), (ELISA) and (RIA) (Rose and Brown, 2006).
1.3.2.4 Sickle Cell Disorder (SCD)
Sickle-cell anaemia belongs to a group of genetic diseases known as 
haemoglobinopathies, which can be passed on to children by their parents via the 
recessive pattern of inheritance. SCD is more prevalent in certain ethnic groups, such as 
in tropics and sub-tropical, areas. Due to global migration, the disease has now spread to 
other parts of the world. The seriousness o f its symptoms means that SCD requires
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specialized treatment and critical care. The economic and psychosocial aspects of SCD 
therefore put great pressure not only on affected individuals, but also on their families and 
the wider community.
SCD is a type o f anaemia characterized by the presence o f haemoglobin S (Hb S). Under a 
microscope, red blood cells appear crescent-shaped instead of round biconcave cells. SCD 
is prevalent in Africa, and also in Central America and the Middle East. Affected 
individuals look pale with swollen hands and feet, and they are more susceptible to 
respiratory infections. In severe cases, it can be fatal. Early diagnosis and treatment with 
prophylactic penicillin reduces morbidity and mortality (Hoffbrand and Pettit, 1993).
This disease is cased by a point mutation in the amino-acid at position 6 of the beta globin 
chain which leads to the substitution of the amino-acid valine for glutamic acid. SCD is a 
recessive disease; that is, it is passed on by parents, both of whom have one gene for sickle 
haemoglobin and one normal allele. Numerous other variants have been identified which 
are associated with a range of clinical severity e.g. HbC, Hb, HbDPunjab, HbE. The life 
span of a normal blood cell is approximately one hundred and twenty days, whereas a 
sickle cell stays viable for only about twenty days, and because of this short life span the 
bone marrow cannot reproduce sufficient blood cells, eventually resulting in anaemia 
(Hoffbrand and Pettit, 1993).
SCD can be diagnosed by haemoglobin electrophoresis test, which identifies the particular
types of haemoglobin, that is, haemoglobin A and F (adult and foetal) and any variants. A
provisional diagnosis can be achieved by carrying out full blood count (FBC). This
measures the status of several features of the blood, for example, the number of red blood
cells in the blood and the amount of haemoglobin; the percentage of blood cells as a
proportion o f the total blood volume; the average amount of haemoglobin in the red blood
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corpuscles; the volume of red blood cells; the number of white blood cells, and the 
percentages of the various types of these, as well as the number of platelets. Hence, the 
presence of anaemia can be revealed by an FBC. Reticulocyte count can also be employed 
in testing for sickle cell anaemia (Hoffbrand and Pettit, 1993).
SCD screening is usually carried out by biochemical techniques such as electrophoresis on 
cellulose acetate (CA), isoelectric focusing (IEF), high performance liquid 
chromatography (HPLC) and DNA methods. These techniques are the most commonly 
used methods to detect variant haemoglobin worldwide. The limitation of the 
electrophoretic methods is that they are manual, labour-intensive procedures. The 
advantage of using the HPLC technique is that it provides an automated and quantitative 
analysis, and requires only a small sample, while its disadvantage is that it is unable to 
detect ‘fast-moving’ variants e.g. HbBarts Both methods have high sensitivity and 
specificity rate (Clark and Thein, 2004).
1.3.2.5 Congenital adrenal hyperplasia (CAH)
CAH is an inherited recessive disorder which is caused by a deficiency in one of the 
important enzymes required for the synthesis of cortisol in the adrenal cortex. Deficiency 
o f the 21-Hydroxylase enzyme is the most frequent cause, and accounts for about 95 % of 
all cases affected with CAH (van der Kamp and Wit, 2004).
The screening test for CAH disorder is performed using filter paper blood spots obtained 
by heel puncture during the fifth day after the birth of the baby. The metabolite 17- 
hydroxy progesterone (17-OHP) is then assayed using one of the following techniques. 
First, there is the ELISA assay used in Japan, second, the RIA which is used in the United 
States, and third, the FIA used in Europe. It has been found that there is a significant 
variation in the cut-off levels from one programme to another. These differences are due
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to the characteristics of the reference population (birth weight and gestational age), while 
other variations are due to the varying thicknesses of the filter paper employed and the 
different antibodies and reagents which are used (van der Kamp and Wit, 2004).
Immunoassay tests for 17-OHP are generally known to produce high false positive rates. 
Another method has been developed, the steroid profiling method, which uses liquid 
chromatography tandem mass spectrometry (LC-MS/MS) on blood spots to determine 17- 
OHP, androstenedion and cortisol simultaneously, This method can identify the false 
positive results often found in newborn screening for CAH (Lacey et al., 2004).
1.3.2.6 Medium Chain Acyl-CoA Dehydrogenase Deficiency 
(MCADD)
Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) is a common 
disorder that causes a defect in mitochondrial p-oxidation. In genetics, the MCADD gene 
is located on chromosome 1 at position p31; the most common MCADD mutation is 
A985G. It is inherited as an autosomal recessive pattern (Wang et al., 1999).
Deficiency of MCADD, occurring in 1:15 000 (Hsu et al., 2008), is a key enzyme 
involved in the metabolism o f mitochondrial fatty acids. The bodies of those affected with 
MCADD cannot metabolise certain fats of medium chain length (C6-C14) into energy. 
This may occur during a period o f fasting where glucose stores are depleted, and so 
individuals with this disease should avoid fasting (Hsu et al., 2008).
The symptoms of MCADD vary from patient to patient, with signs generally appearing 
after a period of fasting. In severe cases, the disease may lead to hypoglycaemia or acute 
encephalopathy. Symptoms include clamminess of skin, fever, fatigue; diarrhoea,
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behavioural changes and vomiting, and these symptoms may appear in infants or young 
children (Kompare and Rizzo, 2008).
Individuals affected with MCADD can be detected through tandem mass spectrometry 
(MS/MS). Blood spot samples are collected and then analysed to detect abnormal 
accumulation of C8 (Kompare and Rizzo, 2008). A positive result is confirmed by a DNA 
mutation test. The MS/MS technique is suitable for a large-scale analysis. Today MS/MS 
is used in many countries such as the USA, UK and Australia for newborn screening 
programmes.
1.3.3 Screening for Cystic Fibrosis
Newborn screening for CF is a recent addition to screening programmes in many countries 
including UK based on the analysis of bloodspot immunoreactive trypsinogen (IRT). 
Elevated levels of IRT are associated with CF. The use of sensitive immunoassays 
methods (e.g. DELFIA) to measure IRT followed by DNA mutation analysis and/or a 
sweat chloride test are required to confirm or exclude the presence of CF. However 
specificity is poor with a relatively large number of false positives. Other screening 
markers which could help reduce the false positive rate would be useful.
1.3.3.1 Genetics of CF
The cystic fibrosis transmembrane conductance regulator (CFTR) gene, which consists of 
27 coding exons spanning over 250 kb on chromosome 7q31.2, with a transcript of 6.5 kb, 
was cloned in 1989 (Kerem et al., 1989; Rommens et al., 1989; Riordan et al., 1989). A 
3- base pair (bp) deletion is the most widespread CF mutation and leads to phenylalanine 
loss at position 508 o f the protein (F508del). The CFTR gene encodes a protein forming 
the chloride (C1-) channel in the apical membrane of exocrine epithelial cells and contains 
1480 amino acids, with a molecular weight of ~170kDa.
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More than 1000 mutations have been identified (Ahmed et al., 2003). F508 del is found in 
about 70% of the CF chromosomes worldwide, although its frequency varies considerably 
among different ethnic groups, ranging between 100% in the Danish Faroe Islands to 18% 
in Tunisia (Hodson, et al., 2007). The gradient in the frequency of F508del diminishes 
notably from northeast to southwest Europe. The majority of the other mutations are 
uncommon, with only 11 being found in over 100 patients. However, there is a high 
incidence of a number of the other uncommon mutations in isolated populations (Hodson 
et al., 2007) (Table 1.6).
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Table 1-6: Incidence of CFTR mutations other than AF508 with high incidence in specific 
populations (Hodson et al., 2007).
Mutation Frequency (%) in specific population Frequency (%) in 
the general 
population
Q359K/T360K Georgian Jews (88)
M1101K Hutterite Brethren (69)
S549K United Arab Emirates (61.5)
W1282X Ashkenazi Jews (48) 
Tunisian Jews (17) 
Israeli Arabs (10.6)
1.2
405+1 G—>A Tunisian Jews (48) 
Libyan Jews (18)
3120 +1G—>A Bantu, Africa (46.4)
South African (17.4)
African American, USA (13.9) 
African American, Africa (12.2) 
Saudi Arabia (10)
N1303K Egyptian Jews (33) 
Israeli Arabs (21) 
Algeria (20) 
Lebanon (10)
1.3
G85E Turkish Jews (30)
1898+5G—>T Taiwan (30)
394deITT Finland (28.8) 
Estonia(13.3)
6 2 1 + lG ^ T Saguenay Lac-Saint-Jean, Canada (24.3) 
Northern Greece (12.1)
0.7
Y122X Reunion Island (24)
3905insT Amish, Mennonite (16.7) 
Switzerland (9.8)
Y569D Pakistani, UK (15.4)
T338I Italy, Sardinia (15.1)
1548deIG Saudi Arabia (15)
R553X Switzerland (14) 0.7
3120+lkb del8.6kb Israeli Arabs (13)
I1234V Saudi Arabia (13)
R347P Turkish population, Bulgaria (11.7) 0.2
Q98X Pakistani, UK (11.5)
G542X South Spain (11.4) 2.4
711+1G—>T Algeria(lO)
4010del4 Lebanon (10)
R1162X Northeast Italy (9.8) 0.3
1525— 1G->A Pakistani, UK (9.6)
*The mutations are listed in a decreasing order of their frequency (in the case of more than 
one population, the frequency was listed according to the highest).
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1.3.3.2 Clinical Characteristics of CF
CF is an autosomal recessive disorder that leads to a shortened lifespan unless it is treated 
with appropriate medication sufficiently early. It is a disorder that involves severe 
pulmonary and gastrointestinal manifestations and it is found in approximately one in 
every 2,000 to one in every 3,500 Caucasians bom in Europe. In North America and 
Hawaii it occurs in one in every 8,400 births to Hispanics, one in every 89,000 births to 
the Asian population of Hawaiian-Americans and the rate among African-Americans is 
one in every 15,000 births (Rodrigues et al., 2008). CF shows considerable heterogeneity 
and often there are no clinical signs apparent at birth.
All the body’s exocrine glands are affected by CF, resulting in the production of abnormal 
mucus. Mucus acts in the body to lubricate and protect the lining of several organs; for 
example, the lungs and stomach. However, due to the thickness and viscosity of the 
mucus of CF patients, they are subject to bacterial infections. Bronchiolar obstruction and 
pulmonary infection eventually lead to damage to the lungs (Proesmans et al., 2008).
In addition, the pancreatic ducts in the digestive system are blocked by this viscous 
mucus, which can lead to hepatic cirrhosis, intestinal obstruction, steatorrhoea, 
malnutrition, diarrhoea, and meconium ileus. This symptom last is often the first 
indication of CF. Furthermore, CF can be the cause of growth problems and male 
infertility, which manifest themselves in late childhood or early adulthood (Proesmans et 
al., 2008).
1.3.3.3 Treatment of CF
There is currently no cure for cystic fibrosis. The treatment strategy is based primarily on 
the treatment of lung infections, loosening and removing the thick and sticky mucus from 
the lungs, by physical therapy, antibiotic medication, and exercise. Chest physiotherapy
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(CPT) is an essential part of treatment patient affected with CF. CPT helps to improve 
ventilation and mucociliary clearance secretions (Fauroux et al., 1999). Exercise is 
important for CF patients, as it prevents deterioration of the lungs as well as being good 
for overall physical condition (Wilkes et al., 2009). Many patients with cystic fibrosis are 
malnourished when diagnosed. Nutritional therapy provides strength and improves 
growth. The nutritional therapy includes supplements of vitamins A, E, D, and K, oral 
pancreatic enzymes, a high-salt diet or salt supplements (Sinaasappel et al., 2002). Other 
medication includes antibiotics, and anti-inflammatories. These medicines may be inhaled 
or oral. Treatment of end-stage organ disease, such as heart-lung transplant may be an 
option (Proesmans et al., 2008).
A large study in Wisconsin, USA examined the impact of newborn screening on clinical 
outcomes in children with CF (Farrell et al., 1997). A total o f 650,341 newborn infants 
were screened for cystic fibrosis by measuring immunoreactive trypsinogen on dried 
blood spots between April 1985 and June 1991 or, between July 1991 and June 1994, by 
the trypsinogen test combined with DNA analysis. Cystic fibrosis was diagnosed in 74 of 
the 325,171 infants in the early-diagnosis group. Nutritional status was evaluated using 
anthropometric and biochemical methods for up to ten years in 56 of the infants in the 
early-diagnosis group and in 40 of those in the control group, who had been diagnosed by 
standard methods. Study result showed that the early-diagnosis group had considerably 
higher height and weight percentiles and a higher head-circumference percentile at the 
time of diagnosis. In the follow-up period, the infants in the early-diagnosis group also 
had appreciably higher anthropometric indexes. It was concluded that newborn screening 
and early treatment offer the opportunity to prevent malnutrition in infants with cystic 
fibrosis (Farrell et al., 1997).
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1.3.3.4 Gestational Characteristics of CF
CF is a disorder which affects most organs o f the body. The main affected parts are the 
lungs and pancreas but it can also affect the liver, reproductive organs and sweat glands. 
About 59 % of affected newborn babes and 90 % of those with one year of age have 
pancreatic insufficiencies which result in poor growth and malnutrition in the first few 
weeks of the baby's life and into child hood (Bronstein et al., 1992). The function of the 
placenta is to provide the infant with the nutrients required during pregnancy (Rama and 
Jagannadha Rao, 2003). These nutrients come from the mother through the umbilical cord. 
CFTR gene function is an ion channel across the cell membrane, and any alteration on this 
gene may cause alteration in placental function. Two studies (Faller et al., 1995; Mylona 
et al., 1996) demonstrate that CFTR is present in the human placental tissue, and it has 
been suggested that any defect in the function o f the CFTR protein in the placenta will 
affect the baby’s health, for instance by premature birth or low birth weight.
It has been shown that there is reduced birth weight in newborns with CF compared with 
normal healthy babies. This was demonstrated a cohort study carried out in the Florence 
region of Italy in 2005 by (Festini et al., 2005) over a period of 11 years, through studies 
of gestational and neonatal characteristics of children with CF.
1.4 NEWBORN SCREENING MARKERS FOR CF
1.4.1 Immuno reactive trypsinogen (IRT)
IRT is a pancreatic product found to be elevated in the majority of babies bom with CF 
(Crossley et al., 1979). IRT is one of the secretory products o f the human pancreas. 
Pancreas acinar cells produce two major isoenzymes of enzymatically inactive 
trypsinogen which are activated to trypsin upon cleavage of a hexapeptide from the N-
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terminus (Paju and Stenman, 2006). Trypsinogen is the major form in the blood and the 
AutoDELFIA Neonatal IRT Kit only measures the major forms. In CF newborns, the IRT 
level increase is probably caused by a blockage of the ductile secretions in the pancreas 
(Crossley et al., 1979).
1.4.2 Pancreatitis Associated Protein (PAP)
It was in 1984 that Keim and his group first discovered the biochemical marker pancreatic 
associated protein (PAP) in the secretory protein of rat pancreatic juice (Keim et al., 
1984). PAP is a 16 kDa protein and in 1992 its human orthologue was identified from the 
pancreatic juice of diabetic patients who had kidney and pancreas transplantation (Keim et 
al., 1984). PAP was found to be greatly over-expressed in the pancreas during acute 
pancreatic disease and to remain expressed for about 3 to 4 days following pancreatitis 
(Closa et al., 2007).
PAP expression takes place in the pancreatic acinar cells in response to many injuries for 
example, hypoxia, toxins, diabetes, transplanted tissues, lipopolysaccharides, acute and 
chronic pancreatitis. The physiological role of PAP in the pancreas and other organs is still 
a matter of debate. Several studies have shown that PAP has certain physiological 
activities; for example, anti-inflammatory, anti-apoptotic, anti-bacterial and proliferative 
effects (Closa et al., 2007). PAP expression can be found in other organs, such as in the 
primary hepatocarcinomas in the liver; in the uterus, particularly in the luminal epithelial 
cells; chronic inflammation in the intestine as a result o f Crohn’s disease; and in the brain 
tissue of patients with Alzheimer’s disease (Closa et al., 2007).
Recent pilot studies in France (Sarles et al., 2005) measuring PAP in addition to IRT, 
suggest that a combination o f IRT and PAP measurements can identify infants for follow-
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up testing with improved sensitivity and specificity. Where bloodspot analysis gives both 
IRT >50 ng/ml and PAP >1.0 ng/ml it is proposed that mutation testing can be avoided 
and diagnoses confirmed by sweat test alone. These data have been obtained in bloodspot 
specimens collected at 3 days of age. If this can be confirmed in other studies on 
specimens taken at 5 days o f age (as in UK) and different protocols for combining PAP 
and IRT are explored, this may offer the potential to reduce the false positive rate 
associated with CF/DNA screening.
1.4.3 Sweat Tests
A sweat test is a confirmatory test used in newborns suspected of having CF. Babies 
affected with CF produce larger quantities of sweat chloride than unaffected babies. The 
method used to measure the sweat in the babies is to put pilocarpine, which is a chemical 
causing the skin to produce sweat, on a small area o f the arm or leg and then place an 
electrode on the skin at two points. A weak electric current is then applied to help to draw 
the pilocarpine into the skin where it stimulates the sweat glands to produce sweat. The 
test area is cleaned and dried and absorbent filter paper which soaks up the sweat is placed 
on the skin. The filter paper is removed after 30 minutes and is then sent to the laboratory 
to determine the sodium and chloride concentrations (Hodson et al., 2007).
1.4.4 Faecal Elastase
Human elastase was first described in 1950 (Balo and Banga, 1950) and characterised in 
1975 by Mallory and Travis as protease E. (Mallory and Travis, 1975). In the pancreas, 
human elastase is synthesised by the acinar cells. Human elastase is composed of 240 
amino acids with a molecular weight o f 26 kd. Human elastase has a special affinity for 
the carboxyl groups o f alanine, valine and lecine (Dominguez-Munoz et al., 1995; 
Sziegoleit et al., 1989).
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Faecal elastase 1 (FE1) concentration level in the pancreatic juices ranges between 170 
and 360 pg/ml, representing about 6% of all secreted pancreatic enzymes. FE1 is bound 
to bile salts without degradation during the intestinal passage. FE1 is concentrated about 
five-fold to six-fold, as water is reabsorbed, making FE1 easer to measure in the stool 
(Sziegoleit, 1984). FE1 is stable for a wide range of pH and can be stored for 5 days at 
room temperature without influencing immunological quantification in the stool 
(Nandhakumar and Green, 2010).
1.4.5 Prenatal Screening for CF (Couple Screening)
Prior to the Wisconsin study which provided evidence to justify neonatal screening for 
CF, a number o f prenatal screening programmes were started based on the identification 
of specific DNA mutations in one or both members of a couple. If both were found to be 
carriers, prenatal diagnosis could be offered. This give couples the choice of avoiding the 
birth of a child with CF through selective termination of affected foetuses.
There has been considerable debate about the suitability and design of antenatal screening 
programmes for CF. Some geneticists support the view that CF screening programmes in 
pregnancy should include the woman’s partner if she gives a positive carrier result in the 
DNA test. In contrast, other geneticists suggest that screening programmes for CF during 
pregnancy will place an unacceptable burden o f decision-making on the couples 
concerned.
There are two types of antenatal screening programme; the first is a two-step screening 
programme which tests women first, and if a woman is found to be a positive carrier for 
CF her partner will be also tested for CF alleles. The second model of testing is the
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“couple” model. In this model both partners should agree to participate before laboratory 
analysis starts (Wald and Leek, 2000).
A prenatal screening programme has been offered in the Edinburgh Maternity Hospital 
and is a good example of a two-step screening model (Mennie et al., 1992). In this model 
information about the CF disorder and prenatal screening is sent to the pregnant women in 
a specially designed leaflet, along with the antenatal clinic appointment. The test is based 
on extraction of DNA from a buccal swab followed by mutation analysis for a panel of the 
most common mutations.
If the pregnant woman is found to be a positive carrier for a CF allele, her partner is also 
tested for CF alleles. If he is also a carrier, they will have 1 chance in 4 of having a child 
affected with CF disease. Where both are carriers prenatal diagnosis is offered to the 
pregnant woman to discover the status of the foetus. If the foetus is affected a couple may 
decide to terminate the pregnancy. If she is a carrier and her partner is negative, no further 
action will be taken.
The two-step model does have certain disadvantages, such as the anxiety evoked for a 
carrier partner, while they wait for the result o f the status of the other, to determine 
whether they are both carriers or not. The second problem is that the appointment at the 
antenatal clinic may well be too late to allow the required action to be taken in the first 
trimester of pregnancy. To solve this dilemma, it has been suggested that a heterozygote 
test should be offered to women at the time when they have a positive pregnancy test 
(Mennie et al., 1992).Significant cost would be incurred using this approach in the whole 
pregnant population.
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Time is very important in the antenatal screening programme and the test must be 
conducted early enough to give the couples sufficient time to think about taking the 
decision to terminate the foetus or not. Screening during pregnancy can be argued to be 
the most effective process for CF screening programmes as it avoids the birth of an 
affected child. On the other hand, early detection of CF through newborn screening and 
the introduction of well designed treatment regimes can reduce the burden of CF disease 
in affected children.
1.5 GESTATIONAL MARKERS OF CF
Antenatal screening programmes and newborn screening programmes both have the same 
goal, which is to identify individuals at risk of diseases. Antenatal screening aims to 
provide couples with reproductive choice, e.g. termination of the foetus if the mother is 
found to be pregnant with an untreatable disorder. Hence, prenatal diagnosis for CF can be 
offered to discover whether the foetus is affected or not. While this can be carried out by 
offering carrier screening by mutation analysis to parents and the analysis of CVS from at 
risk pregnancies, it would be of interest to study the effect o f CF on the physiology of 
pregnancy. This latter approach may provide a non-invasive method of assigning the risk 
of CF in the foetus.
Several maternal serum markers have been shown to be linked to a variety of adverse 
outcomes in pregnancy. Among these are alpha-fetoprotein (AFP), pregnancy-associated 
plasma protein (PAPP-A), Human chronic gonadtrophin (hCG), Free phCG, 
Unconjugated estriol (UE3) and Inhibin-A. Serum concentrations of these markers show 
various changes in the case o f low birth weight, early delivery, pre-eclampsia, 
spontaneous preterm birth, and still birth (Muttukrishna et al., 1997; Smith et al., 2002; 
Smith et al., 2004; Smith, et al. 2006). It is not known if any o f these markers which are
3 5
synthesised or transported by the placenta may show changes in pregnancies in which the 
foetus is affected by CF.
1.5.1 Alpha-fetoprotein (AFP)
AFP is synthesised by the embryonic yolk sac cells and subsequently by the foetal liver 
(Tomasi, 1977). Several studies have suggested that AFP is synthesised by villous tissue 
in the first trimester of pregnancy (Lafuste et al., 2002)
AFP levels in the foetus increase up to 13 weeks of gestation to reach a maximum level 
and then decrease to term. During the second trimester of pregnancy, the AFP level 
present in amniotic fluid is about 1% of the foetal serum levels, and in maternal serum, 
AFP levels increase to a peak at 32 weeks of gestation (reviewed by Newby et al., 2005).
The function of the placenta is to provide the infant with the nutrients required during 
pregnancy. AFP reaches the maternal circulation from the foetal circulation across the 
placenta and from the amniotic fluid across the foetal membranes and decidua (review by 
Newby, et al., 2005). CFTR gene function is an ion channel across the cell membrane 
(Welsh and Smith, 1993), and any alteration on this gene may lead to changes in the 
tissues that produce mucus, sweat, saliva and tears. Moreover, it has been proposed that 
any defect in the function of the CFTR protein in the placenta may have an effect on the 
health of the infant; for example, by premature birth or low birth weight. However, the 
physiological mechanism of AFP interchange between foetus and maternal circulation 
remains unclear and it is not known if maternal serum AFP levels are affected when the 
foetus has CF.
Any variation in AFP from the normal concentration level in the maternal circulation 
during pregnancy indicates a complication in the pregnancy; for example, AFP
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concentration levels increase in amniotic fluid and maternal serum with foetal 
malformation, in particular neural tube defects (Ryynanen, et al., 1983). In the second 
trimester, the maternal serum level of AFP concentration is decreased in pregnancies 
affected by foetal Down syndrome (Cuckle et al., 1984; Merkatz et al., 1984; Tabor et al., 
1984).
1.5.2 Human Chorionic Gonadotrophin (HCG)
HCG is member of the glycoprotein hormone (GPH) family that also includes leutinizing 
hormone (LH), follicle stimulating hormone (FSH) and thyroid stimulating hormone 
(TSH). GPHs are heterodimers consisting of an a-subunit and a P-subunit which are non- 
covalently bound to each other. The a-subunit is nearly identical to other glycoprotein 
hormones such as TSH, FSH and LH.
HCG has a molecular weight of 36,000 -  46,000 Da. hCG is synthesised in the 
syncytiotrophoblast cells (Albertini et al., 1982). HCG is found in various tissues of 
human body; for instance, the uterus, lungs, pancreas, pituitary glands, gonads, placenta 
and foetal membranes (Braunsteins et al., 1979).
The corpus luteum plays an important role in the production of oestrogen and 
progesterone. The function of hCG is to maintain the progesterone production of the 
corpus luteum during early pregnancy, a function it shares with LH. In addition, its other 
functions include stimulating steroidogenesis in the placenta (Keay, et al., 2004).
In early pregnancy, to determine whether the women is pregnant or not, hCG is used as a 
chemical marker in pregnancy tests (Hussa, 1982). At 6-8 days after conception, hCG will 
appear in the serum and reach a peak level 9-10 weeks after the last menstrual period.
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In the second trimester, increased hCG levels in maternal serum levels have been found to 
be linked with foetal Down syndrome (Bogart et al., 1987) but it is not known if maternal 
serum hCG levels are altered when the foetus has CF.
1.5.3 Pregnancy-Associated Plasma Protein A (PAPP-A)
Pregnancy-Associated Plasma Protein A (PAPP-A) is secreted from the trophoblastic 
tissue of placenta. It is a glycoprotein with a structural gene located in chromosome 9. 
During a normal pregnancy, PAPP-A increases rapidly in the first trimester, and then 
increases at a lower rate in the second trimester. However, in pregnancies affected by 
Down syndrome, PAPP-A concentration is decreased and this effect in more marked in 
the first trimester than in the second trimester (Fialova and Malbohan, 2002).
PAPP-A is used in the Down syndrome screening protocol as an additional marker for the 
identification of pregnancies at high risk of the condition. In addition, PAPP-A has been 
found to decrease on average in pregnancies affected with Trisomy 18, acute coronary 
syndromes and Cornelia de Lange syndrome (Fialova and Malbohan, 2002) and it is not 
known if maternal serum PAPP-A levels are affected when the foetus has CF.
1.5.4 Free Beta Human Chorionic Gonadotrophin (FfHCG).
If the foetus is affected with Down syndrome, the F|3hCG level is found to be elevated in 
1st and 2nd trimesters of pregnancy (Cuckle, 1996; Wald, et al., 1996). F(3hCG with other 
biochemical markers such as AFP and uE3 with maternal age are effective methods in 
prenatal screening for Down syndrome in the second trimester (Cuckle, 1996). This 
marker can also be found to be elevated during the first trimester of pregnancies where a 
foetus is affected with Down syndrome (Macri, et al., 1993). It is not known if maternal 
serum FphCG level are affected when the foetus has CF.
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1.5.5 Unconjugated Estriol (UE3)
Unconjugated estriol (UE3) is a steroid hormone synthesised by the placenta from the 
foetal precursor molecule, 16 alpha-hydroxy-dehydroepiandrosteronesulphate (16 a-OH 
DHEAS). UE3 concentration has been shown to be lower in pregnant women with a 
Down syndrome foetus (Jorgensen and Trolle, 1972). It is not known if the UE3 level of 
maternal serum is affected when the foetus has CF.
1.5.6 Inhibin-A
Inhibin is glycoprotein produced by gonads and placental tissues. Inhibins are divided into 
two subunits, a  and (3. The p subunit is divided into form pA and pB, to form Inhibin-A or 
Inhibin-B (Aitken, et al., 1996). Inhibin-A concentration level increases in the second 
trimester and shows elevation in DS pregnancies (Van Lith et al., 1992). Inhibin A levels 
have been reported as elevated in pregnancies with pre-eclampsia (Cuckle et al., 1998). It 
is not known if maternal serum Inhibin-A level are affected when the foetus has CF.
Data on the above markers are available for a proportion of pregnant women in the west of 
Scotland who opt for prenatal screening for Down syndrome and neural tube defects 
through the regional prenatal screening programme. In this study, the outcome of these 
pregnancies will be audited to identify any case of cystic fibrosis and to make a 
comparison of the level of each marker in the CF and unaffected pregnancies.
1.6 NEWBORN SCREENING PROTOCOLS FOR CF
Currently, various protocols are used in CF screening programmes, with each having its 
advantages and disadvantages.
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1.6.1 IRT/IRT Protocol
These programmes use the IRT marker as a primary test. If it is found to be elevated e.g > 
99th centile of the normal range in dried blood spots, confirmation of this elevation will 
be obtained by repetition of the test on a second dried blood sample. If both samples show 
elevated IRT, a sweat test is used to confirm a diagnosis.
The advantages to using the IRT/IRT protocol without using a DNA test are that its 
specificity and sensitivity are good in the second sample test and carriers are not detected. 
However, its disadvantages are poor specificity in the first sample test leading to a 
relatively high number of repeated blood spot samples, which leads to increasing the 
anxiety of the baby’s family, and a high sweat test rate for definitive diagnosis (Wilcken, 
2007).
1.6.2 IRT/DNA/IRT Protocol
The Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene was identified 
in 1989 (Riordan et al., 1989), and since then many mutations have been identified 
contributing to the diagnosis of the CF. Delta F508 is the most common mutation for CF 
in the Northern European Caucasian population and is included in all mutation panels used 
in the diagnosis of CF.
This protocol is used in several countries around world. First, an IRT sample test is carried 
out and if elevated (i.e. above a chosen cut off e.g. 60 ng/ml), a repeat IRT on the same 
card is carried out in duplicate. If the mean o f all 3 tests shows a high level of the marker 
(> 99.5th centile), a further blood spot sample is used for DNA analysis to test for the 
common mutation AF508, as well as for other selected CF mutations, depending on the
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ethnic mix of the population. The DNA test is performed with the same dried blood spots. 
If two mutations are identified, the baby is diagnosed as having CF, while if  only one 
mutation is identified, the baby either has CF due to the presence of a second unidentified 
mutation (which can be revealed by sequencing) or may be a carrier for the disease. A 
further bloodspot sample is taken at around 21-30 days o f age where there is an initial 
raised IRT and one mutation. Depending on the result an extended mutation test panel and 
/ or a sweat test are used to provide a definitive diagnosis.
The advantages of using IRT/DNA/IRT compared with IRT/IRT are increased positive 
predictive value (PPV), a reduction in the number of sweat test analyses and good 
sensitivity and specificity. The disadvantages of this strategy are the detection of CF 
carriers, and missing CF in certain ethnic groups. CF carrier detection poses significant 
reporting problems and may lead to genetic counselling and cascade testing in families 
(Wilcken, 2007).
1.6.3 IRT/PAP Protocol
Various studies have indicated that PAP concentration level is elevated in the blood of 
newborn babies affected with CF. Sarles and his group (Sarles et al., 2005) investigated 
the use of a combination of PAP and IRT as a screening protocol in newborn babies in 
France. Over 200,000 babies in five regions in France were screened for CF using the PAP 
test in parallel with the routine IRT test. Using two different combinations of PAP and 
IRT cut off values, they showed that the addition of PAP measurement in dried blood 
spots for screening newborn babies for CF gave the same performances as the IRT / DNA 
protocol but without the need for DNA mutation analysis. The protocol advantage is the 
reducing workload and cost associated with avoiding of DNA mutation analysis and 
consequently no detection of CF carriers. The disadvantage of this approach is that PAP
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testing is carried out in all newborn babies in addition to IRT. This significantly raises the 
cost of the primary screening test which is unlikely to be offset by the reduction in DNA 
mutation testing.
1.7 AIMS
Programmes with the purpose of screening for and detecting particular conditions in 
unborn children and neonates are not a recent innovation. Nonetheless, the tests for certain 
conditions are not sufficiently sensitive or specific and their predictive value is low. For 
instance, it is possible for bloodspot screening for cystic fibrosis may fail to identify 
affected infants or may identify carriers, who are not the intended target of screening.
1. Newborn Bloodspot Screening 
Research Question
Is the sensitivity and specificity of blood spot screening for CF improved when an 
additional screening marker, PAP, is used in combination with an existing marker (IRT)? 
Specifically:
1. Can the rate of detection of affected infants be maintained or improved?
2. Can the rate of carrier detection be reduced by the addition of PAP measurements?
3. Can the requirement for DNA analysis for confirmation of a diagnosis of CF be reduced 
by the addition of PAP measurements?
2. Prenatal Maternal Serum Screening
Research Question: Does the measurement of a range of maternal serum markers in 
samples from women carrying a child with CF have any predictive value for the birth of 
an affected child?
Specifically:
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1. Are there any concentration changes in the maternal serum markers AFP, hCG, PAPP- 
A, Free |3-hCG, UE3 or Inhibin-A which may be predictive of a CF pregnancy?
2. Are there any other gestational characteristics (low birth weight and prematurity) which 
are associated with CF pregnancies?
4 3
CHAPTER 2 : 
MATERIALS
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2.1 Subjects
Two types of samples were used in the study. First, dried blood spot samples were 
examined from babies with cystic fibrosis (CF) to determine whether pancreatitis- 
associated protein (PAP) in combination with immuno-reactive trypsinogen (IRT) can 
improve the sensitivity and specificity of CF screening and reduce the amount of DNA 
testing required to confirm a diagnosis of CF.
Second, maternal serum samples from mothers of children affected with CF were studied 
for variations in the concentration of the range of serum markers known to be associated 
with adverse outcomes of pregnancy in order to determine whether they have any 
predicative value for CF.
2.2 Dried Blood Sample
The Scottish Neonatal Screening Programme started in 1965. Around sixty thousand dried 
blood spots (on Guthrie cards) are received annually from all regions of Scotland by mail. 
The programme aims to test newborn babies for phenylketonuria (PKU), congenital 
hypothyroidism (CHT) and cystic fibrosis (CF) in the early stage of the baby's life to allow 
the affected infants to be treated appropriately. In October 2010, screening for SCD and 
MCADD was added. Many types of filter paper cards are used for newborn screening; for 
example, Schleicher & Schuell # 903, Whatman BFC180, and Toyo Roshi 545. The filter 
paper type used in the Scottish programme is the SNS 903.The design of the card is shown 
in Figures 2.1 and 2.2. The blood spot card includes basic details of the baby on the front 
and on the reverse of the card (table 2- 1).
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Table 2-1: Demographic information requested on the dried blood spot card
Baby’s information Baby’s surname 
Baby’s first name
Mother’s or baby’s alternative surname (not maiden)
Address
Post Code
Place of Birth
Baby’s date of birth
Gender
Gest. Age at Birth 
Birth weight 
Ancestry
G.P.’s Name
G.P.’s Address
G.P.’s information G.P.’s Practice Code
Mother bom in UK
Mother’s date o f birth
Date of first full milk feed
Breast
Type of feed at blood spot
Mother’s information Milk Formula
collection
Other
Date Specimen Taken
Specimen taken by
Specimen information Contact Telephone Number
Hospital
Premature
Is the baby in On Antibiotics
Other information Blood transfusion; if yes,
Has baby had a date of last transfusion
Drug therapy
Comments, e.g. Family history
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Five circles are presented on the absorbent part o f the card to receive the blood spots. The 
heel is punctured with a lancet or similar device and the blood allowed to flow within the 
area o f each circle. Layering should be avoided. The spots are allowed to dry and can then 
be safely sent to the laboratory by post. The standard method for collecting the blood spots 
is summarised on the reverse of the card and include the following instructions:
Baby’s heel needs to be warm.
Clean and dry, then squeeze skin taut
Puncture firmly in area shown, wait for drop to form, wipe away first drop and then obtain 
the second large hanging drop, collect one drop onto centre of circle and for the other 
remaining circles.
Allow the card to air dry before placing in glassine bag and then immediately post in pre­
paid envelope.
On the back o f the card the baby’s ancestry code is described in (Table 2.2).
Table 2-2: Baby’s ancestry code description
Ancestry Code Description
A British/Irish
White C Any other White background
D White and Black Caribbean
E White and Black African
Mixed White and AsianF
G Any other mixed background
H Indian
J Pakistani
Asian BangladeshiK
L Any other Asian background
M Caribbean
Black N African
P Any other Black background
R Chinese
Other S Any other ethnic category
z Not stated
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Blood spots are generally collected on day five (ideally within a range of 5-8 days) of the 
baby’s life. The demographic information required on the card should be completed at the 
time of collection. Following analysis, all negative screening results and any repeat 
specimens are required to be notified to the Department of Child Health for the area where 
the child was bom, within 48 hours. Positive screening results are reported by telephone to 
the appropriate paediatrician /child health department within 24 hours.
CF screening in Scotland based on the measurement of IRT is carried out in the Newborn 
Screening Laboratory in the Biochemical Genetics Department, Yorkhill Hospital, and 
Glasgow. For this study, blood spots for pancreatitis associated protein (PAP) evaluation 
were obtained by punching an extra dried blood spot from all samples showing an 
elevated IRT level (i.e. > 70 ng /ml). In addition, 4 dried blood spots received before, and 
another 4 dried blood samples received after each card with an increased IRT were used as 
controls. Moreover, extra dried blood samples were taken from 189 babies bom with low 
birth weight and from 182 babies bom prematurely (< 37 weeks of gestation).
The sample discs of 3.2 mm in diameter are punched out using a semi-automated 
punching machine (multi-puncher, PerkinElmer). (Figure 2.3). When the cards are 
punched, it is important to select cards with both sides of the spots filled with blood to 
ensure accuracy of the analysis. All the punched dried blood spots were then collected in 
Eppendorf tubes and stored in a freezer at minus 20°C, pending analysis.
A review of the available blood spots with elevated IRT showed that there were 314 
available, along with 2886 controls, plus 189 from premature and 182 from low birth 
weight babies. There were 29 identified CF cases and 32 CF carriers. Therefore, the total 
study samples were 3632 blood spots (Table 2.3).
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Figure 2-1: The front of the blood spot card used in the Scottish screening programme.
Figure 2-2: The reverse of the blood spot card used in the Scottish screening programme
Figure 2-3: Semi-automated bloodspot multi-puncher used in the Scottish screening 
programme.
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Table 2-3: Summary of the bloodspot specimens used in the study.
Blood sample groups Number of blood spot samples
Control samples 2886
Increased IRT 314
Premature 189
Low birth 182
CF cases 29
CF carriers 32
Total 3632
2.3 Retrospective IRT Study for CF Affected Babies
All 198 babies affected with CF identified by the routine newborn screening programme 
in Scotland between 2003 and December 2010 were reviewed. Homozygosity for the 
common delta F508 mutation was found in 88 , with another 110 having various other 
combinations o f mutations. All cases were gathered from the records o f the Biochemical 
Genetics Department. The IRT concentration levels were identified for each o f the babies 
with CF. The IRT median for the cases with common delta F508 mutation and that for the 
cases with one o f the various other mutations were analysed using the SPSS statistics 
programme.
2.4 Retrospective IRT Study for CF Carriers
The IRT concentration levels were identified for all CF carrier babies bom  during the 
period 2003 December 2010. From the total number o f these babies, 148 babies with the 
common delta F508 mutation and another 82 with other mutations were identified, making 
230 babies in all with either delta F508 or one o f several other mutations. The data were
obtained from the Biochemical Genetics Department records. The SPSS statistics 
programme was used to analyse the IRT medians for the common delta F508 cases and the 
cases with different mutations.
2.5 Maternal Serum
The Duncan Guthrie Institute o f Medical Genetics, Biochemical Genetics Department, at 
Yorkhill Hospital provides a prenatal screening service for Down syndrome (DS) and 
neural tube defects (NTD) for pregnant women in the west o f Scotland. The screening test 
is based on the measurements o f several maternal serum markers and the aim is to give an 
estimate o f the likelihood that a foetus will be affected with Down syndrome (DS) or 
neural tube defect (NTD).
Blood samples (5-10mls) were collected at the antenatal clinic during the first (11-13 
weeks) or second trimester (15-20 weeks), for prenatal screening. All samples were sent 
to the Biochemical Genetics department for the measurement o f alpha-fetoprotein (AFP), 
human chronic gonadotrophin (hCG), free P-human chorionic gonadotropin (P-hCG), 
pregnancy-associated plasma protein A (PAPP-A), unconjugated oestriol UE3, and 
inhibin-A as appropriate.
Collected blood samples received at the Biochemical Genetics department were labelled 
with a laboratory number and aliquot o f serum was separated by centrifugation and used 
for analysis. Samples were assigned different coloured forms. Yellow forms for second 
trimester hCG,AFP screening for DS, green forms for 1st trimester Free p-hCG and 
PAPP-A screening for DS and white forms for 2nd trimester AFP screening for NTD. The 
remainder o f  the serum, about 1-3 mis, was stored in numbered tubes in a freezer at -20 °C
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and details o f each sample were entered in a computerised data base (Lifecycle Laboratory 
Information Management System).
To identify the blood samples for the study, a series o f pregnant women who had given 
birth to a baby affected with CF were identified by cross-checks with the prenatal 
screening database, which contains information on the mother’s name, address, and date 
o f birth. Another database was constructed for affected babies, identified by cross-checks 
with the newborn screening database, which contains information on the baby's name, 
address and date o f birth, as well as the mother’s name and date o f birth. This was 
followed by matching all the information o f mothers and their CF-affected babies and 
transferring all the matched information to a single database containing all the basic 
information on the mothers and their affected babies.
A study group o f 55 women with CF pregnancies was found and the corresponding serum 
samples recovered from frozen storage. An additional 330 pregnancies, both second 
trimester (15-20 weeks) and first trimester cases (10-13 weeks) were randomly selected as 
controls. All the samples together were transferred and arranged in a special tray and kept 
at minus 20 °C until analysis (table 2.4).
A number o f samples o f both first and second trimester cases were rejected for various 
reasons, including there being an insufficient volume o f blood to give an adequate volume 
for assay (<0 .4ml serum) or no identification on the sample tube, or haemolysed sample.
At the time o f analysis, serum samples were recovered from frozen storage, allowed to
thaw at room temperature, and vortex mixed. The samples were then labelled with
computer-generated lab numbers to identify each sample, together with matching
computer-generated bar codes on the aliquot for assay.
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CHAPTER 3 : METHODS
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3.1 NEWBORN MARKER MEASUREMENTS
The current routine newborn screening test for CF is based on the measurement o f 
immunoreactive trypsinogen (IRT) using the Delfia fluoroimmunoassay method (Perkin 
Elmer, Finland). In this study pancreatitis-associated protein (PAP) was also measured 
using a commercially-available enzyme linked immunoassay (Dynabio SA, Marseilles, 
France). The results from tandem mass spectrometry (MS/MS) testing for PKU in 
neonates measuring phenylalanine (PHE) and tyrosine (TYR) were also available.
3.1.1 Measurement of Immunoreactive Trypsinogen (IRT)
IRT is a pancreatic product found to be elevated in the majority o f babies affected with 
CF. Where the initial IRT level is > 60 ng /ml, the test will be repeated within the 
laboratory in duplicate using blood from the same card and if  the mean o f these 3 results is 
less than 70ng /ml, CF is not suspected. Faecal contamination may be suspected when 
there is large variation between the 3 individual IRT levels. When results o f 70 ng /ml or 
above are found, the dried blood sample is sent to the Molecular Genetics lab for CFTR 
mutation analyses. During the course o f this study, a DNA diagnostic kit containing a 
panel o f 30 o f the most frequent mutations was used (CV-kit V.3, Tepnel Diagnostics).
In the DNA lab, if  two mutations are found, CF is diagnosed and a telephone call is made 
to the nominated CF physician and a letter sent to Child Health Department, the CF 
physician, G.P. and hospital. If  no mutation is detected and the baby is o f Caucasian 
ethnicity, the report will be that CF is not suspected, but if  the child is from a non- 
Caucasian ethnic group, there will be a request for a repeat o f the sample at day 27 o f the 
baby’s life.
When only one mutation is detected, this indicates a probable carrier but it is possible that 
it may be a case o f  CF as another rare (untested) mutation might be present. The routine
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procedure is to request another sample to be taken at day 27 o f the baby’s life. If  the result 
is 60ng/ml or above the report will be that there is a high risk o f  CF, and a sweat test and 
genetic counselling will be required. If the result is less than 60ng/ml, the report will be 
that there is one mutation carrier and that genetic counselling should be offered (Figure 
3.1).
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Initial IRT test
White
Caucasian
Other
ethnic
No mutation identified
Result o f  less than 
60 ng/ml
Result o f  less than 
60 ng/ml
Result o f  60 ng/ml 
Or above
Report as cystic 
fibrosis not suspected
Report one mutation 
carrier - offer genetic 
counselling
Two mutations 
identified, CF 
diagnosed
Result o f  less than 70ng / ml
Result o f 60ng /ml and above
Retest within the laboratory 
in duplicate
Report: Ethnic group 
CF not suspected 
Possible carrier
Sent for DNA analysis 
for 30-mutation screen
One mutation identified -  carrier 
or possible case o f  CF
Result o f  70 ng/ml or 
above
Report: high risk 
CF- sweat test 
Genetic counselling
Request repeat letter sent to Child 
Health (specimen to be taken at 
27 days o f  life)
Telephone call to 
nominated CF 
physician; letters to 
Child Health Dept., 
CF physician, G.P 
and hospital
Figure 3-1: Flowchart explaining the CF protocol for Scottish newborn babies.
3.1.2 Principle of IRT assay
The AutoDELFIA fluoroimmunometric assay system was used to measure IRT in 
newborn samples. This system is based on a direct sandwich technique which utilises two 
monoclonal antibodies directed against different epitopes on the IRT molecule. The first 
anti-IRT monoclonal is coated on to the wells o f microtitre plates. Blood spots are 
punched into each well and the IRT in the sample binds to the monoclonal antibodies and 
is immobilised. Europium (Eu) labelled anti-IRT IgG is then added to the reaction, which 
binds to a different epitopic site on the IRT molecule. After incubation, this is washed to 
remove unbound Eu-labeled IRT IgG and excess sample eluate. The addition o f an 
enhancement solution, which is an acidic chelating detergent, dissociates Europium ions 
from labelled antibodies into a solution where they form fluorescent chelates with 
components o f the enhancement solution. The fluorescence is proportional to the quantity 
of IRT in the sample (Figure 3.2). The analysis is semi-automated using the AutoDELFIA 
immunoassay analyser.
B lo o d  s p o t  
s a m p le
o I n c u b a t i o n )
E u - la b e le d  
a n t i - I R T  Ig G
I R T
m o le c u le
c o a te d  w e l l  w i t h  
a n t i - I R T  Ig G
Fluorescence
Measurement
Figure 3-2: AutoDELFIA IRT principle of the assay.
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3.1.3 Measurement of Pancreatitis-Associated Protein (PAP)
3.1.3.1 Blood Spot Samples
Over the course o f the study, PAP was measured prospectively in dried blood spots from a 
total o f 3632 samples. There were 2886 infants with normal IRT (<70 ng/ml) and 314 
infants with elevated IRT (>70 ng/ml). In addition, samples from low birth weight babies 
(< 2,500g) (total 189), samples from premature babies (< 37 weeks gestation) (total 182), 
samples from confirmed CF cases (total 29), and samples from CF carriers (total 32) were 
tested. In addition there was one bloodspot sample from a child with a confirmed 
diagnosis o f  CF which had a low level o f IRT (20 ng/ml) and had therefore been missed 
by screening. Four dried blood spots received before and another four dried blood samples 
received after each spot with an increase in IRT were used as controls (total 2886).
The sample discs o f 3.2 mm in diameter were punched out using a semi-automated 
punching machine (multi-puncher, PerkinElmer). The punched spots were selected from 
cards with both sides o f the spots filled with blood. All the punched dried blood spots 
were then put in small, labelled tubes and stored in a freezer at -20°C, pending analysis.
3.1.3.2 Plate Map
Microtitration plates coated with anti-PAP antibodies were divided into 8 sections, each 
section containing 9 wells, one for the dried blood sample, with known elevated IRT 
levels, and the other 8 wells for the control dried blood spots. The plate map also 
contained two wells, one for a sample from a baby already known to have low birth 
weight and another for a premature baby (Figure 3.3).
Seventy-four samples were run in each assay, 8 o f which were samples known to have 
elevated IRT, with the remaining 66 being matched as control samples. In the plate, 12
wells were used for the standard solutions, 8 wells for quality control sera and 2 wells for 
the blanks.
3.1.3.3 PAP Assay
An enzyme-linked immunoassay (ELISA sandwich) was used for the analysis o f the dried 
blood samples using the MucoPAP kit, (manufactured by DYNABIO France). Punched 
dried blood spots from labelled tubes were placed in the wells o f 96-well U-bottom plates 
according to the plate map, to which 150 ul o f PBS buffer is added.
Sixteen hours were then allowed for the elution o f the blood spots at 4°C, and then the 
standard prepared from freeze-dried recombinant PAP (rhPAP), was reconstituted with 
487pl volume H2O to obtain a solution o f 4 ng/ml. The standard solution concentrations 
used to construct the standard curve were: 0.0075, 0.015, 0.03, 0.06, 0.125 and 0.25 ng/ml 
(Figure 3.4).
The control serum was reconstituted with 800 pi H2O to obtain a solution o f 2.4ng/ml. 
The high value was 1.2ng/ml and the low value control was 0.15ng/ml. Using an 
electronic multichannel pipette, 100 pi o f the samples were deposited in the 96-well 
microtitration plate coated with anti-PAP antibodies (lOOpl/well), followed by 3h 
incubation at room temperature. After washing, the biotinylated antibody (lOOpl/well) was 
distributed, and then incubated for 30 min at room temperature . After 4 washes, Avidin- 
POD (lOOpl/well) was allocated, and then incubated for 15 min at room temperature, 
followed by distribution o f the substrate-chromogen after washes and incubation o f the 
plate for 10-15 min in the dark. The reaction was then stopped with H2SO4 (lOOpl/well). 
The absorbance o f the wells was read by a spectrophotometric plate reader at 450nm with 
a 630 nm filter used as a reference (figure 3.5). PAP concentrations in eluates must be 
multiplied by a factor o f 65 to obtain PAP blood concentrations. The factor 65 was
6 0
calculated because the 3.2 mm punched card corresponds to 3.1 pi o f blood with the 
dilution being 3.1/200=1/65.
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Figure 3-3: Plate protocol for blood spot samples. Wells 1-2 are blanks; 3-14 are standards, 
15 ,16 ,17 ,18 , 93, 94, 95, 96 are controls. Wells R1-R8 contain blood spots from babies with  
elevated IRT plus matched controls, P contain premature blood spot sam ple and L is low  
birth weight sample.
61
LEUEL 5.M :EUflLUfSTE:STD. CURUE 42 HPflP
2.6
X-AXIS
2 . 4 -
conc : LIN/LOG 
s c a l e  :2 .2-
2 . 0 -
1.8- r e s p  : B(bound)  
s c a l e  :1 .6-
1 . 4 -
FITTING ALGORITHM
1.2
SPLINE SMOOTHED
1 .0 -
coiic  : LOG 
r e s p  : B(bound)
0 .8-
0 .6 -
0 . 4 -
0 . 2 -
0 .0 5  0 . 1  0 . 20.02
Figure 3-4: Example of PAP experiment standard curve.
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Figure 3-5: An enzyme-linked immunoassay for PAP: principle of the assay.
3.1.4 Measurement of Phenylalanine (PHE) and Tyrosine (TYR)
In Scotland, as in the majority o f developed countries, newborn babies are screened for 
phenylketonuria (PKU) by measuring the PHE and TYR levels in dried blood spots (DBS) 
of capillary blood obtained from heel pricks.
Testing for PHE and TYR levels is conducted by a simplified form o f liquid 
chromatography tandem mass spectrometry (LC MS/MS). DBS from patients are punched 
into 96-well microtitre plates with a semi-automated ‘multi-puncher’. The DBS are then 
eluted on a plate shaker for 30 minutes, using methanol which also contains a known 
concentration o f internal standards for both PHE and TYR. These internal standards are 
isotopomers, which vary in mass from the native species by several Daltons (Da).
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A regulated flow o f mobile phase is provided by a liquid chromatography (LC) pump. An 
automated sample manager injects a 20ul aliquot of eluent from one o f the microtitre plate 
wells into the mobile phase, which then ‘carries’ this aliquot into the MS/MS for analysis.
3.1.4.1 Method of Operation
The DBS o f every patient is identified by a unique barcode as it is punched into the 
microtitre plate, using a Perkin Elmer ‘MultiPuncher’. This data then goes to a system 
server computer where it is entered into a daily sample list template to be downloaded 
onto the PC controlling the MS/MS. With the daily worklist set up on this PC, and the 
extracted microtitre plates having been loaded, a syringe on the sample manager (Waters 
2777) transfers the 20ul aliquot by loop injection into the mobile phase (80% Acetonitrile: 
20% water + 0.1% Formic Acid). Before the next sample, the syringe goes through several 
wash steps in order to avoid carry-over.
The MS/MS (Waters Micromass QuattroMicro API tandem mass spectrometer) has five 
separate components (see also Figure 3.6):
1. The ESI and ion source
2. MS 1: the first quadrupole analyser
3. Collision cell
4. MS2: the second quadrupole analyser
5. The ion detector
The mobile phase, with the patient sample, enters an ElectroSpray where the dissolved 
analytes undergo Electro Spray Ionisation (ESI) into a highly charged electric field (3kV). 
The ions are pulled into the instrument through a small-aperture sample cone in the ion 
source (1) by a combination o f opposite charge on this cone and the high vacuum inside 
the MS/MS. This ion stream is electromagnetically focussed into an ion ‘beam ’ and passes
through M SI, the first quadrupole analyser (2). Quadrupoles can be tuned so that only 
ions with a specific mass-to-charge ratio (m/z) will pass through with a stable trajectory, 
while all others will be dispersed out o f the sides.
After passing through M SI, a given ionic species then enters the collision cell (3) 
containing a low density o f an inert gas, generally argon (Ar), where individual ions 
collide with the gas atoms and fragment in a process known as collision induced 
dissociation (CID). This process o f fragmentation is predictable and consistent for each 
molecular species and results in product, or ‘daughter’, ions with a known and specific 
m/z.
The product ions then enter the MS2, second quadrupole (4), which is tuned to allow 
through only the principle daughter ion o f interest. These ‘final’ product ions then enter 
the Ion Detector (5) for measurement.
The mass filtering settings o f M SI and MS2 are combined in such as way that MS2 will 
scan, at any given point in time, only for the specific daughter ions derived from the ionic 
species that M SI is tuned to allow through (the precursor or ‘parent’ ions). This process, 
known as multiple reaction monitoring (MRM) (4 channel), is repeated for each ionic 
species o f interest, in this case PHE, TYR and their respective internal standards. As the 
internal standards are o f a known concentration, the response from these species can be 
compared to that o f the native species and employed to calculate their relative 
concentrations.
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3.2 Gestational Characteristics o f CF Pregnancies
3.2.1 Serum Marker
AFP, HCG, PAPP-A and free pHCG were measured using the Dissociation Enhanced 
Lanthanide Fluro Immuno Assay method (DELFIA). The analyses were automated using 
the AutoDELFIA system, which consists o f two main units that are linked together 
(Figure 3.7). First, the sample processor is responsible for transferring aliquots o f maternal 
serum samples and carrying out any dilutions as necessary. Second, the plate processor is 
responsible for carrying out reagent dispensing, shaking the microtitre plate, washing, and 
measurement o f analyte concentration. In addition, an external PC with Windows has a 
user guide which controls the setting up o f the assay and loading and processing o f 
samples. The WIACALC programme on Multicalc 2000 and SPSS statistical progamme 
were used to determine the result. The unconjugated estriol (UE3) and inhibin-A (Inhibin- 
A) assay were carried out on the Access 2 immunoassay system manufactured by 
Beckman Coulter, as shown in Figure 3.8.
M t r f i
Figure 3-7: AutoDELFIA system for maternal serum screening sample
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3.2.2 AutoDELFIA Immunoassay System Theory of Operation
The AutoDELFIA immunoassay system theory of operation is started with 
Step 1: Pipetting
• 4 sampling probes equipped with liquid level and clot detection aspirate sample 
aliquots and dispense them into microtitre plates.
• Buffer and tracer are added using two dispensers 
Step 2: Incubation
• Plates are then incubated at 25°C. The system can access any plate if  required 
during incubation time.
Step 3: Add enhancement solution
• After incubation, plates are withdrawn from the shaker for the washing step 
followed by adding enhancement solution to each well
Step4: Measurements
• Plate then moved to instruments fluorometer for measurement 
Step 5: Calculate results
• Result then calculated using MultiCalc software program.
Figure 3-8: Access 2 immunoassay system.
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3.2.3 The Access 2 Immunoassay System Theory of Operation
The Access 2 immunoassay system theory o f operation is started with 
Step 1: Pipetting
• Reaction vessel (RV) containing samples in which estriol and inhibin-A are to be 
measured is moved from RV to pipetting position
Step 2: Incubation
•  RV containing estriol and inhibin-A moves from pipetting position to incubator 
belt
Step 3: Washing
• After incubation RV moves to wash position on wash /read carousel 
Step 4: Substrate Addition
• RV containing estriol and inhibin-A moves from wash position to substrate 
addition position
Step 5: Washing
• RV moves from substrate to luminometer position 
Step 6: Ejection
•  RV containing estriol and inhibin-A moves from luminometer position to 
incubator .belt and then ejected into RV waste bag
3.2.4 Measurement of AFP
The AutoDELFIA fluoroimmunometric assay system was used to measure human alpha- 
fetoprotein (AFP) in maternal serum samples. The method is based on a direct sandwich 
technique which utilises two monoclonal antibodies directed against different epitopes on 
the AFP molecule. The first anti-AFP monoclonal is coated onto the wells o f microtitre 
plates. Serum samples are added to the plates and the AFP in the sample binds to the 
monoclonal antibodies and is immobilised. Eu-labeled anti-AFP IgG is then added to the
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reaction, which binds to a different epitopic site on the AFP molecule. After incubation, 
the plate this is washed to remove unbound Eu-labeled AFP IgG and excess maternal 
serum. The addition o f an enhancement solution, which is an acidic chelating detergent, 
dissociates Europium ions from labelled antibodies into a solution where they form 
fluorescent chelates with components o f the enhancement solution. The fluorescence is 
proportional to the quantity o f AFP in the serum sample (Figure 3.9).
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Figure 3-9: AutoDELFIA AFP: principle of the assay.
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3.2.5 Measurement of HCG
The AutoDELFIA fluoroimmunometric assay system is used to measure human hCG in 
maternal serum samples. The system is based on the direct sandwich principle where two 
monoclonal antibodies directed against different sites on the (3- and a  hCG subunits are 
used. Serum samples containing hCG are added to the wells o f a microtitre plate coated 
with an anti-phCG monoclonal antibody. This binds the dimeric hCG molecules present in 
the serum. Then, Eu-labelled anti-a hCG IgG is added to the reaction, which binds to the 
second epitopic site o f the a  subunit o f the immobilised hCG molecule. After the second 
incubation, the plate is washed to remove unbound Eu-labelled anti-ahCG IgG and 
maternal serum containing the hCG molecule. The addition o f enhancement solution, 
which is an acidic chelating detergent, dissociates europium ions from labelled antibodies 
in a solution where they form fluorescent chelates with components o f the enhancement 
solution. The fluorescence is proportional to the quantity o f hCG in the serum sample 
(Figure 3.10).
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Figure 3-10: AutoDELFIA hCG: principle of the assay.
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3.2.6 Measurement of PAPP-A
PAPP-A is found in serum complexed 2 :2 with proMBP. As proMBP is present at 5-10 
times the concentration o f PAPP-A an assay specific for PAPP-A which does not cross 
react with proMBP is required.
The AutoDELFIA fluoroimmunometric assay system is used to measure PAPP-A in 
maternal serum. The system is based on the indirect sandwich technique. In the first 
incubation, a microtitre plate well coated with streptavidin reacts with biotin-labelled anti- 
PAPP-A IgG. The microtitration strips are then washed, and in the second incubation, 
standards, controls and maternal serum samples containing PAPP-A molecules are reacted 
with tracer antibodies labelled with chelates o f europium. Then, the addition o f 
enhancement solution dissociates europium ions from labelled antibodies producing a 
solution where they form fluorescent chelates. The fluorescence is proportional to the 
quantity o f PAPP-A in the serum sample (Figure 3.11).
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Figure 3-11: AutoDELFIA PAPP-A: principle of the assay.
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3.2.7 Measurement of FfHCG
The AutoDELFIA fluoroimmunometric assay system was used to measure free beta 
subunit o f hCG in maternal serum samples. The system is based on the direct sandwich 
principle. Two monoclonal antibodies detected against different epitopes on the P subunit 
are used. The first antibody is immobilised on the surface o f the wells o f a microtitre plate. 
Serum is added to the wells and the free P subunit present in the samples binds to the 
monoclonal antibodies. After washing, a second samarium-(Sm) labelled anti-beta subunit 
antibody is added to the wells and binds to the second epitopic site on the immobilised p- 
subunit molecule. After incubation, the plate is washed to remove unbound Sm-labelled- 
anti-hCG IgG and maternal serum containing the phCG molecule. The addition o f 
enhancement solution, which is an acidic chelating detergent, dissociates samarium ions 
from labelled antibodies into a solution where they form fluorescent chelates with 
components o f the enhancement solution. The fluorescence is proportional to the quantity 
of FphCG in the serum sample (Figure 3.12).
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Figure 3-12: AutoDELFIA FphCG: principle of the assay.
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3.2.8 Measurement of UE3
The Access 2 immunoassay system manufactured by Beckman Coulter was used to 
measure UE3. The Access UE3 assay is 1-step competitive binding technique assay. 
Rabbit anti-estriol polyclonal antibodies are reacted with serum samples containing estriol, 
an estriol-alkaline phosphatase conjugate and paramagnetic particles coated with goat anti­
rabbit IgG. After incubation at 36.5 °C for 20 minutes, maternal serum samples containing 
estriol compete with estriol-alkaline phosphatase conjugate for a limited number o f 
binding sites on the specific anti-estriol antibody. Bound materials are held in a magnetic 
field while unbound materials are washed away. Light generated by the reaction after 
adding the substrate is measured with a luminometer. Estriol concentration in the maternal 
serum sample is inversely proportional to the light production (Figure 3.13).
Estriol-alkaline
phosphatase
conjugate
Maternal sample 
containing estriol
Rabbit an ti-estriol PAb Param agnetic particles 
coated with goat 
anti-rabbit IgG
Wash 3 tim esIncubation
Competitive
binding
Incubation
Dioxetane-PAdd substra te Dioxetane Detect light
Figure 3-13: Access 2 uncongealed estriol principles.
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3.2.9 Measurement of Inhibin-A
The Access 2 immunoassay system, manufactured by Beckman Coulter was used to 
measure Inhibin-A. The Access Inhibin-A assay is a 2-step sandwich technique assay. 
Serum samples containing Inhibin-A are reacted with paramagnetic particles coupled an 
with anti-Inhibin-A monoclonal antibody. After incubation at —36 °C for 19 minutes 
followed by a wash step to remove excess sample and reagents, an anti-inhibin, 
monoclonal antibody-alkaline phosphatase conjugate is added to a reaction mixture and 
incubated at ~36 °C for 15 minutes. Bound materials are held in a magnetic field while 
unbound materials are washed away. Light generated by the reaction after adding the 
substrate is measured with a luminometer. The inhibin-A concentration in the maternal 
serum sample is directly proportional to the light production (Figure 3.14).
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Paramagnetic particles 
coated with m ouse anti- 
Inhibin A M AB
+ W a s h  3  t im e s
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MAb a lk a lin e  
p h o s p h a ta s e  c o n ju g a te
S a n d w ic h
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Figure 3-14: Inhibin-A principle of the assay
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3.3 Statistical Methods
Descriptive statistics are used to organise and summarise data. Inferential statistics are 
used to test one set o f data against another or generalise from a sample to a larger group.
3.3.1 Descriptive Statistics
3.3.1.1 Mean
The mean is used to measure the central location but is influenced by outliers. The mean is 
calculated by adding up all the values and dividing this sum by the number o f data points. 
Means were calculated using the SPSS v l5  program.
3.3.1.2 Percentiles
Percentiles are described as the value below which a certain percentage o f observations 
fall. For instance, the 90th percentile is the value below which 90% o f the values fall. 
SPSS 15 was used to calculate percentiles.
3.3.1.3 Standard Deviation
The standard deviation (SD) is the measure o f the spread o f the data from the mean. A 
small SD indicates the tendency o f the values to be closer to the mean while a large SD 
indicates that the values in the dataset are a spread further away from the mean. SD was 
calculated using the following equations:
(1) SD= / £ ( * /  “ * ) 2 or (2) logio (90th centile) -  logio (10th centile)
V n ~  2 5 6
Where * the mean and n is the number o f cases. SDs were calculated using SPSS 15
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3.3.1.4 Coefficient of Variation
Assay reproducibility for all the markers in the study was measured using the coefficient 
o f variance (CV). CV represents the ratio o f the standard deviation (SD) to the mean (*  ) 
expressed as a percentage. The following equation was used to calculate the CV.
c r  = i o o x ( S N 
[ x )
3.3.1.5 Correlation Coefficient (r)
The level o f association between two variables, for example X and Y, is called the 
correlation coefficient. The r value has a range between -1 and +1. A positive value points 
to a positive correlation and a negative value points to a negative correlation. If  there is no 
association between the X and Y, the r value would be close to 0. The formula to calculate 
r value for two variables is:
where xi and yj are the values o f X and Y for the individual value. To check for outliers, a 
simple box-plot was used. SPSS 15 programme was used to calculate correlation 
coefficients.
3.3.1.6 Median
The median is calculated by arranging the data set in order from the lowest to highest 
values. The median is the middle value o f this ordered set. SPSS 15 programme was used 
to calculate the medians.
3.3.2 Inferential Statistics
3.3.2.1 Mann-Whitney Test
The Mann Whitney test is based on ranking or ordering the data from two groups. The 
data from the two groups are combined and ordered from the lowest to the highest. The 
ranks from each group are summed and the test is based on examining the sum o f the 
ranks in each group divided by the number in that group. SPSS 15 programme was used to 
calculate Mann Whitney test.
3.3.2.2 Regression Analysis
Regression analysis is used to estimate the relationships between two variables. 
Regression analysis was used to determine the relationship between IRT and PAP and 
other variables and between AFP, HCG, FBHCG, PAPP-A, UE3 and inhibin-A levels and 
gestation in weeks. To estimate the relationship between markers, various models were 
used for instance, exponential, quadratic and inverse. When choosing the best-fitted 
model, the overall fit o f the data and the adjusted r2 values were considered. This was 
done using the curve estimation routine in SPSS 15.
3.3.3 Multiple of Median of the Appropriate Gestation
All gestation-related markers levels were converted to a multiple o f the control median 
(MoM) at the appropriate gestational week. This allows changes o f marker levels with the 
gestational age to be compared PAP and IRT levels were also converted to MoM where 
appropriate. The following equation was used to calculate MoM values:
Marker concentration
MoM = ______________________ ___________________________
Regressed median concentration
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The MoM was calculated using the regression equation from the best fitted model for each 
marker.
3.3.4 Likelihood Ratios (LR) for CF Derived from IRT and PAP
The predictive value o f the data for the affected and unaffected samples was examined 
using the (LR) method. Risks are derived from the overlapping logio Gaussian 
distributions for affected babies with CF (Total 29 cases) and with unaffected babies with 
CF (Total 2886). LR were calculated for CF cases, CF carriers and increased IRT 
unaffected samples using the following equations.
LR for PAP:
<2 = (logio PAP - Mean x ) / SD x)2 
= (logio PAP -  Mean y ) / SD y)2 
LR = (SDy) / (Dx)* EXP (-0.5 * (PAP-a - PAP-b))
LR for IRT:
q  = (logio IRT -  Mean x ) / SD x)2 
I■) = (logio IRT -  Mean y ) / SD y)2 
LR = (SDy) / (SDx)* EXP (-0.5 * (IRT-a - IRT-b))
Where x = affected and y = unaffected
The overall LR from IRT and PAP was calculated using the following equation: 
IRT-LRXPAP-LR
3.3.5 EasyPlot Software
EasyPlot software (version 3.00-11) is used for scientific graphing. EasyPlot was used in 
the gestational study for drawing the curves using regression equation from the best fitted
model for each marker. In the newborn study, the EasyPlot programme was used to
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differentiate between the median for CF cases and CF carrier mutations types for both IRT 
and PAP. The programme was also used in the newborn screening study for plotting the 
overlapping logio Gaussian distribution.
CHAPTER 4 
RESULTS
4.1 NEWBORN BLOOD SPOT MARKERS OF CYSTIC 
FIBROSIS
The study o f newborn screening for cystic fibrosis using dried blood spots was designed to 
search for ways to make testing more specific and to reduce the number o f carriers 
detected through DNA testing o f screen-positive babies. The current routine newborn 
screening test is based on measurement o f immunoreactive trypsinogen (IRT) using the 
Delfia fluoroimmunoassay method (Perkin Elmer, Finland), followed by DNA analysis to 
search for mutations in the CF gene. In addition, a new marker o f CF, Pancreatitis- 
Associated Protein (PAP) was measured using a commercially-available enzyme linked 
immunoassay (Dynabio SA, Marseille, France).
Other data available from routine bloodspot screening were measurements o f 
phenylalanine (PHE) and tyrosine (TYR) by tandem mass spectrometry and these markers 
are also investigated in this sample series.
A total o f 3632 sample were used in this study, o f which 1827 (50 %) were from baby 
boys and 1791 (49%) were from baby girls. There was incomplete gender information on 
18 o f the babies.
The data is divided into 6 groups which include: control samples (total 2886), samples 
with an increased IRT level (> 70 ng ml )( total 314), samples from low birth weight 
babies (< 2,500g ) (total 189), samples from premature babies (< 37 weeks gestation ) 
(total 182), samples from confirmed CF cases (total 29 ), and samples from CF carriers 
(total 32 ).
Various types o f  information were collected to allow examination o f  the effect o f  several 
variables in each samples group. These included date o f  birth, date blood spot collected,
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gender, age at blood spot collection, the ethnic background, birth weight, length o f 
gestation, immunoreactive trypsinogen (IRT), phenylalanine (PHE), tyrosine (TYR) result 
and type o f  CF mutation. In addition, pancreatitis-associated protein (PAP) was measured 
in all blood spots and these data analysed and compared with the other marker data in each 
sample group.
4.2 Control Blood Spot Samples
Out o f 3632 blood spot samples, 2886 (79%) samples were control samples, o f which 
1465 (50 %) were boys and 1407 (48 %) were baby girls, with the gender o f the remaining 
14 samples not recorded on the dried blood spot card.
The ethnic backgrounds o f all 2886 babies in the control group were identified. Most o f 
these babies, i.e. 2528 (87 % o f the total sample) were o f white ethnic background and 244 
(8%) samples belonged to various other ethnic backgrounds. Gender information was 
missing for 6 samples (i.e., it was not recorded on the dried blood spot card) and in 108 
samples the ethnic background was not stated.
In addition, date the specimen was collected was recorded for 2886. For 2659 (91%) o f  the 
samples, the dried blood spot specimens were obtained before the tenth day o f the baby’s 
life, while 240 samples (8%), were obtained on or after day 10 o f the baby’s life. The 
lowest, highest and median values o f each marker IRT, PAP, PHE and TYR, were 
identified and are presented in table 4.1.
The frequency distribution o f the IRT, PAP, PHE and TYR levels in 2886 controls blood 
spot sample are shown in figures 4.1 -  4.4. Each o f the above marker distributions was 
positively skewed and log transformation (logio) was required to normalise the
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distributions. These are shown in figures 4.5 - 4.8. The mean and standard deviation 
values for each marker derived from the logio distributions are shown in table 4.2.
Table 4-1: The lowest, highest and median levels of IRT, PAP, PHE and TYR in 2886 blood 
spot control samples
BIOCHEMICAL NO. OF CONTROL SAMPLES
MARKERS BABIES
Lowest Highest Median
IRT (ng / m l ) 2886 3.4 71.1 19.3
PAP (ng / ml) 2886 0.001 17.517 0.192
PHE (pmol/L) 2886 25.7 179.5 56.2
TYR (fimol/L) 2886 12.9 968.4 93.8
Table 4-2: Mean and standard deviation Log10 for IRT, PAP, PHE and TYR in the blood spot
control samples
BIOCHEMICAL
MARKERS
NO. OF 
BABIES
MEDIAN MEAN
OF
LOGio
STD. 
DEVIATION OF 
LOGio
IRT (ng / m l ) 2886 19.3 1.2887 0.203
PAP (ng / ml) 2886 0.192 -0.7389 0.477
PHE (pmol/L) 2886 56.2 1.7549 0.101
TYR (pmol/L) 2886 93.8 1.9794 0.168
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Figure 4-1: Untransformed distributions of IRT concentration in 2886 unaffected newborn 
babies
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Figure 4-7: Log-transform ed distributions of PHE concentration in 2886 unaffected newborn  
babies.
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Figure 4-8: Log-transform ed distributions of TYR concentration in 2886 unaffected newborn  
babies.
All subsequent data analysis was carried out on logio transformed data.
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4.2.1 Male and Female Babies in the Control Sample
It was considered o f interest to study males and females in the control samples separately. 
Therefore, the control samples were divided into two groups. Group one comprised the 
male babies (1465) and group 2 female babies (1407).
4.2.1.1 Male Babies
Information on male birth weight was recorded for a total o f 1455 samples. O f these, 169 
(11%) had a birth weight under 2500g, while 230 (15%) weighed more than 4000g.
Gestation at birth was recorded for 1365 male babies. The maternal gestation period for 
182 (12%) o f  the baby boys in the control group was less than 37 weeks while for two 
babies it was more than 42 weeks. The shortest period o f maternal gestation was 25 
weeks and the maximum gestation period was 43 weeks. 1334 dried blood spot specimens 
were obtained in the first 10 days o f life, while 124 samples were obtained on or after day 
10.
For the 1455 baby boys in the control group, the lowest and highest and the median values 
of IRT, PAP, PHE and TYR markers were identified, and these are shown in table 4.3.
Table 4-3: Lowest, highest and median levels of IRT, PAP, PHE and TYR in baby boys in the 
control group.
Biochemical
markers
No. of 
babies
Male neonates
Lowest Highest Median
IRT (ng / m l ) 1465 3.4 66.3 18.9
PAP (ng / ml) 1465 0.002 15.06 0.17
PHE (pmol/L) 1465 28.1 179.5 56.4
TYR (pmol/L) 1465 21.7 569.1 92.3
90
4.2.1.2 Female Babies
The birth weight o f 1399 samples from female babies was recorded, while information 
was missing for 8 samples (i.e., it was not recorded on the dried blood spot card). Out o f 
these 1399 samples, 163 (11%) had a birth weight less than 2500g, while 132 (9%) 
weighed more than 4000g.
Information on the duration o f the gestation at birth was recorded for 1336. The gestation 
at birth o f 157 (11%) o f the baby girls in the control group was less than 37 weeks while 
only one baby girl in this group was bom later than 42 weeks. The shortest recorded 
period o f maternal gestation was 25 weeks and the maximum gestation period was 43 
weeks.
In 1303 (92 %)  o f  the baby girls in the control group, the dried blood spot specimens were 
obtained before 10 days o f life, while in 98 (7%) o f cases, the dried blood spot specimens 
were obtained on or after the 10th day o f the baby’s life.
Fore the 1415 baby girls in the control group, the lowest and highest and the median 
values o f IRT, PAP, PHE and TYR markers were identified, and these are shown in table 
4.4.
Table 4-4: The lowest, highest and median of levels of IRT, PAP, PHE and TYR in female 
babies in the control group
Biochemical
markers
No. of 
babies
Female neonates
Lowest Highest Median
IRT (n g /m l) 1407 3.6 71.0 19.68
PAP (ng / ml) 1407 0.001 17.516 0.20
PHE (pmol/L) 1407 25.7 152.7 55.9
TYR (pmol/L) 1407 12.9 968.4 96.07
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Median, IRT, PAP, PHE and TYR levels in both males and females were compared using 
Mann-Whitney test to see if  there are any difference between them. Female babies had 
statistically significantly higher IRT (p = 0.013), PAP (p< 0.001) and TYR values (p = 
0.047) than males. There was no statistically significant different in PHE medians in males 
and females (p = 0.280).
4.2.1.3 Variation in Blood Spot Marker Levels with Day of 
Sampling.
In the control group (2876 samples) the regression analysis at age o f sampling showed 
PAP level significant decreased (p < 0.001) with earlier age at sampling (Figure 4.10). No 
significant associations were found for IRT (p = 0.959), PHE (p=0.276) or TYR (p = 
0.249). (Figure 4.9, 4.11,4.12)
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Figure 4-9: Scatter plot with estimated regression line showing the relationship between  
IRT (log10) concentration levels in 2876 control samples at the age of sample collection.
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PHE (log10) concentration levels in 2876 control samples at the age of sample collection.
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Figure 4-12: Scatter plot with estimated regression line showing the relationship between 
TYR (log10) concentration levels in 2876 control samples at the age of sam ple collection.
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4.3 Elevated IRT Blood Spot Sample Analysis
O f 3632 blood spot samples, 314 (8%) were from infants selected on the basis o f an 
elevated IRT level and absence o f any mutation in the CF gene. O f these, 169 were from 
female infants and 144 from males. The gender o f the remaining one sample was not 
recorded on the dried blood spot card.
The following information for each infant was recorded in the project database: date o f 
birth; date sample taken; gender; ethnic background; birth weight, age when sample was 
taken, and gestation at birth. As part o f the routine newborn screening test, IRT, PHE, 
TYR results were available along with the results o f the PAP analysis.
Ethnic backgrounds o f all o f the infants with elevated IRT levels were identified. The 
majority, 269 babies, were o f white ethnic background with 45 babies from various other 
ethnic backgrounds.
The blood spot data from the samples, both male and female, were compared using a 
SPSS-generated box plot for the following markers: IRT, PAP, PHE and TYR. This 
provides a visual comparison for each marker (Figures 4.13, 4.14, 4.15, 4.16).
4.3.1 IRT
The result o f the SPSS-generated box plot for IRT o f female babies showed that 50% o f 
IRT levels were between 78 and 113 ng/ml, with a median o f 88.1 ng/ml. The highest 
value was 653.2 ng/ml and the lowest value was 70.1 ng/ml.
Regarding male babies, the IRT analysis revealed that 50% o f IRT levels were between 77 
and 120 ng/ml and the median 86.9 ng/ml. The highest value was 503.3 ng/ml and the
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lowest set value was 70 ng/ml (Figure 4.13). There was no statistically significant 
ditterence in the IRT distributions between males and females with increased IRT (p = 
0.560).
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Figure 4-13: Box plot of IRT (log10) marker for female (169 sample) and male babies 
(144 sample). Asterisks indicate extreme IRT values, while circles indicate outlier IRT 
values.
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4.3.2 PAP
The SPSS-generated box plot for PAP levels o f baby girls showed that 50% o f PAP levels 
were between 0.19 and 0.69 ng/ml, with a median o f 0.34 ng/ml. The highest value was
28.5 ng/ml and the lowest value was 0.02 ng/ml. (Figure 4.14).
The PAP observation showed that half o f the baby boys had PAP levels between 0.13 and 
0.73 ng/ml, with a median o f 0.30 ng/ml. The highest value was 13.3 ng/ml and the lowest 
value was 0.01 ng/ml. There was no statistically significant difference in the PAP 
distributions between males and females with increased IRT (p =0.109)
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Figure 4-14: Box plot of PAP (log10) marker for female (169 sample) and male babies (144 
sample). Circles indicate outlier PAP values.
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4.3.3 PHE
Regarding the PHE levels of baby girls, the PHE observation from the SPSS-generated 
box plot revealed that 50% of these were between 54 and 75 pmol/L and the median was
64.5 pmol/L. The highest value was 280 pmol/L and the lowest value was 30.1 pmol/L 
(Figure 4.15)
For baby boys, the PHE observation showed that 50% had PHE levels o f between 54 and 
78 ng/ml and the median was 65.2 pmol/L .The highest value was 155 pmol/L and the 
lowest set value was 37 pmol/L.
There was no statistically significant differences in the PHE distributions between males 
and females with increased IRT (p = 0.406).
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Figure 4-15: Box plot of PHE (log10) marker for female (169 sample) and male babies (144  
sample). Asterisks indicate extreme PHE values, while circles mark indicate outlier PHE 
values.
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4.3.4 TYR
The results o f the SPSS-generated box plot o f TYR levels in baby girls showed that 50% 
had TYR levels between 75 and 118 pmol/L and a median o f 95.5 pmol/L. The highest 
value was 422 pmol/L and the lowest recorded value was 17 pmol/L (Figure 4.16).
H alf o f the baby boys had TYR levels o f between 68 and 115 pmol/L, and the median was 
91.7 pmol/L, The highest value was 654. 5 p mol/L and the lowest recorded value was
12.5 p mol/L.
There was no statistically significant differences in the TYR distributions between males 
and females with increased IRT (p = 0.279).
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Figure 4-16: Box plot of TYR (log10) marker for female (169 sample) and male babies (144 
sample). Asterisks indicate extreme TYR values, while circles mark indicates outliers TYR  
values.
Using the Mann-Whitney test, the differences in IRT, PAP, PHE and TYR levels were 
compared in males and females within the high IRT group and with the levels ot the same 
marker in control groups.
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This showed that there is a significant difference between level o f IRT, PAP and PHE in 
the increased IRT group and level o f IRT, PAP and PHE in the control group. The median 
level o f IRT, PAP and PHE is higher in the high IRT group than the level o f IRT, PAP and 
PHE in control samples.
The p value for each marker was (p <0.001). There was no significant difference between 
level o f TYR in the increased IRT group and level o f TYR in the control group (p = 
0.427).
4.3.5 Birth Weight
The birth weight o f each o f the 314 babies in the sample was recorded. It was seen that 55 
o f these weighed less than 2500g, while 31 weighed more than 4000g.
4.3.6 Gestation at Delivery
Information on duration o f pregnancy at birth was recorded for 293 infants from the 314 
elevated IRT samples. This information was unavailable for the remaining 24 samples. 
The gestation period for 44 o f the infants in the elevated IRT group was less than 37 
weeks, while for one infant it was 43 weeks. The average maternal gestation period was 
38 weeks, and the shortest was 25 weeks. The longest was 43 weeks.
4.3.7 Age at Sampling
The age o f the infant at which the specimen was obtained was recorded for 313 o f the 314 
infants with elevated IRT. It was recorded that in 285 samples the dried blood spot 
specimens were obtained before 10 days o f life, while 28 samples were obtained on or 
after day 10 o f the baby’s life (tables 4.5 and 4.6).
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The youngest baby at the time o f taking a blood sample was 3-day-old female, bom at 32 
weeks gestation, with an IRT level o f 76.6 ng /ml and PAP level with 0.05 ng/ml. The 
oldest baby to have a blood sample taken was 91 days o f age; this was a female bom at 40 
weeks gestation, with an IRT level o f 88 ng /ml and PAP level o f 4.0ng/ ml. Figure 4.17 
and 4.18 show the levels o f IRT and PAP relative to the age o f sampling.
Table 4-5: Mean and median at age of sampling PAP in increased IRT group.
Age /days
3 4 5 6 7 8 9 > 1 0
Sex F M F M F M F M F M F M F M F M
Number 1 0 24 25 90 70 29 23 7 4 2 6 2 1 13 15
Total 1 49 160 52 11 8 3 28
Mean
PAP
(ng/ml)
Median
0.0473 0.3847 0.6236 0.5374 0.6672 0.9343 2.0536 2.6453
PAP
(ng/ml)
0.04738 0.2817 0.3073 0.3405 0.6939 0.5598 1.1766 0.9725
Table 4-6: Mean and median of IRT in increased IRT group in 313 samples in fem ale  
neonates and male neonates at the age of specimen collection.
Age
/days 3 4 5 6 7 8 9 > 1 0
Sex F M F M F M F M F M F M F M F M
Number 1 0 24 25 90 70 29 23 7 4 2 6 2 1 13 15
Total 1 49 160 52 11 8 3 28
Mean
IRT
(ng/ml)
Median
76.58 118.88 106.51 109.54 128.072 90.37 122.95 94.50
IRT
(ng/ml)
76.58 89.95 87.56 90.160 92.430 84.86 121.61 82.38
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Figure 4-17: Box plot of IRT in increased IRT (log™) group in female neonates and male 
neonates at the age of specimen collection. Asterisks indicate extreme values, while circles 
indicate outlier values.
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Figure 4-18: Box plot of PAP in increased PAP (log10) group in female neonates and male 
neonates at the age of specimen collection. Circles indicate outlier values.
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Moreover, for all 314 samples already known to have elevated IRT levels, scatter plots 
with estimated regression line showing the relationship between PAP (logio) concentration 
level and IRT, PHE and TYR levels are presented in Figures 4.19, 4.20, and 4.21.
There was a significant association between PAP and PHE (p =0.048) while no 
significant associations between PAP and IRT (p =0.656), and PAP with TYR (p =0.075) 
were found.
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Figure 4-19: Scatter plot with estimated regression line showing the relationship between  
PAP (log10) concentration level and IRT (log10) concentration level in 314 babies with  
elevated IRT.
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Figure 4-20: Scatter plot with estimated regression line showing the relationship between  
PAP (log10) concentration level and PHE (log10) concentration level in 314 babies with  
elevated IRT.
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Figure 4-21: Scatter plot with estimated regression line showing the relationship between 
PAP (log10) concentration level and TYR (log10) concentration level in 314 babies with  
elevated IRT
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4.4 PREMATURE BABIES
O f 3632 blood spot samples, 182 were from infants already known to have been bom 
prematurely (i.e., before 37 weeks o f gestation). O f these, 85 were from female infants and 
95 from males. The gender o f the two remaining samples was not recorded on the dried 
blood spot card.
The following information for each infant was recorded in the project database: date o f 
birth; date sample was taken; gender; ethnic background; birth weight, age when sample 
was taken, and duration o f gestation at birth. As part o f the routine newborn screening test, 
IRT, PHE and TYR results were available.
The ethnic backgrounds o f babies already known to have been bom  prematurely were 
identified. The majority (161) o f the babies were o f white ethnic background with 10 
babies from various other ethnic backgrounds. No ethnic back ground information was 
available for a further 10 babies.
Out o f a total o f 182 babies, the shortest recorded period o f gestation at birth was 25 
weeks and the maximum gestation period was 36 weeks. For the 182 babies, median 
values o f IRT, PAP, PHE and TYR markers were calculated for each week o f  gestation. 
Table 4.7 and 4.8 show the median levels o f the above markers and for each sex at each 
week o f gestation.
Table 4-7: Median IRT, PAP, PHE, and TYR in premature femal babies.
Gestation Number Median IRT Median PAP Median PHE Median TYR  
(weeks)_______________ (ng /m l)_____ (ng/ml)_______ Qi mol /L) Qi mol /L)
25 I 21.6 1.1 79.6 72.3
27 3 32.2 2.2 36.8 106.8
28 2 28 3.5 49 119.8
29 2 22.8 1.7 68.5 219.4
30 3 22.2 0.17 65.6 237.1
31 6 19.4 0.2 71.5 281.2
32 8 20.7 0.14 52.9 115.8
33 5 39.9 0.15 57 122.2
34 12 19.6 0.15 72 122
35 17 17.9 0.12 56.1 98.5
36 26 19.9 0.19 54.4 103.1
Table 4-8: Median IRT, PAP, PHE and TYR in premature male babies.
Gestation Number Median IRT Median PAP Median Median
(weeks) (ng /m l) (ng/ml) PHE TYR
_______________________________________________________ (li mol /L) p i mol /L)
26 1 47.2 2.1 69.5 50.5
27 1 19.2 0.17 54.8 70
28 1 33.8 0.08 53.3 136.7
29 2 32.9 2.4 41.7 175
30 6 21 1.3 60.3 162.2
31 6 21.6 0.11 58.4 123.7
32 22 22 0.13 64.1 152.8
33 9 22.9 0.10 51.9 133.4
34 9 20.1 0.27 54.5 128.3
35 17 21.5 0.18 56.7 100.7
36 21 16.6 0.20 62.5 91.2
Using the Mann-Whitney test, the differences in IRT, PAP, PHE and TYR levels were 
compared in males and females within the premature group. The data showed no statistical 
significant difference between males and females for IRT (p = 0.534), PAP (p = 0.658), 
PHE (p =0.968), and TYR (p =0.695).
In addition to discover any relationship between premature (less than 37 weeks) babies 
and levels o f IRT, PAP, PHE and TYR concentrations measured in ng/ml, a linear 
regression was performed (figure 4.22 , 4.23, 4.24, and 4.25).
All markers showed a downward trend with advancing gestation. This was statistically 
significant for IRT (p <0.001), PAP (p <0.001) and TYR (p =0.015) but not statistically 
significant for PHE (p = 0.226).
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Figure 4-22: Scatter plot with estimated regression line showing the relationship between  
>RT (log10) concentration levels in 182 premature samples and gestation at birth.
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Figure 4-23: Scatter plot with estimated regression line showing the relationship between  
PAP (log10) concentration levels in 182 premature samples and gestation at birth.
3.00- -0.005218772951839123 *X + 1.946665987288037
2.75-
2.50-
2 .25-
1.75-
1.50-
o
Gestation (weeks)
Figure 4-24: Scatter plot with estimated regression line showing the relationship between 
PHE (log10) concentration levels in 182 premature samples and gestation at birth.
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Figure 4-25: Scatter plot with estimated regression line showing the relationship between 
TYR (Iog10) concentration levels in 182 premature samples and gestation at birth.
For 152 o f the babies, the dried blood spot specimens were taken before the first 10 days 
o f life, while in another 30 dried blood spot samples were collected on or after day 10 day.
In addition, for all 182 babies known to be bom prematurely, scatter plots with an 
estimated regression line showing the relationship between the ages o f specimen and IRT, 
PAP, PHE and TYR concentration are presented (figure 4.26, 4.27, 4.28 and 4.29). 
Regression analysis showed that PAP levels decreased significantly (p < 0.001) with 
earlier age at sampling whereas there was a significant increase in the PHE level (p
114
-0 .006) associated with earlier sampling. No significant associations were found for IRT 
(p = 0.0742) and TYR (p = 0.551) with age at sampling.
The youngest baby at the time of taking a blood sample was 4 days old and the oldest 
baby to have a blood sample taken was 50 days old; the latter was a female bom at 29 
weeks gestation with IRT level o f 13.3 ng /ml and PAP level 2.2ng/ml.
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Figure 4-26: Scatter plot with estimated regression line showing the relationship between  
IRT (logio) concentration levels in 182 premature samples at the age of sam ple collection.
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Figure 4-27: Scatter plot with estimated regression line showing the relationship between  
PAP (Iog10) concentration levels in 182 premature samples at the age of sample collection.
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Figure 4-28: Scatter plot with estimated regression line showing the relationship between 
PHE (log10) concentration levels in 182 premature samples at the age of sam ple collection.
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Figure 4-29: Scatter plot with estimated regression line showing the relationship between  
TYR (log10) concentration levels in 182 premature samples at the age of sam ple collection.
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4.5 LOW BIRTH WEIGHT BABIES
O f 3632 blood spot samples, 189 were from infants known to have been bom  with low 
birth weight (less than 2500 grams). One hundred o f these were female infants, while 88 
were male. The gender o f the one remaining sample was not recorded on the dried blood 
spot card.
Date o f  birth; date sample was taken; gender; ethnic background; birth weight, age at 
sampling and; length o f gestation at birth were all recorded in the project database. IRT, 
PHE and TYR results, as part o f the routine newborn screening test, were available. In 
addition, an enzyme-linked immunoassay was used to measure pancreatitis-associated 
protein (PAP).
The ethnic backgrounds o f babies already known to have been bom  with low birth weight 
were identified. The majority (163) babies were o f white ethnic background with 16 
babies from various other ethnic backgrounds. There were 10 babies where ethnic 
background was not recorded.
From a total o f 189 low birth weight babies, the shortest recorded period o f gestation was 
25 weeks, while the maximum gestation period was 42 weeks. 136 o f the dried blood spot 
samples were from babies bom at less than 37 weeks and 44 babies were bom  at 37 weeks 
or later.
In 140 o f these babies, the dried blood spot specimens were obtained before the first 10 
days o f  age while in the other 48, the dried blood spot specimens were collected on or 
after day 10. The youngest baby was 3 days old. The oldest baby when the sample was 
collected was 59 days old.
1 1 9
IRT, PAP, PHE and TYR levels at the age o f specimen collection were analysed for all 
188 babies with low birth weight. Scatter plots with estimated regression lines showing 
the relationship between the ages o f specimen and IRT, PAP, PHE, and TYR 
.concentration level are presented in figures 4.30, 4.31, 4.32 and 4.33. Regression analysis 
showed that PAP levels in LBW babies decreased significantly with earlier sampling 
(p<0.001) (figure 4.31) while there was a significant increase in the PHE level (p = 0.001) 
associated with earlier sampling. No significant associations were found for IRT (p = 
0.187) and TYR (p =0.888) with age at sampling. These results are similar to those found 
for the same analysis in premature babies.
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Figure 4-30: Scatter plot with estimated regression line showing the relationship between  
IRT (log10) concentration levels in 189 low birth weight infant (less than 2500 gram s) and 
age at sample collection.
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Figure 4-31: Scatter plot with estimated regression line showing the relationship between  
PAP (log10) concentration levels in 189 low birth weight infant (less than 2500 grams) and 
age at sample collection.
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Figure 4-32: Scatter plot with estimated regression line showing the relationship between  
PHE (log10) concentration levels in 189 low birth weight infant (less than 2500 grams) and 
age at sam ple collection.
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Figure 4-33: Scatter plot with estimated regression line showing the relationship between 
TYR(log10) concentration levels in 189 low birth weight in infant (less than 2500 grams) and 
age at sam ple collection.
The birth weight o f all 189 babies in the sample was recorded and all missing samples 
were excluded, the lowest being recorded as 760g and the highest 2490g. To calculate the 
median for all above markers, the blood samples were divided into three groups.
The first group included all babies bom with a birth weight less than 1500 grams 
comprising 48 samples. O f these, 27 were female infants and 21 males. The median IRT 
in this group was 19.7 ng/ml, median PAP was 0.58 ng/ml, median PHE 53.3 p mol/L and 
median TYR 86.8pmol/L.
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The Second group comprised infant between 1500 to 1999 grams, and included 46 
samples. O f these, 24 were from female infants and 22 from males. The median values 
were for IRT 24 ng/ml, PAP 0.6ng/ml, PHE 58.4 p mol/L and TYR 117.4 p mol/L.
The third group included infants weighting between 2000 to 2499 grams, and consisted o f 
95 samples. O f these, 49 were from female infants and 45 from males and for one sample 
the gender is not recorded on the blood card. The median IRT was 23.4 ng/ml, PAP 0.19 
ng/ml, PHE 54.2 pmol/L and TYR 104.3 p mol/L. (Figures 4.34, 4.35, 4.36 and 4.37).
The relationship between low birth weight and levels o f IRT, PAP, PHE and TYR 
concentration was examined by linear regression. The only significant association was 
with PAP (p =0.002) where the level decreased with increasing weight. No significant 
changes were found for IRT (p =0.212), PHE (p =0.180) and TYR (p =0.436) (Figures 
4.38, 4.39, 4.40 and 4.41).
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Figure 4-34: Box plot shows the median of IRT (log10) for babies born weighing less than 
1500 grams, babies born weighing between 1500 to 1999 grams and those weighing  
between 2000 to 2499 grams. Circles indicate outlier values.
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Figure 4-35: Box plot shows the median of PAP (log™) for babies born weighing less than  
1500 grams, babies born weighing between 1500 to 1999 grams and those weighing  
between 2000 to 2499 grams. Circles indicate outlier values.
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Figure 4-36: Box plot shows the median of PHE (log10) for babies born weighing less than  
1500 grams, babies born weighing between 1500 to 1999 grams and those weighing  
between 2000 to 2499 grams. Circles indicate outlier values.
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Figure 4-37: Box plot shows the median of TYR (log10) for babies born weighing less than  
1500 grams, babies born weighing between 1500 to 1999 grams and those weighing  
between 2000 to 2499 grams. Circles indicate outlier values.
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Figure 4-38: Scatter plot with estimated regression line showing the relationship between 
IRT (log10) concentration level and low birth weight (less than 2500 grams).
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Figure 4-39: Scatter plot with estimated regression line showing the relationship between  
PAP (log10) concentration level and low birth weight (less than 2500 grams).
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Figure 4-40: Scatter plot with estimated regression line showing the relationship between 
PHE (log10) concentration level and low birth weight (less than 2500 grams).
3.00-
[y= 2.916888875043767e-005 * x + 1.963799496455513 |
o  O
O
°  o
O  Observed 
-----Linear
_2.50-
"o
E
O °  o
°  o  o  °
°  o  O °  °
°  ^  o o  QD °  °  °  0  ( ^ 0  OO
° o o  o  o o  
°  °„ <6> o  o  O o  °  Q O o  ©°0)
„  ° , ,  o °
2.00-
1—
O
o
_ l
1.50-
1.00-^
O Ofl o  o OQ o
o  o  O O ® ° °  %  °  °  1 = ^ ® °
O o  o  °  <$>o 
^  O ^  O o  o  
o  o  o  O 0 ° 0  O 0 ^ 3  o
o  °  o  <§) 
o  o  o
o
o
— 1-----------------------------1—-------------------------1-----------------------------1-----------------------------1—
500 1000 1500 2000 2500
Low birth w eight / gram s
Figure 4-41: Scatter plot with estimated regression line showing the relationship between  
TYR (log10) concentration level and low birth weight (less than 2500 grams).
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4.6 MARKER LEVELS AND ETHNICITY WITHIN EACH
SAMPLE GROUP
4.6.1 Distribution of Ethnic Groups
The ethnic background and marker level within each sample group were studied. The 
ethnic categories were: British (A) and any other white background (C), white and Black 
Caribbean (D), White and Black African (E), White and Asian (F), any other mixed 
background (G), Indian (H), Pakistani (J), Bangladeshi (K) , any other Asian background 
(L), Caribbean (M), African (N), any other Black background (P), any other ethnic group 
(S), and not stated (Z) (table 4.9).
In control samples the ethnic backgrounds o f all 2886 babies were reviewed. 2528 (87 %  
of the total sample) were o f white ethnic background and 244 (8%) samples belonged to 
various other ethnic backgrounds. Information was missing for 6 samples (i.e., it was not 
recorded on the dried blood spot card) and in 108 samples the ethnic background was not 
stated.
Ethnic backgrounds o f all o f the infants with elevated IRT levels were identified. The 
majority (269 babies) were o f white ethnic background with 42 babies from various other 
ethnic backgrounds and in 3 samples the ethnic background was not stated.
The ethnic backgrounds o f babies bom prematurely were identified. The majority (161) 
babies were o f white ethnic background with 10 babies from various other ethnic 
backgrounds. Information was missing for 1 sample (i.e., it was not recorded on the dried 
blood spot card). The ethnic background was not stated in 10 babies and information on 
one baby from total 182 was absent.
1 2 9
The ethnic backgrounds o f babies bom with low birth weight were identified. The 
majority (163) babies were o f white ethnic background with 16 babies from various other 
ethnic backgrounds. There another 8 samples where the ethnic back ground was not stated 
and information was missing for 2 samples (i.e. it was not recorded on the dried blood 
spot card).
The ethnic backgrounds o f the CF cases were as follows: 26 cases were white British (A); 
2 cases were Pakistanis in the Asian or Asian British group (J), and there was one case 
classified as Asian or Asian British or any other Asian Background (L).
Thirty o f the 32 CF carriers were of white British (A) ethnic background, while one was 
white o f  any other white background (C), and one was in the mixed race group o f  white 
and black African (E).
Table 4-9: Distribution of ethnic groups within each sample group.
Ethnic group Sample group
Controls Increased 
IRT
Prem LBW CF
Cases
CF
carrier
A & C* 2528 269 161 163 26 30
Other* * 244 42 10 16 3 2
No info /not stated 114 3 11 10 0 0
Total 2886 314 182 189 29 32
* Include: British (A) and any other white background (C).
** Include: White and Black Caribbean (D), White and Black African (E), White and 
Asian (F), any other Mixed background (G), Indian (H) Pakistani (J), Bangladeshi (K)
Any other Asian background (L), Caribbean (M), African, (N), any other Black 
background (P), any other ethnic group (S).
4.6.2 Median Marker levels in Different Ethnic Groups.
To see if  there was any difference in the IRT, PAP, PHE and TYR markers among all 
ethnic categories, the data was divided in two groups. Group 1 included all British (A) and 
any other white back ground (C). Group 2 included all other ethnic backgrounds (Table 
4.10).
Medians were calculated for IRT, PAP, PHE and TYR in the British /Irish and ‘other’ 
ethnic groups (Table 4.10). The only statistically significant difference between these 
groups was for TYR in the controls. There were too few individuals from ‘other’ ethnic 
groups in the CF and CF carrier sample groups for meaningful comparison.
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4.7 BABIES WITH CYSTIC FIBROSIS.
Out o f 3632 babies screened, 29 samples were positively identified as CF cases, o f which 
14 were girls and 15 boys. The ethnic backgrounds o f the CF cases were as follows: 26 
cases were white British (A); 2 cases were Pakistanis in the Asian or Asian British group 
(J), and; 1 case in the Asian or Asian British group o f any other Asian Background (L). 
These CF cases data are summarised in table 4.11.
4.7.1 Marker Levels in Cystic Fibrosis Cases
The median PAP concentration in controls was 0.19 ng/ml and in the 29 CF cases 1.91 
ng/ml, equivalent to 10 MoM. The corresponding median for IRT was 19.3 ng/ml in the 
control and 161.5 ng/ml in the CF cases, equivalent to 8.3 MoM. The lowest PAP level in 
the CF cases was 0.24 ng/ml (1.2 MoM). The median PHE concentration in control was 
56.2 p mol/L and in the 29 CF cases 54.0 ng/ml, equivalent to 0.96 Mom. The median 
TYR concentration in controls was 93.8 p mol/L and in the 29 CF cases 59.0 p mol/L, 
equivalent to MoM 0.63 (Table 4.12).
Apart from PHE (p = 0.890), all markers shows statistically significant differences using 
Mann-Whitney test. IRT (p = < 0.001) and PAP (p = < 0.001) levels were significantly 
elevated while TYR levels were significantly reduced (p = < 0.001), (Table 4.12).
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Table 4-12: IRT, PAP, PHE and TYR medians with p value in 29 cases and 2886 control
samples.
M A RK ERS
N
CO N TR O L
M EDIAN
CF CASES M ED IAN
N
p  Value *
IRT (ng /m l) 2886 19.3 29 161.5 (p <0.001)
PAP (ng /ml) 2886 0.19 29 1.91 (p <0 .001)
PHE (pmol/L) 2886 56.2 29 54.0 p = 0.890
TYR (pmol/L) 2886 93.8 29 59.0 (p <0 .001)
* Mann-Whitney test
4.7.2 Mutations Identified in Confirmed CF Cases
Out o f 3632 screened babies, 29 cases were identified as positive for CF. In thirteen 
cases, the infants were homozygous for common mutation delta F508 (Table 4.11). All 
thirteen cases were o f white British (A) ethnic background. There were a total o f 16 cases 
with other combinations o f mutations including two cases identified by sweat test. One o f 
these cases had a single mutation (F508), while the other mutation was not identified. No 
mutations were identified in the second case. Thirteen cases were o f white British (A) 
ethnic background, two CF cases were o f Asian or Asian British Pakistani (J) ethnic 
background and one case was o f other Asian background (L) (Table 4.11).
The median IRT, PAP, PHE and TYR concentration in the 13 cases homozygous for delta 
F508 and 16 cases with other mutations were compared (table 4.13). The IRT marker data 
are shown in Figure 4.42 and PAP marker data in Figure 4.43. There were no significant 
differences in median level between the two mutation groups for any markers (table 4.13).
Table 4-13: Comparison of levels of 4 markers between common delta F508 mutation and 
other mutation types in CF cases
M arkers AF508 / AF508 O T H E R
M U TATIO N
p  value
N Median (Range) N Median (Range)
IRT ng/ml 13 187.7 (128.5-336.0) 16 147.8 (74.9-330) NS
PAP ng/ml 13 2.54 (0 .62-10 .9 ) 16 1.03 (0.24-19.7) NS
PHE pmol/L 13 55.0 (34.9-106) 16 53.5 (42.8-91.9) NS
TYR p/mol/L 13 56.4 (38.3-403.1) 16 60.6 (12.6-106.9) NS
NS = not significant (Mann-Whitney test)
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Figure 4-42: Distribution of IRT concentration according to the type of m utation present.
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Figure 4-43: Distribution of PAP concentration according to the type of mutation present.
4.8 MARKER LEVELS IN CYSTIC FIBROSIS CARRIERS
Thirty-two samples were identified as CF carriers by virtue o f having a single mutation 
and a normal (<60 ng/ml) repeat IRT. O f these 32, there were 16 male and 16 female 
babies. Thirty o f the identified CF carriers were o f white British (A) ethnic background, 
while one was white o f any other white background (C) and one was in the mixed race 
group o f white and black African (E). These carrier data are summarised in table 4.14
The median PAP concentration in controls was 0.19 ng/ml and in the 32 CF carrier 
0.44ng/ml, equivalent to 2.2 MoM. The corresponding median for IRT was 19.3 ng/ml in 
the controls and 77.6 ng/ml in the CF carriers, equivalent to 4.0 MoM. The lowest IRT 
level in the 32 CF carriers was 68.0 ng/ml, and the lowest PAP level in the CF carrier 0.04 
ng/ml equivalent to (0.2 MoM).The median level o f PHE in the carriers was 60.4 p mole/L 
and median level o f TYR was 76.8 p mole /L (Table 4.15).
Apart from PHE (p = 0.244), all markers showed statistically significant differences using 
Mann-Whitney test. IRT (p < 0.001) and PAP (p = < 0.001) levels were significantly 
elevated, while TYR levels were significantly reduced (p = < 0.001) (Table 4.15).
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Table 4-15: IRT, PAP, PHE and TYR medians with p value in 32 CF carriers and 2886 control 
sample
M A RK ERS
N
C O N TRO L
M EDIAN
CF C A R R IE R  
M EDIAN
N
p  Value*
IRT (ng / m l ) 2886 19.3 32 77.6 (p <0.001)
PAP (ng /ml) 2886 0.19 32 0.44 (p <0.001)
PHE (pmol/L) 2886 56.2 32 60.4 p = 0.244
TYR (pmol/L) 2886 93.8 32 76.8 (p <0.001)
* Mann-Whitney test
4.8.1 Mutations Identified in CF Carriers
The mutations identified in the 32 CF carriers are summarised in table 4.14. The most 
common mutation, delta F508 was detected in 22 o f the CF carriers. Twenty carriers were 
o f white British (A) ethnic background, while one belonged to the white o f any other 
white background group (C) and one was from the white and Black African group (E).
In total, 10 other mutations were found. The other mutations identified in the 32 CF carrier 
cases were the following: P67L (one sample), R560T (one sample), 1078delT (one 
sample), G551D (two samples) and R117H (Five samples). All o f these were o f white 
British (A) ethnic background.
The median IRT and PAP concentrations were analysed in two groups, those with 
deltaF508 mutation and those with other mutation. The IRT marker data are shown in 
figure 4.44 and PAP marker data in figure 4.45.
IRT, PAP, PHE and TYR concentrations were compared between the two groups o f 
mutation types (AF508 vs. other mutation) using Mann-W hitney test. There were no
142
significant differences in median level between the two mutation groups for any markers 
(table 4.16).
Table 4-16: Comparison of levels of 4 markers between delta F508 mutation and other 
mutation types in CF carriers______________________________________________________
M arkers AF508 O T H E R  M U TATION p  value*
N Median (Range) N Median (Range)
IRT ng/ml 22 77.5 (68.0-244.8) 10 79.9 (70.0 - 94.4) NS
PAP ng/ml 22 0.47 (0.04-3.21 ) 10 0.40 (0.17-1.42 ) NS
PHE pmol/L 22 60.6 (32.9-199.8) 10 58.3 (42 .6 -84 .1 ) NS
TYR pmol/L 22 69.0 (32.3-142.5) 10 77.2 (24.3-133.0) NS
NS = not significant (Mann-Whitney test)
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Figure 4-44: Distribution of IRT concentration in CF carriers according to the type of 
mutation present.
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Figure 4-45: Distribution of PAP concentration in CF carriers according to the type of 
mutation present.
4.9 BIRTH WEIGHT AND GESTATION IN CF CASES AND  
CARRIERS.
Blood spots from 3632 infants were used in this study consisting o f 2886 normal (control) 
babies, 29 babies with CF and 32 CF carriers. Birth weight information was not available 
for 19 controls. Gestation information was missing for 172 controls and for 1 CF case and 
4 CF carriers.
4.9.1 BIRTH WEIGHT STUDY
It was found that 3 newborns out o f 29 CF cases were reported as being o f low birth 
weight, i.e. weighing less 2500 g and out o f 32 CF carriers, 4 cases were reported as being 
o f low birth weight. Out o f 2867 newborns matched as controls, 338 were reported were
© °
o o
8
Median 0.47 41  ® „  ..g  9------  Median 0.40
O Q
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reported as low birth weight. The median value o f the birth weight in the control samples 
is 3380 g, while it is 3090.g in the CF samples (p=0.013) and 3625 g in CF carrier 
(p= 0.301 ). This finding suggests that babies bom with CF have a significantly lower birth 
weight while carrier babies have normal birth weight (Table 4-17).
Table 4-17: Median birth weight and gestation medians with p value in CF cases, CF carrier 
and control samples
Group N MEDIAN p  Value *
Control BW 2867 3380 (g)
(P =0.013)
BW CF cases 29 3090 (g)
BW CF carrier 32 3625 (g) (P =0.301)
* Mann-Whitney test
4.9.2 GESTATION STUDY
Four newborns out o f 28 CF cases were bom  prematurely (bom before 37 weeks o f 
gestation), and 6 newborns out o f 28 CF carriers were bom  prematurely. Out o f 2714 
newborns matched as controls, 345 were bom prematurely. The median value o f the 
gestation in the control samples is 40 weeks, while it is 39 weeks in the CF cases 
(p=0.251) and 40 weeks in CF carriers (p=0.436), which suggests that babies affected 
with CF, or carriers o f CF are bom within the normal gestation period (table 4-18).
Table 4-18: Gestation medians with p value in CF cases, CF carrier and control samples
Group N MEDIAN p  Value*
Control Ges 2714 40 (weeks)
Ges. CF cases 28 39 (weeks) (p=0.251)
Ges. CF Carrier 28 40 (weeks)
(p=0.436)
* Mann-W hitney test
1 4 5
4.10 RETROSPECTIVE STUDY OF IRT IN CF CASES 
DETECTED RY ROUTINE NEWBORN SCREENING
All 198 babies affected with CF identified by the routine newborn screening programme 
in Scotland between 2003 and December 2010 were reviewed. Homozygosity for the 
common delta F508 mutation was found in 88 , with another 110 cases having various 
other combinations o f mutations.
IRT concentrations were compared between the two groups o f mutation types 
(homozygous common delta AF508 vs. other mutation) using the M ann-Whitney test. 
There were significant differences in median levels between the two mutation groups 
(table 4.19). The concentration level o f IRT in cases homozygous for the common delta 
F508 was higher than the IRT level concentration in other mutations (Figure 4.46).
4.10.1 Retrospective Study of IRT Levels in CF Carriers According to 
Mutation.
The IRT concentration levels were identified for all 230 CF carrier babies bom  between 
2003 and December 2011. From the total number o f these babies, 148 carriers had the 
common delta F508 mutation and a further 82 had other mutations.
IRT concentrations were compared between the two groups o f mutation types (AF508 vs. 
other mutation) (figure 4.47). Using the Mann-Whitney test, no significant difference in 
median level between the two mutation groups in the CF carriers was found (Table 4.20).
Table 4-19: Comparison of IRT concentration between homozygosity for the common delta
F508 mutation and other mutation types in CF cases
M utation N um ber M edian
(ng/ml)
(Range ng/ml) p  value*
Delta F508 
Homozygous
88 166.50 (75-337)
(p <0.001)
Other mutation 110 133.50 ( 70-373)
* Mann-Whitney test.
400
300
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Figure 4-46: IRT median level in CF cases born with homozygous common delta AF508  
mutation and other mutation.
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Table 4-20: Comparison of IRT concentration between common delta F508 mutation and
other mutation in CF carriers.
M utation N um ber M edian
(ng/ml)
(Range n g /m l) p  value
Delta F508 148 88 (69-360)
(p =0.130)
Other mutation 82 80.50 ( 68-251)
400
300
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&  200 
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cc
100
o
Figure 4-47: IRT median levels in carrier babies born with AF508 mutation and other 
mutation.
Median 88  f —   1------  Median 80.50
F508 Other Mutation
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4.11 DISCRIMINATORY POWER OF PAP 
MEASUREMENTS
Data were obtained on PAP analysis on 3632 samples in this project. A key aim o f the 
study was to develop an algorithm using the results o f both IRT and PAP markers to 
minimise the number o f samples referred for DNA analysis due to increased IRT levels 
and therefore reduce the number o f carriers detected, whilst maintaining detection o f CF 
cases.
The lowest PAP concentration from the 29 CF positive cases was identified; this was 0.24 
ng/ml (equivalent to 1.2 MoM). The second lowest PAP level detected in a CF positive 
case was 0.26 ng /ml and the third lowest was 0.27 ng/ml, while the highest PAP level 
detected among the 29 CF positive cases was 19.7 ng/ml (table 4.21). Therefore, a PAP 
level o f 0.24 ng/ml (equivalent to 1.2 MoM) would be an appropriate cut-off to avoid 
reducing the number o f CF cases identified.
In addition, the PAP levels in the 32 CF carriers were reviewed. The data revealed that the 
lowest PAP value level detected in all 32 o f the CF carriers was 0.04 ng/ml, while the 
highest PAP value level in these cases was identified as being 3.21 ng/ml. Eight blood 
spot samples from the total number o f CF carriers identified in the study had PAP values 
o f less than 0.24ng/ml (suggested PAP cut-off), and the remaining 24 samples having PAP 
values above the suggested PAP cut off.
Thus, if  selection o f infants for DNA mutation analysis was based on both an IRT level > 
70 ng/ml and a PAP level > 0.24 n g / m l , eight fewer CF carriers would be detected and 
25% fewer DNA test would be required (See table 4 .22).
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Table 4-21: PAP, IRT and mutations in 29 CF cases arranged in ascending order of PAP 
concentration.
CF cases IRT ng / ml PAP ng / ml Mutation
1 74.88 0.24 R556X/2789+5G>A
2 330.00 0.26 F508/G542X
3 166.19 0.27 F508/621+1G>T
4 98.77 0.29 F508/R117H
5 167.45 0.42 F508/2789+5G>A
6 236.04 0.62 F508/F508
7 80.75 0.64 R117H/G542X
8 150.54 0.70 F508/1461INSA5AT
9 136.00 0.75 F508/F508
10 289.56 0.76 F508/G551D
11 166.10 1.23 F508/F508
12 96.92 1.31 F508/R117H
13 187.72 1.43 F508/F508
14 136.08 1.65 F508/R560T
15 128.49 1.90 F508/F508
16 205.03 2.09 F508/F508
17 149.91 2.22 F508/Sweat Test
18 138.09 2.55 F508/F508
19 188.31 2.58 F508/G551D
20 145.63 2.58 G551D/621+1G>T
21 237.57 3.29 F508/F508
22 336.00 4.31 F508/F508
23 161.54 5.32 F508/F508
24 225.81 7.66 F508/F508
25 255.32 7.69 F508/D493X
26 134.58 8.60 F508/F508
27 221.29 10.91 F508/F508
28 126.67 12.09 Y569D/Y569D
29 81.00 19.70 Sweat test
1 5 0
Table 4-22: IRT and PAP concentrations in 8 CF carrier samples located below the 
suggested PAP cut-off of 0.24 ng/ml.
Sample No Gender Birth
weight
Gestation IRT ng/ml PAP ng/ml Mutations
1 Female 1900 32 78.65 0.04 F508
2 Male 3850 41 128.67 0.05 F508
3 Male 3730 ? 72.95 0.07 F508
4 Female 4180 41 72.00 0.11 F508
5 Male 3700 40 89.44 0.13 F508
6 Female 3110 39 92.77 0.14 F508
7 Female 3140 ? 77.54 0.18 R117H
8 Male 550 24 108.00 0.22 F508
4.11.1 PAP and IRT Levels in Relation to Type of Mutation
The PAP concentration showed a tendency to be higher in the CF cases homozygous for 
the common delta F508 mutation than the levels in CF cases with other mutations (see 
table 4.13). The median PAP concentration in CF cases homozygous for the common delta 
F508 mutation was 2.54 ng/ml, while for other combinations o f mutations the median PAP 
concentration was 1.03 ng/ml.
Furthermore, the IRT concentration levels showed a tendency to be higher in the CF cases 
homozygous for the common delta F508 mutation than that in CF cases with other 
mutations. The median IRT concentration in CF cases homozygous for the common delta 
F508 mutation was 187.7 ng/ml, while in CF cases with other combinations o f mutations 
it was 147.8 ng/ml (table 4.13).
Statistical testing(Mann-Whitney test), however, showed that the differences for PAP and 
IRT were not significantly different. These data are summarised in table 4.13 along with 
the PHE and TYR results in the two classes o f mutation. Analysis o f PAP concentration 
levels in CF carriers showed a tendency for PAP to be higher in carriers heterozygous for
1 5 1
the common delta F508 mutation than in CF carriers with other mutations. The median 
PAP concentration in CF carriers heterozygous for the common delta F508 mutation was 
0.47 ng/ml, while in cases with other mutations it was 0.40 ng/ml (table 4.16).
Conversely, IRT concentration levels did not tend to be higher in CF carriers heterozygous 
for the common delta F508 than in CF carriers with other mutations. The median IRT 
concentration in CF carriers heterozygous for the common delta F508 mutation was 77.5 
ng/ml, while in cases with other mutations the median IRT concentration was 79.9 ng/ml 
(Table 4.16). These data, along with data for PHE and TYR in cases and carriers with the 
two classes o f mutation, are summarised in table 4.13 and 4.16. Mann-W hitney testing 
showed that there were no statistically significant differences for any markers.
4.12 USE OF LIKELIHOOD RATIOS METHOD IN THE 
NEWBORN SCREENING OF CF
As noted in section 4.2, IRT and PAP concentrations are loglO normally distributed in 
controls (Figures 4.1, 4.2 and 4.5, 4.6). Using the parameters o f the IRT and PAP in CF 
cases (table 4.12) shows that they also fit a logio Gaussian distribution (Figure 4.48, 4.50). 
However, there is no complete separation o f the levels o f either marker between normal 
and affected infants (Figures 4.49 and 4.51). Therefore nether marker is an absolute 
predictor o f CF.
Using Gaussian statistics, the likelihood that a particular IRT or PAP level is associated 
with a CF infant rather than an unaffected infant can be estimated from the overlapping 
distributions. For example, in Figure 4.49 an IRT concentration o f 70.80 ng/ml (logio 
1.85) is 8.2 times (i.e. a:b) more likely to be associated with a CF infant than with 
unaffected infant. Similarly in figure 4.51, a PAP level o f 1.26 ng/ml (logio 0.1) gives a 
likelihood ratio o f 4.1 times (i.e., a:b) more likely to be associated with a CF infant than 
with an unaffected infant. Moreover, the product o f the individual likelihood ratios can be 
calculated thus combining the information from two markers due to their being only a low 
correlation between IRT and PAP levels in CF cases (Pearson correlation p = 0.669).
Table 4.23 shows the likelihood ratio derived from IRT and PAP levels in 29 CF cases. 
The likelihood ratios for both markers are multiplied together to give the overall risk for 
each affected CF baby. The lowest overall risk for both markers is 4.84 and the highest 
value is > 50,000
Table 4.24 shows the likelihood ratios derived from the IRT and PAP levels in 32 carriers. 
The likelihood ratios for both markers are multiplied together to give the overall risk for
1 5 3
each CF carrier. The lowest CF carrier overall risk for both markers is 1.45 and the highest 
value is > 50,000.
Individual likelihood ratios were also calculated for the 314 increased IRT samples using 
the IRT and PAP levels. The likelihood ratios for both markers are multiplied together to 
give the overall risk for each increased IRT sample. The lowest overall risk for both 
markers is 1.10 and the highest value is > 50,000.
Table 4.25 shows the distribution o f the overall likelihood ratios in CF cases, CF carriers 
and babies with increased IRT level. The suggested cut-off risk for IRT and PAP o f 30 for 
CF cases, CF carrier, and Increased IRT would be an appropriate risk to select and would 
result in reducing the number o f CF carriers from 32 to 16 (50%) and reduce further DNA 
analysis from 314 to 180 (43%) with losing one CF case only. Setting a likelihood ratio 
and referrals for DNA analysis by 500 would reduce the number o f DNA test by 75% and 
earners by 88%. However, detection o f 3 CF cases would be missed.
y=( 1 /0.3035*(sqrt(2*pi)))*exp(-0.5*((x-2.1770)/0.3035) )
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Figure 4-48: Log10 Gaussian distributions for IRT in 29 CF cases.
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y=(1/0.3035*(sqrt( 2*pi)))*exp(-0.5*((x-2.1770)/0.3035)21 
y=(1/0.2111*(sqrt( 2*pi)))*exp(-0.5*((x-1.2868)/ 0.2111)2)
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Figure 4-49: Overlapping Log10 Gaussian distributions for IRT in affected and unaffected 
babies.
y=(1/0.6429*(sqrt(2*pi)))*exp(-0.5*((x-0.299985)/0.6429)2)
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Figure 4-50: Log10 Gaussian distributions for PAP in 29 CF cases
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y=(1/0.6429*(sqrt( 2*pi)))*exp(-0.5*((x-0.299985)/0.6429)2) 
y=(1/0.4183*(sqrt( 2*pi)))*exp(-0.5*((x+0.7171)/ 0.4183) )
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Figure 4-51: Overlapping Log10 Gaussian distributions for PAP in affected and unaffected  
babies.
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Table 4-25: Distributions of likelihood ratios in CF cases, CF carriers and babies with  
elevated IRT, derived from IRT and PAP results
LR CF Cases CF carrier f  IRT unaffected
<20 1 14 116
Threshold
21-30 0 2 18
risk 1
31-40 1 3 22
41-50 1 2 12
51-60 0 2 7
61-70 0 1 7
71-80 0 0 7
81-90 0 2 6
91-100 0 0 1
101-200 0 1 19
201-300 0 1 9
301-400 0 0 10
Threshold 
risk 2
401-500 0 0 3
501-600 1 0 3
601-700 1 1 2
701-800 0 0 3
801-900 0 0 2
901-1000 0 0 3
1001-2000 0 1 11
2001-3000 0 0 6
3001-4000 1 0 4
4001-5000 0 0 4
>5000 23 2 39
1 6 1
4.13 GESTATIONAL MARKERS OF CYSTIC FIBROSIS
Maternal serum samples from mothers o f children affected with CF were studied for 
variations in the concentration o f a range o f serum markers known to be associated with 
adverse outcomes o f pregnancy to determine whether they have any predictive value for 
CF. A total o f 55 serum samples taken during pregnancies for which the outcome was the 
live birth o f a child with CF were identified. An additional total o f 330 pregnancies were 
randomly selected as controls matched to the same gestational range. Both second 
trimester (15 to 20 weeks) and first trimester cases (10 to 13 weeks) were included. The 
serum markers were AFP, hCG, PAPP-A, Free P-hCG, UE3 and Inhibin-A.
4.13.1 AFP Concentration Level in Maternal Serum Samples from 
Mothers of Children Affected with CF
In the 330 control pregnancy serum samples, the lowest AFP concentration was 4.80 
U/mL (equivalent to 0.35 MoM) while the highest concentration level was 99.30 U/mL 
(equivalent to 2.22 MoM). The median AFP concentration level in the 330 control serum 
samples was 27.1 U/mL (equivalent to 0.98 MoM). Figure 4.52 shows the median AFP 
concentration level in maternal serum control samples and table 4.26 present the median 
values at each week o f gestation. Figure 4.53 shows AFP (MoM) in samples from CF 
pregnancies. Figure 4.54 shows a box plot comparison o f AFP level in controls and CF 
pregnancies.
The lowest AFP concentration level in the 55 serum samples o f pregnancies where the
outcome was the live birth o f a child with CF was 5.00 U/mL (equivalent to 0.47 MoM),
while the highest concentration level was 86.60 U/mL (equivalent to 3.47 MoM). The
median AFP concentration level in the 55 maternal serum samples from mothers o f
children affected with CF was 29.27 U/mL (equivalent to 1.11 MoM).
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Figure 4-52: Median AFP concentration level at each week of gestation in maternal serum  
control samples.
Table 4-26: Control median at each weeks of gestation for AFP. 
G estation__________________________ AFP M EDIAN (U/mL)
9 7.00
11 10.65
12 12.60
13 17.35
14 18.00
15 26.10
16 29.10
17 28.22
18 37.12
19 35.23
20 61.90
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Figure 4-53: AFP MoM in samples from CF pregnancies.
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Figure 4-54: Box plot comparison of AFP in 55 CF samples and 330 control serum sample. 
Circles indicate outlier AFP values.
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4.13.2 HCG Concentration Level in Maternal Serum Samples from 
Mothers of Children Affected with CF
In the 330 control pregnancy serum samples the lowest hCG was found to be 1.34 U/mL 
(equivalent to 0.04 MoM) and the highest concentration level was 180.60 U/mL 
(equivalent to 2.58 MoM). The median hCG concentration level in these serum samples 
was 27.51 U/mL (equivalent to 0.99 MoM). Figure 4.55 shows the median hCG 
concentration level in maternal serum control samples and table 4.27 presents median 
values at each weeks o f gestation. Figure 4.56 shows hCG (MoM) in samples from CF 
pregnancies. Figure 4.57 shows a box plot comparison o f hCG level in controls and CF 
pregnancies.
The lowest hCG concentration level in the 55 serum samples from pregnancies where the 
outcome was the live birth o f a child with CF was found to be 8.50 U/mL (equivalent to 
0.35 MoM) and the highest concentration level was 117.55 (equivalent to 1.22 MoM). The 
median hCG concentration level in the 55 maternal serum samples from mothers o f 
children affected with CF was 25.88 U/mL (equivalent to 0.95 MoM).
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Figure 4-55: Median hCG concentration level in maternal serum control samples.
Table 4-27: Median values at each weeks of gestation for hCG.
G estation hCG  M EDIAN (U/mL)
9 58.20
11 91.82
12 75.45
13 71.12
14 68.93
15 30.50
16 23.91
17 16.30
18 21.20
19 9.49
20 20.25
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Figure 4-56: HCG MoM in maternal serum samples from CF pregnancies.
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Figure 4-57: Box plot comparison of hCG in 55 CF samples and 330 control serum sam ples. 
Asterisks indicate extreme hCG values while circles indicate outlier hCG values.
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4.13.3 PAPP-A Concentration Level in Maternal Serum Samples from 
Mothers of Children Affected With CF
The lowest PAPP-A was 92 U/mL (equivalent to 0.01 MoM) in the 330 control pregnancy 
samples, and the highest concentration level was 102000 U/mL (equivalent to 16.04 
MoM). In these samples, the median PAPP-A concentration level was 6794.50 U/mL 
(equivalent to 0.99 MoM). Figure 4.58 shows the median PAPP-A concentration level in 
maternal serum control samples and table 4.28 presents median values at each weeks o f 
gestation. Figure 4.59 shows PAPP-A (MoM) in samples from CF pregnancies.
In the 55 serum samples from pregnancies where the outcome was the live birth o f a child 
with CF the lowest PAPP-A concentration level, was 221 U/mL (equivalent to 0.11 MoM) 
and the highest concentration levels was 23717 (equivalent to 3.74 MoM). The median 
PAPP-A concentration level in 55 maternal serum samples from mothers o f children 
affected with CF was 7510. 0 ng/ml (equivalent to 0.98 MoM). Figure 4.60 shows a box 
plot comparison o f PAPP-A levels in CF pregnancies and controls.
Table 4-28: Median values at each week of gestation for PAPP-A
Gestation PAPP-A  M ED IAN  (raU/L)
9 332.0
11 3044.2
12 2769.1
13 3085.6
14 9938.0
15 6799.0
16 7748.0
17 7184.0
18 11565.0
19 12000.0
20 12595.0
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Figure 4-58: Median PAPP-A concentration level in maternal serum control samples.
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Figure 4-59: PAPP-A MoM in maternal serum samples from CF pregnancies.
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Figure 4-60: Box plot comparison of PAPP-A in 55 CF samples and 330 control serum  
samples. Asterisks indicate extreme PAPP-A values while circles indicate outlier PAPP-A  
values.
4.13.4 Free 0-hCG Concentration Level in Maternal Serum Samples 
from Mothers of Children Affected with CF
The highest concentration level was 185.00 ng/ml (equivalent to 10.63MoM) in the 330 
control pregnancy serum samples, while the lowest free p-hCG was 2.60 ng/ml 
(equivalent to 0.42 MoM). The median free P-hCG concentration levels in these samples 
was 14.40 ng/ml (equivalent to 1.00 MoM). Figure 4.61 shows the median Free P-hCG 
concentration level in maternal serum control samples and table 4.29 present median 
values at each week o f gestation. Figure 4.62 shows free p-hCG (MoM) in samples from 
CF pregnancies.
The highest concentration level was 122.96 ng/ml (equivalent to 1.85 MoM) in the 55 
serum samples taken during pregnancies where the outcome was the live birth o f a child 
with CF and the lowest free (3-hCG concentration level in these samples was 3.27 ng/ml 
(equivalent to 0.65 MoM). In the 55 serum samples taken from pregnancies where the 
outcome was the live birth o f a child with CF the median free (3-hCG concentration level 
was 13.80 ng/ml ml (equivalent to 0.93 MoM). Figure 4.63 shows a box plot comparison 
o f free P-hCG levels in CF pregnancies and controls.
Table 4-29: Median values at each week of gestation for free p-hCG.
G estation Free P-hCG (ng/m L)
9 30.90
11 115.56
12 44.93
13 54.85
14 44.28
15 17.00
16 12.90
17 7.86
18 15.25
19 4.71
20 8.53
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Figure 4-61: Median free p-hCG concentration level in maternal control serum samples.
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Figure 4-62: Free p-hCG (MoM) in maternal serum samples from CF pregnancies.
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Figure 4-63: Box plot comparison of free p-hCG in 55 serum CF samples and 330 control 
serum samples. Circles indicate outlier free p-hCG values.
4.13.5 UE3 Concentration Level in Maternal Serum Samples from 
Mothers of Children Affected with CF
In 322 control pregnancy serum samples, the lowest UE3 was shown to be 0.26 nmo/L 
(equivalent to MoM 2.13), whereas the highest concentration level was 10.46 nmo/L 
(equivalent to 1.76 MoM). In these samples, the median UE3 concentration level was 2.48 
nmo/L (equivalent to 1.01 MoM). Figure 4.64 shows the median UE3 concentration level 
in maternal serum control samples and table 4.30 presents median values at each weeks o f  
gestation. Figure 4.65 shows UE3 (MoM) in samples from CF pregnancies.
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The lowest UE3 concentration level in the 53 serum samples from pregnancies where the 
outcome was the live birth o f a child with CF was 0.14 nmo/L (equivalent to 0.33 MoM), 
with the highest concentration level being 6.87 nmo/L (equivalent to 1.65 MoM). The 
median UE3 concentration level in 53 maternal serum samples from mothers o f children 
affected with CF was 2.51 nmo/L (equivalent to 1.07 MoM). Figure 4.66 shows a box plot 
comparison o f UE3 in CF pregnancies and controls.
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Figure 4-64: Median UE3 concentration level in maternal control serum samples.
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Table 4-30: Median values at each weeks of gestation for UE3
G estation UE3 (nmol/L)
9 0.2550
11 0.3660
12 0.6370
13 0.6705
14 0.6660
15 2.2810
16 2.6600
17 3.1975
18 4.0805
19 3.8400
20 4.5900
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Figure 4-65: UE3 MoM in maternal serum samples from CF pregnancies.
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Figure 4-66: Box plot comparison of UE3 in 53 serum CF samples and 325 control serum  
sample. Asterisks indicate extreme UE3 values while circles indicate outlier UE3 values.
4.13.6 Inhibin-A Concentration Level in Maternal Serum Samples from 
Mothers of Children Affected with CF
The lowest inhibin-A found in the 325 control pregnancy serum samples was 1.3 pg/mL 
(equivalent to 0.01 MoM), and the highest concentration level was 822.0 pg/mL 
(equivalent to 3.68 MoM). The median inhibin-A concentration level in the 325 control 
pregnancy serum samples was 183.5 pg/mL (equivalent to 0.990 MoM). Figure 4.67 
shows the median inhibin-A concentration level in maternal serum control samples and 
table 4.31 present median values at each week o f gestation. Figure 4.68 shows inhibin-A 
(MoM) in samples from CF pregnancies.
The lowest inhibin-A concentration level found in the 53 serum sample o f pregnancies 
where the outcome was the live birth o f a child affected with CF was 60.6 pg/mL
(equivalent to 0.35 MoM) and the highest concentration level was 497.80 pg/mL 
(equivalent to 1.77 MoM). The median inhibin-A concentration level in the 53 maternal 
serum samples from mothers o f children affected with CF was found to be 173.20 pg/mL 
ml (equivalent to 0.97 MoM). Figure 4.69 shows a box plot comparison o f Inhibin-A in 
CF pregnancies and controls.
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Figure 4-67: Median inhibin-A concentration level in maternal control serum samples.
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Table 4-31: Median values at each weeks of gestation for inhibin-A.
Gestation Inhibin-A (pgl/mL)
9 317.70
11 280.95
12 235.65
13 308.15
14 290.60
15 179.20
16 180.40
17 137.00
18 152.00
19 213.75
20 168.20
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Figure 4-68: Inhibin-A in maternal serum samples and CF samples from pregnancies.
178
I-------------------------------------------1--------------------------
CF sam ple Control sam ple
Figure 4-69: Box plot comparison of inhibin-A in 53 serum CF samples and 325 control 
serum samples. Circles indicate outlier inhibin-A values.
4.13.7 Maternal Serum Marker Levels in CF Pregnancies
An analysis o f markers AFP, hCG, PAPP-A, free (3-hCG, UE3 and inhibin-A using Mann- 
Whitney test shows that these concentration levels remained unchanged in the mother’s 
serum when her child had cystic fibrosis (see table 4.32)
Table 4-32: AFP, hCG, PAPP-A, free (3-hCG, UE3 and inhibin-A medians with p value in CF 
serum sample and control serum sample
MARKERS (MoM) N CONTROL
SERUM
MEDIAN
N CF SERUM  
MEDIAN
p  Value
AFP 330 0.98 55 1.11 (p = 0.335)
hCG 330 0.99 55 0.95 (p = 0.539)
PAPP-A 330 0.99 55 0.98 (p = 0.632)
Free 0-hCG |3-hCG 330 1.00 55 0.93 (p = 0.824)
UE3 322 1.01 52 1.07 (p -0 .840)
Inhibin-A 322 0.99 52 0.97 (p = 0.650)
CHAPTER 5 : 
DISCUSSION
1 8 0
5.1 NEWBORN BLOODSPOT MARKERS OF CF
The objective o f prenatal and newborn screening is to identify babies with health 
problems. Such screening provides certain information concerning the health o f babies. 
Prenatal testing is carried out during pregnancy from the early stages o f gestation, while 
newborn testing, as the name suggests, is carried out just after birth. There are major 
differences between prenatal screening and newborn screening. Prenatal screening can 
give a diagnosis before the baby is bom opening up the possibility o f prevention o f the 
birth o f an affected child. Newborn screening aims to provide early detection o f a disorder 
meaning that better medical intervention can be made. In Scotland, newborn screening for 
CF started in February 2003, based on the use o f IRT to select infants for referral for DNA  
mutation testing. This study aimed to look for ways to make current IRT testing more 
precise by using an additional marker, PAP. The objective was to decrease the number o f  
babies referred and carriers detected by DNA testing o f screen positive babies and 
examine the cost implications o f a change in protocol.
5.1.1 Current CF Screening
5.1.1.1 Workload and Cost
In Scotland between Febmary 2003 and end o f 2010 a total o f 450,000 babies were 
screened for CF and o f these, 3,122 were referred for DNA analysis because o f an 
elevated IRT result (>70 ng/ml), a referral rate o f 0.69%. This exceeds the 0.5% target 
based on using a 99.5th centile IRT cut-off and is due to a positive bias in the DELFIA 
IRT assay. While this reduces the likelihood o f  missing a CF case with relatively low IRT, 
it increases workload and costs.
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Over the 8-year period that IRT screening has been in routine use, 198 babies have been 
detected with CF (incidence 1:2272) giving a positive predictive value o f 6.3% for the 
screening protocol. The cost o f DNA mutation analysis (31 or 29 mutation panel) o f 3,122 
screen positive babies is estimated at £62,440 equivalent to approximately £20/test or 
£7,805/year (personal communication o f Dr A Cooke). In addition, over the same period, 
a total o f 230 carriers were detected through DNA testing o f screen positive babies. This 
gives a carrier rate within the screen positive group o f about 1 in 12, which is 
approximately double the frequency in the general Scottish population. CF carriers are 
therefore relatively commonly picked up in the screen positive group. However, it is a 
requirement o f the screening protocol that where a carrier is detected this is reported to the 
parents by the family doctor/practice nurse and a referral offered for genetic counselling. 
Although carriers are clinically unaffected, to be told that their baby is a carrier may cause 
anxiety in the parents and lead to counselling and cascade testing in the wider family. 
Thus, further significant costs arise in the programme due to the incidental detection o f  
carriers.
Modifying the current protocol by changing the IRT cut-off to, for example the 99.7th 
centile (approx 90 ng/ml) and following-up only 0.3% o f babies would reduce the number 
o f DNA referrals to about 180/year in Scotland, which is about half the current rate. 
However, this change in cut-off would mean that CF cases with IRT concentrations 
between 70 ng/ml and 90 ng/ml would not be detected. An audit o f the 198 CF cases 
detected over 8 years showed that there were 25 with an IRT value between 70 and 90 
ng/ml, which would therefore have been missed if  the 99.7th centile has been used as a 
cut-off.
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Thus, the scope for modifying the current single marker protocol to reduce referrals for 
DNA testing and detection o f carriers but maintain high detection o f CF cases is limited. 
Additional markers o f CF which can increase the specificity o f screening are required.
5.1.1.2 Alternative Newborn Bloodspot Markers
In this study and elsewhere, a number o f possible markers for CF screening have been 
examined.
Elevated sweat chloride is a strong indicator o f  CF but it is impractical to use as a 
screening test in newborn babies as the process o f collecting the sweat is difficult and time 
consuming. Sweat testing has a valuable role as a diagnostic back-up test for DNA.
Faecal elastase is found in reduced concentration in the babies with pancreatic 
insufficiency. At day 3 in term infants the normal levels are expected and by two weeks o f  
age in those bom less than 28 weeks gestation; therefore the test should not be performed 
before this time (Davies, 2006) and the collection and analysis o f stool samples is 
impractical for mass newborn population screening.
Direct testing o f DNA extracted from dried bloodspots for a panel o f CF mutations is 
potentially possible for newborn screening and would theoretically result in the detection 
o f most CF cases. However, the presence o f hundreds o f rare mutations would require 
sequencing to identify the mutations in all CF cases and in addition, all carriers and many 
mutations associated with mild disease would be detected, leading to major counselling 
problems.
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The aforementioned markers fail the Wilson and Jungner criteria for screening tests as 
they are too time consuming or expensive to be considered as suitable for newborn 
screening. The ideal marker is one that can be easily measured in large numbers o f babies 
quickly and cheaply using the bloodspots already collected on the Guthrie card. In 2005, 
Sarles et al reported on the use o f a second pancreatic marker, PAP, which could be 
measured in bloodspots and was found in elevated concentrations in babies with CF.
5.1.1.3 Pancreatitis Associated Protein (PAP)
Sarles et al (2005), in their studies in France, have shown that pancreatitis-associated 
protein (PAP) concentrations are also elevated in the blood o f newborn babies affected 
with CF.
Sarles’ studies started between November 2002 and December 2003, measuring IRT and 
PAP in all the newborn babies in 5 regional screening centres in France (n=204,749). 
They were all screened for CF through the French national screening programme, which 
was initiated in April, 2002. The routine screening strategy used is the following: a single 
IRT test at day 3 and then, for those found to have elevated IRT levels (defined as 
>50ng/mL up to February 2003 and >65 ng/mL subsequently), analysis o f  20 CFTR 
mutations.
Babies in whom one or two mutations are found then undergo sweat testing. If no 
mutations are found, another blood spot is collected at day 21 to repeat the IRT and where 
IRT is >45 ng/mL, a sweat test is carried out. A diagnosis o f CF is made if  the sweat 
chloride results are >60 mEq/L. Babies whose first sweat test result is 40 to 59 mEq/L are 
followed up and checked at 3, 6 and 12 months.
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ELISA was the choice for PAP analysis, (MucoPAP, DYNABIO S.A., Marseille, France). 
Blood spot samples o f 3mm in diameter were punched from the screening cards and 
elution o f dried blood was carried out in 150 pL o f phosphate-buffered saline. Assays 
were carried out in duplicate, at the same time as IRT. Both assays were conducted 
locally and results sent to the main centre before diagnosis.
The Sarles protocol for CF screening is to test all newborns for PAP and IRT, after which 
two groups o f newborns, those with IRT>50 ng/mL and with PAP >1.8 ng/mL, and those 
with IRT > 1 0 0  ng/mL and PAP>1.0 ng/mL are recalled for sweat testing. Sarles et al 
(2005) presented data which showed that this two-stage screening strategy would have the 
same performance as the IRT/DNA mutation strategy. However, this approach requires 
testing IRT and PAP in all newborns.
If such a policy was adopted in Scotland, this would require the measurement o f PAP in 
addition to IRT in over 60,000 babies per year. The commercially available PAP ELISA 
(Dynabio S.A., Marseille, France) is priced at 423 Euros per 96-well plate (approximately 
£350) which is sufficient for analysis o f  80 bloodspot specimens in singleton (the 
remainder o f the plate wells are taken up by standards, QCs and blanks). This equates to 
about £4.38 per sample and would add a total o f £271,560 to the annual cost o f running 
the Scottish CF newborn screening programme.
Because o f the high cost o f this protocol, an alternative strategy has been explored in this 
study, testing PAP only in those babies who have an elevated IRT screening result. This 
greatly reduces costs (to £1533/year), although the practicalities o f testing mean that only 
part o f  each plate can be used in the present ELISA format and this would increase costs 
above the theoretical minimum.
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5.1.2 Marker Levels in Confirmed CF Cases
In this study, out o f 3632 babies screened, 29 samples were positively identified as CF 
cases, o f which 14 were girls and 16 boys. The median PAP concentration in controls was 
0.19 ng/ml and in the 29 CF cases 1.91 ng/ml, equivalent to 10.0 MoM. This confirms that 
there is an association between elevated PAP and CF as reported by Sarles et al (2005). 
The corresponding median for IRT was 19.3 ng/ml in the control and 161.5 ng/ml in the 
CF cases, equivalent to 8.3 MoM. The lowest PAP level in the CF cases was 0.24 ng/ml 
(1.2 MoM). This PAP level therefore sets the lowest cut-off which can be used if  the 
detection o f CF cases is to be maintained when a PAP cut-off is included in the screening 
protocol along with IRT. A disadvantage o f this approach therefore is that the detection 
rate o f CF cannot be increased by incorporation o f PAP as it is already set at a maximum 
by selecting babies with elevated IRT. However, if  detection can be maintained and the 
screen positive rate reduced by developing a combined IRT/PAP protocol, this would 
improve the current screening programme.
The other commonly used newborn screening markers for phenylketonuria, phenylalanine 
(PHE) and tyrosine (TYR) were also examined for any association with CF. The median 
PHE concentration in controls was 56.2 pmol/L and in the 29 CF cases 54.0 pmol/L, 
equivalent to 0.96 Mom. The median TYR concentration in control was 93.8 pmol/L and 
in the 29 CF cases 59.0 pmol/L, equivalent to 0.62 MoM. Result showed, apart from PHE 
(p = 0.890) all markers show a statistically significant difference using the Mann-Whitney 
test. IRT (p = <0.001) and PAP (p = <0.001) levels were significantly elevated, while 
TYR levels were significantly reduced (p = <0.001) (see table 4.12). It is not clear what 
mechanism may be operating to cause this small reduction in TYR levels.
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5.2 PREDICTIVE VALUE OF IRT AND PAP
5.2.1 Use of Cut-offs for IRT and PAP
In this study, if  referral for DNA testing was based on an IRT level >99.5th centile and a 
PAP level >1.2 multiples o f the control median, 25% fewer DNA analyses would be 
required and the number o f carriers detected reduced from 32 to 24 for no loss o f detection 
o f CF cases (see table 4.21 and table 4.22).
This modest improvement in screening specificity falls short o f the performance described 
by Sarles et al (2005) and suggests the strategy o f testing PAP only in babies with an 
elevated IRT is less effective than testing all babies.
5.2.2 Use of Likelihood Ratio Method for IRT and PAP
Some o f the disadvantages o f using a fixed cut-off level for IRT and PAP can be 
overcome by using the likelihood ratio statistical method. The probability that a certain 
IRT or PAP level is associated with an infant affected by CF rather than one who is 
unaffected can be estimated from the overlapping control and CF distributions. For 
instance, it is 8.2 times more likely that an IRT concentration o f 70.80 ng/ml (logio 1.85) 
will be associated with a CF infant than an unaffected one. Similarly, a PAP level o f  1.26 
ng/ml (logio 0.1) is 4.1 times more likely to be associated with an infant affected by CF 
than with an infant who is unaffected (see Figure 4.49 & Figure 4.51). Moreover, the 
product o f the individual likelihood ratios can be calculated, thus combining the 
information from two markers due to their being only a low correlation between IRT and 
PAP levels in CF cases (Pearson correlation p = 0.669).
In 29 CF cases, the likelihood ratios for the two markers are multiplied together to give the 
overall risk for each affected CF baby (table 4.23). For babies affected by CF, the lowest
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overall risk (not CF: CF) for both markers is 1:4.8 and the highest value is 1: > 50,000. If 
the case with the lowest likelihood ratio is excluded (and therefore lost to detection), the 
next lowest likelihood for a CF case is 1:36.99 (not CF: CF), which will be detected if  a 
cut-off likelihood ratio of, say, 1:30 (not CF: CF) is chosen as the referral likelihood ratio 
for mutation testing. The effect o f this on the number o f referrals and carrier detection can 
be seen by reviewing the likelihood ratios in the elevated IRT group (n=314, Appendix A) 
and carrier group (n=32, table 4.24).
A summary o f the results (table 4.25) shows the IRT and PAP risk in CF cases, CF 
carriers and those with increased IRT levels. The suggested combined risk cut-off for IRT 
and PAP o f 1:30 (not CF: CF) for CF cases, CF carriers, and those with increased IRT 
levels would be an appropriate risk to choose in order to reduce the number o f CF carriers 
from 32 to 16 (50%) and reduce further DNA analysis from 314 to 180 (43%), losing only 
a single CF case (Table 4.25).
5.3 Other PAP Studies
5.3.1 Study 1
In the south o f Australia a study (Ranieri et al., 2009) was conducted to evaluate an IRT- 
PAP/DNA CF screening strategy. In this study, PAP was measured (MucoPAP, 
DYNABIO S.A., Marseille, France) with the adjustment o f using europium labelled 
streptavidin and IRT (NeoIRT, Perkin-Elmer, Turku, Finland) on blood spots. A total 
2,250 samples (cohort A) gave a normal population distribution with median, 95th and 
99th percentile values for PAP of 0.14, 0.43 and 0.8 ng/mL, and for IRT o f 17, 58 and 73 
ng/mL respectively. These concentrations for PAP and IRT are similar to those described 
in the present study. PAP was also determined in newborns (n = 256) with an IRT >99th 
percentile and with (cohort C) or without (cohort B) one CFTR mutation. In cohorts B and
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C, the median and 95th percentile values for IRT were 87.5, 177 ng/mL and 106, 499 
ng/mL, and for PAP they were 0.16, 0.6 ng/mL and 0.27, 2.8 ng/mL respectively. The 
PAP values in cohort B were not found to differ significantly from the normal population 
(p=0.12, Kolmogorov-Smimov test), while just 5% were found to have a PAP level >99th 
percentile. In cohort C, identified with an IRT >99th, one CFTR mutation and a normal 
sweat test, 35% had a PAP level >99th percentile. Therefore based on the use o f  the 99th 
centile as cut-off, the study results suggest that including PAP as described decreases by 
65% the number o f newborns requiring CFTR mutational analysis.
5.3.2 Study 2
In a published abstract in the Journal o f  Cystic Fibrosis (Vigano, et al., 2008), a multi­
centre feasibility study was carried out comprising two sites in the USA, one in Germany 
and one in Italy with the aim o f assessing the utility o f the combined IRT-PAP CF 
protocol in comparison with the conventional IRT/CFTR strategy. IRT and PAP were 
measured in 18,080 newborns. IRT was measured in dried blood spots collected at age 
3-5  days by a time-resolved fluoroimmunoassay (Perkin-Elmer Life Sciences, Turku, 
Finland). Based on the calculation o f the percentiles o f data obtained in the different 
centres, hypothetical cut-offs were set at IRT>50 ng/mL and PAP >1.8 ng/mL or IRT>100 
ng/mL and PAP>1.0 ng/mL, the same as those chosen by Sarles et al (2005). The 
IRT/PAP strategy appeared to have good potential, as it was shown to have the ability to 
reduce the number o f mutation analysis needed to 0.3%, which reduced both the cost o f  
the screening and the number o f carriers identified. However, this study was limited in 
that the sample size was fairly small and it did not permit the sensitivity in detecting mild 
CF forms to be evaluated.
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5.3.3 Study 3
Another published study o f PAP in the Journal o f  Cystic Fibrosis (Vemooij-van Langen, 
et al., 2009) was carried out in the Netherlands using two strategies in each sample. 
Immunoreactive trypsinogen (IRT) and pancreatitis-associated protein (PAP) were used in 
the first strategy. Where concentrations o f IRT >50ng/ml and PAP >1.8ng/ml or IRT 
>100 ng/ml and PAP >1.0 ng/ml were found, the test was rated positive. Samples with 
IRT >50ng/ml were analysed for 36 CF-mutations in the second strategy. An extended 
gene-analysis (EGA) was carried out in samples with one CF-mutation and when two CF- 
mutations were identified the tests were rated positive.
72,874 newborns were screened and 127 tested positive with the IRT/PAP protocol. O f 
these, ten CF cases were identified. A further 11 CF-patients were identified from 18 tests 
with IRT-DNA-EGA. Eighty-four carriers and seven compound heterozygotes with 
R117H-7T as a second mutation were also revealed with the IRT-DNA-EGA. A 
retrospective analysis with both strategies was carried out in heel-prick samples o f  18 
known CF cases in order to assess the sensitivity. Thirteen cases were identified with the 
IRT-PAP and 18 with the IRT-DNA-EGA. Specificity and PPV for the IRT-PAP were 
99.8% and 8.2%, and 99.99 % and 61% for the IRT-DNA-EGA. Based on the results o f  
the screening programme and the retrospective analysis, sensitivity was 82% and 100%. It 
was concluded that improved test performance was obtained using the IRT-DNA-EGA 
strategy in comparison to current strategies, but that this was not the case for the IRT-PAP 
strategy.
5.3.4 Study 4
A recent PAP study in the south-west o f  Germany has been reported (Sommerburg et al., 
2010). In this study, a prospective and sequential IRT/PAP approach was taken. IRT was
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the first tier and PAP the second, and this approach was compared to a commonly used 
IRT/DNA protocol in a population-based newborn screening study conducted in the south­
west o f Germany. Prospective quantitation o f PAP and genetic analysis for the presence o f  
four mutations in the CFTR gene with the greatest prevalence in southwest Germany 
(F508del, R553X, G542X ,G551D) was carried out in all newborn babies with IRT> 
99.0th percentile. If either PAP was >1.0 ng/mL and/or at least one CFTR mutation was 
detected, the newborn screening result was considered positive. Furthermore, IRT>99.9th 
percentile was also rated positive. Referral to a CF centre to test sweat Cl concentration 
followed a positive rating. Of 73,759 newborns tested, 98 (0.13%) were found to be 
positive with IRT/PAP and 56 (0.08%) with IRT/DNA. O f these 135 CF NBS-positive 
infants, 13 were diagnosed with CF after sweat testing, with similar detection rates for 
IRT/PAP and IRT/DNA. The PAP concentration o f one o f the 13 babies diagnosed with 
CF was <1.0 ng/mL.
It was concluded that sequential measurement o f IRT/PAP offers good sensitivity and 
specificity while permitting reliable, cost-effective CF screening o f newborn babies. It 
also avoids the need for genetic testing and its associated ethical issues.
5.4 PAP / IRT Screening Performance
Taken together, the results o f the above studies and the present study show that PAP has a 
useful predictive value as a newborn screening marker o f CF when combined with IRT. 
However the performance in each o f the studies varies according to the protocol used and 
none matches the results reported by Sarles et al (2005), where sensitivity and specificity 
were high enough to allow diagnosis o f CF cases in the screen positive group by sweat 
testing without the need for mutation testing, thus avoiding detection o f carriers. However, 
this requires measuring PAP and IRT in all newborns at considerable cost. In the present
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study, based on the measurement o f PAP only in those babies with an elevated IRT, it has 
been shown that the referral rate for mutation testing can be reduced by 43% and carrier 
detection by 50% of that obtained by the use o f IRT alone, using the likelihood ratio 
method. In practice, this would be a cost effective modification to the existing UK 
newborn screening programme, although the ELISA assay format would require 
modification (e.g. to the DELFIA fluoroimmunoassay method) to allow efficient testing o f  
the small number o f babies with elevated IRT detected each day.
5.5 Alternative Screening Strategies
5.5.1 Improving Specificity
Using likelihood ratios and the IRT/PAP protocol described in this study, results have 
been presented which show that this approach can reduce the number o f referrals for DNA  
analysis by up to 43% for the cost o f PAP testing in only about 0.69% o f newborn babies. 
However, one CF case which was picked up by IRT screening would have been missed 
when PAP was also included in the screening protocol.
5.5.2 Improving Sensitivity
A possible alternative strategy which could increase detection rates whilst still minimising 
the number o f screen positive babies would be to measure PAP in a greater proportion o f  
newborns in the screened population. Instead o f using the 99.5th centile as the IRT 
threshold for selecting babies for PAP testing, a larger follow-up using the 99th, 95th or 
even the 90th centile could be used. Following up 10% of elevated IRT results for PAP 
testing would increase workload to about 6,000 additional tests per year, but would still be 
more economic than testing all babies as described by Sarles et al (2005) and may detect 
additional CF cases which would have been missed using the 99.5th centile. Current
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screening sensitivity o f the routine IRT/DNA protocol is 96% (personal communication 
from M. Fitch).
A review o f IRT levels in CF cases missed by the Scottish newborn screening programme 
from 2003-2010 (n=l 1) shows that IRT levels ranged from 17.6 ng/ml - 60.9 ng/ml. Thus 
only one additional case would have been detected by the standard protocol if  a lower IRT 
cut-off o f 60 ng/ml had been in use which, in turn, would have greatly increased the 
referral rate for DNA testing. A bloodspot sample was available from one missed case in 
the present study, which had an IRT level o f 20.9 ng/ml (equivalent to 1.10 MoM) and 
was homozygous for the common deltaF508 mutation. PAP analysis produced a very high 
level o f 13.5 ng/ml, equivalent to 71.05 MoM. Lowering the IRT threshold for PAP 
analysis to a manageable follow-up rate would be unlikely to improve the performance o f  
the combined IRT/PAP screening strategy.
5.6 Disadvantage of the Sequential IRT / PAP Approach
Before the population can be screened using PAP, the babies must first be identified by 
the IRT assay. Initial IRT screening takes 24 hours from receipt o f the Guthrie card to a 
result and elevated levels are confirmed by re-analysis o f the same Guthrie card in 
duplicate, which takes a further 24 hours. Usually at that point bloodspots are sent to the 
molecular genetics laboratory for mutation testing. This step is however, delayed by a 
further 24 hours pending PAP analysis, adding a further day before mutation testing can 
be carried out and a diagnosis o f CF confirmed or excluded and screen positive results 
referred to a CF specialist.
However, this delay is unlikely to have a negative effect on the success o f treatment. Most 
CF infants are clinically well at birth and the NHS Quality Improvement Scotland 
standard for treatment is that 95% o f positive cases have started treatment within 35 days 
o f age and 100 % o f positive CF cases have started treatment within 43 days o f age unless
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deliberately delayed for further testing, assessment or treatment. The additional time 
required to include PAP testing is therefore unlikely to delay treatment for babies with 
bloodspot samples taken around 5-8 days o f age.
5.7 Factors Affecting Bloodspot Marker Measurements
5.7.1 Marker levels and Mutations in CF Cases
Sarles et al (2005) presented data which suggests that PAP levels may show lower levels 
in cases where the mutation types are associated with a milder CF phenyotype.
O f the 29 CF cases examined in this study, 13 were homozygous for the common 
mutation delta F508. Of the other 16 cases, two were confirmed by sweat test where the 
full mutations have not yet been identified. Of the remaining 14 cases, all were compound 
heterozygotes with 10 having delta F508/other mutation and four cases having other 
combinations: R556X/2789+5G>A, R117H/G542X, G551D/621+1G>T and
Y569D/Y569D (table 4.11).
IRT, PAP, PHE, and TYR concentrations were compared between the two groups o f  
mutation types (Delta F508 homozygous vs. other mutations). It was noted that both IRT 
and PAP medians were markedly lower in the "other" mutation group compared to the 
delta F508 homozygous group (IRT: 147.8 ng/ml vs. 187.7 ng/ml [figure 4.42]; PAP: 1.03 
ng/ml vs. 2.54 ng/ml [figure 4.43]) with only two o f the 10 CF cases with the lowest PAP 
results being homozygous for the delta F508 mutation.
Using the Mann-Whitney test, there were no statistically significant differences in median 
level between the two mutation groups for any markers (table 4.13). Studies on a larger
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series o f CF cases and mutation types should be carried out to explore this possibility 
further.
5.7.2 Marker Levels and Mutations in CF carriers
Delta F508 was detected in 22 o f the CF carriers. The other mutations identified in the 32 
CF carriers were the following: P67L (one sample), R560T (one sample), 1078delT (one 
sample), G551D (two samples) and R117H (Five samples) as shown in table 4.14. In 
contrast to the CF cases, the median concentration for each marker showed little difference 
between the two types o f mutation. IRT, PAP, PHE and TYR concentrations were 
compared between the two groups o f mutation types (AF508 vs. other mutation) using 
Mann-Whitney test. The result showed no significant differences in median level between 
the two mutation groups for any markers (table 4.16).
5.7.3 Age at bloodspot sampling
Variations in blood spot marker levels with day o f sampling were investigated. In the 
control group (2876 samples) the regression analysis at age o f sampling showed PAP 
levels to be significantly decreased (p <0.001) with earlier age at sampling. No significant 
associations were found for IRT (p = 0.959), PHE (p=0.276) or TYR (p = 0.249) (Figures 
4.9, 4.10, 4.11 and 4.12). In Scotland, the majority o f bloodspot samples for newborn 
screening are collected at 5-8 days o f age, with about 5% o f samples being obtained later. 
In France and some other countries, bloodspot sampling is carried out earlier (24-72 
hours). It is important therefore, that normal ranges and distribution parameters for each 
marker are established locally, as published data from centres which use earlier sampling 
will be unreliable.
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5.7.4 Premature Babies
Marker studies were carried out in 182 infants already known to have been born 
prematurely (i.e., before 37 weeks o f gestation). To discover any relationship between 
premature babies and levels o f IRT, PAP, PHE and TYR concentrations a linear 
regression analysis (Figures 4.22, 4.23, 4.24, and 4.25) was carried out. All markers 
showed a downward trend with advancing gestation. This was statistically significant for 
IRT (p <0.001), PAP (p <0.001) and TYR (p =0.015) but not statistically significant for 
PHE (p = 0.226). Therefore, when using IRT and PAP to screen for CF there will be a risk 
of false-positive results in premature babies unless higher IRT and PAP cut-offs are used.
5.7.5 Low Birth Weight Babies
O f 3632 blood spot samples, 189 were from infants known to have been bom with low  
birth weight (less than 2500 grams). The relationship between low birth weight and levels 
o f IRT, PAP, PHE and TYR concentration was examined using linear regression which 
showed that the only significant association was with PAP (p=0.002) where the level 
decreased with increasing birth weight. No significant changes were found for IRT (p 
=0.212), PHE (p =0.180) and TYR (p =0.436) (Figures 4.38, 4.39, 4.40 and 4.41). 
Therefore, in any screening progamme for CF which uses PAP there will be a tendency to 
overestimate the risk in very low birth weight babies.
5.7.6 Ethnicity
To see if  there was any difference in the IRT, PAP, PHE and TYR markers among all
ethnic categories, the data was divided into two groups. Group 1 included all British/Irish
(A) and any other white background (C). Group 2 included all other ethnic backgrounds
(Table 4.9). The median was calculated for IRT, PAP, PHE and TYR in group 1 (A and C)
and group 2 (all others). The result showed that the only statistically significant difference
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between these groups was for TYR in the controls. There were too few individuals from 
‘other’ ethnic groups in the CF and CF carrier sample groups for meaningful comparison 
(table 4.10).
It has previously been reported (Cheillan et al., 2005) that IRT levels are higher in 
Africans than in Europeans and therefore a higher IRT screen positive rate would be 
expected within that ethnic group. A further study from the USA (Giusti, 2008) raised the 
question o f the need to correct for this difference in African-American infants. It is 
possible that PAP might be similarly elevated. Lack o f any finding o f higher IRT or PAP 
in the present Scottish study is probably due to the fact that only about 10% o f the 
newborn screening population in Scotland are from non A & C groups and there are too 
few subjects in this study from these other ethnic groups for accurate medians to be 
established. Further studies are required in populations where there is a significant 
proportion o f other ethnic groups.
5.8 Gestational Markers of CF
In section 4.9, results from the present study were presented which showed that in 
pregnancies where the outcome was the birth o f a child with CF, birth weight was 
significantly reduced. This indicates that the patho-physiological effects o f CF are present 
before birth. It has also been shown that the CFTR mutation is expressed in placenta 
(Faller et al., 1995; Mylona et al., 1996) and it is possible that these changes may be 
reflected in a change in placental function where the foetus has CF. The placenta 
synthesises and secretes a large number o f hormones that are required for the maintenance 
o f pregnancy. Many o f these have been investigated in pregnancies with adverse outcomes 
and found to be altered in concentration. However, none have been investigated in CF 
pregnancies.
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In the UK, as a routine part o f antenatal care, a series o f  maternal serum markers are 
measured in pregnant women. During the first half o f pregnancy, screening tests for Down 
syndrome are offered to all pregnant women. These tests are based on the analysis o f a 
group o f serum markers measured at 10-13 weeks or 15-20 weeks o f  gestation. The 
markers used are, at 10-13 weeks, free beta hCG and PAPP-A - both products o f the 
syncytiotrophoblast o f the placenta. In the second trimester the markers used are AFP, 
UE3, hCG or free beta hCG and inhibin A. AFP is synthesised in the foetal liver but 
reaches the maternal circulation by active transport across the placenta. UE3 is also partly 
o f foetal origin, while hCG is a product o f the syncytiotrophoblast. Inhibin A is also 
produced by the syncytiotrophoblast. If the pregnancy is affected by Down syndrome, a 
characteristic pattern o f change in the maternal serum concentration o f these markers can 
be used to estimate a probability that the foetus has Down syndrome. Where this 
likelihood is above a predetermined threshold, invasive prenatal diagnosis (CVS or 
amniocentesis) is offered.
In addition to their predictive value for Down syndrome, some o f these prenatal screening 
markers also show changes in other adverse outcomes o f pregnancy. For example, 
elevated AFP is reported to be associated with Sudden Infant Death Syndrome (Smith, et 
al., 2004) and spontaneous preterm birth (Smith, et al., 2006) , while lower levels o f  
PAPP-A are associated with LBW, early delivery, preeclampsia and still birth (Smith, et 
al., 2002). Inhibin A levels have been reported as being increased in pregnancies with pre­
eclampsia (Cuckle et al., 1998). As these markers are routinely tested in the majority o f  
pregnancies, this offers an opportunity to test their predictive value for CF.
In the present study, the serum markers AFP, hCG, PAPP-A, Ffree P-hCG, UE3 and
inhibin-A were analysed in 55 serum samples taken during pregnancies for which the
outcome was the live birth o f a child affected with CF. An additional total o f  330
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pregnancies o f normal outcome were randomly selected as controls matched to the same 
gestational range. Both second-trimester (15 to 20 weeks) and first-trimester cases (10 to 
13 weeks) were included.
5.8.1 AFP
In the 330 control pregnancy serum samples the median AFP concentration level was 27.1 
U/mL (equivalent to 0.98 MoM ). The median AFP concentration level in the 55 maternal 
serum samples from mothers o f children affected with CF was 29.27 U/mL (equivalent to 
1.11 MoM). Figure 4.53 shows the distribution o f AFP (MoM) in samples from CF 
pregnancies. Although slightly elevated compared to controls, the concentration levels o f  
AFP are not significantly different in the mother’s serum when her child had cystic 
fibrosis (p = 0.335, Mann-Whitney test).
5.8.2 HCG
The median hCG concentration level in the 330 control serum samples was 27.51 U/mL 
(equivalent to 0.99 MoM). The median hCG concentration level in the 55 maternal serum 
samples from mothers o f children affected with CF was 25.88 U/mL (equivalent to 0.95 
MoM). The result presented in Figure 4.56 shows the distribution o f hCG (MoM) in 
samples from CF pregnancies. This median is close to that in the controls and is not 
statistically significantly different from normal (Mann-Whitney test, p = 0.539)
5.8.3 PAPP-A
The median PAPP-A concentrations level in 330 control pregnancy samples was 6794.50
U/mL (equivalent to 0.99 MoM). The median PAPP-A concentration level in 55 maternal
serum samples from mothers o f children affected with CF was 7510.0 ng/ml (equivalent to
0.98 MoM). The results presented in figure 4.59 show the distribution o f PAPP-A (MOM)
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in samples from CF pregnancies. This median is close to that in the controls and is not 
statistically significantly different from normal (Mann-Whitney test p = 0.632).
5.8.4 FREEp-HCG
The median free p-hCG concentration levels in the 330 control pregnancy serum samples 
was 14.40 ng/ml (equivalent to 1.00 MoM), while in the 55 serum samples taken during 
pregnancies where the outcome was the live birth o f a child with CF the median free p- 
hCG concentratios level was 13.80 ng/ml (equivalent to 0.93 MoM). Figure 4.62 shows 
the distribution o f free p-hCG (MoM) in samples from CF pregnancies. This median is 
close to that in the controls and is not statistically significantly different from normal 
(Mann Whitney, p = 0.824).
5.8.5 UE3
In 322 control pregnancy serum samples, the median UE3 concentration level was 2.48 
nmol/L (equivalent to 1.01 MoM). In the 52 serum samples from pregnancies where the 
outcome was the live birth o f a child with CF, UE3 level was 2.51 nmol/L (equivalent to 
1.07 MoM). The results presented in Figure 4.65 show the distribution o f UE3 (MoM) in 
samples from CF pregnancies. This median is close to that in the controls and is not 
statistically significantly different from normal (Mann Whitney, p =0.840).
5.8.6 Inhibin-A
The median inhibin-A concentrations levels in the 325 control pregnancy serum samples
was 183.5 pg/mL (equivalent to 0.99 MoM), while the median inhibin-A concentrations
level in the 53 maternal serum samples from mothers o f children affected with CF was
found to be 173.20 pg/mL ml (equivalent to 0.97 MoM). The results presented in Figure
4.68 show the distribution o f inhibin-A (MoM) in samples from CF pregnancies. This
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median is close to that in the controls and is not statistically significantly different from 
normal (Mann Whitney, p = 0. 650 ).
5.9 Prenatal Screening Markers in CF Pregnancies
Although these markers show various changes in the case o f low birth weight, 
prematurity, pre-eclampsia, Down syndrome, Edwards’ syndrome, and chromosomal 
abnormalities (Smith et al 2002), no significant changes were found in this study for any 
o f these markers in CF pregnancies. However some minor changes are evident and AFP in 
particular did show a marked concentration increase. Although not statistically significant, 
this suggests that further studies on a larger series o f CF pregnancies may be worthwhile.
The case for routine prenatal population screening for CF has been considerably weakened 
in the UK with the introduction o f newborn bloodspot screening and evidence from the 
Wisconsin study (Farrell, et al., 1997) that early identification o f affected neonates 
combined with improved treatment regimes improves the long term outlook for affected 
children. However, identification o f pregnancies at increased risk through serum marker 
screening would be a useful alert o f the possibility o f the birth o f an affected child, 
allowing even earlier diagnosis and intervention. Further studies on an extended range o f  
maternal serum markers would therefore be o f  interest.
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6.1 CONCLUSION
Newborn screening for CF is established in many countries. However, the clinical and cost 
effectiveness o f newborn screening for CF has been questioned. The primary test involves 
IRT measurement and subsequent DNA analysis for infants with an elevated IRT 
concentration. Due to the relatively poor specificity o f the IRT test, around 0.5% o f the 
newborn population are referred for DNA testing and consequently a significant number 
o f CF carriers are also identified. Alternative markers are required which can improve 
specificity.
In this study, PAP has been shown to be a potential marker in newborn screening for CF. 
An innovative strategy used in this study for newborn screening for CF is the likelihood 
ratio statistical method to combine IRT and PAP results and select those infants at highest 
risk for DNA testing. This approach reduces the number o f carriers detected. By carrying 
out PAP testing only in those infants with an elevated IRT, the significant cost o f whole 
population screening is avoided, and the cost o f PAP testing is offset by the reduced 
number o f DNA tests carried out.
The serum markers tested in this research were not found to be good predictors o f CF. 
However, there are other markers such placental growth factors and ADAM  12 that have 
not yet been tested, and there is a case for these to be tested in future research.
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